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Abstract 
 
Epidermal growth factor receptor (EGFR) is often over-expressed or over-activated in 
cells of solid tumors and can be targeted by specific inhibitors (EGFRIs), like erlotinib, 
gefitinib, cetuximab and panitumumab. Unfortunately, EGFRIs only seem to work in a 
subset of patients suffering from EGFR-expressing tumors. Efficient biomarkers to reliably 
select patients who will benefit from an EGFRI therapy and determine their optimal 
dosage are still needed. One of the most common adverse drug reactions observed 
during therapy with all approved EGFRIs is the development of a typical skin rash. It has 
been shown in various studies that occurrence and severity of this EGFRI-induced rash 
are positively correlated with patient outcome (prolonged overall and progression-free 
survival). However, the rash usually takes several weeks to manifest and is usually 
treated with topical or systemic medication. Hence, its severity may be suppressed, 
rendering it unsuitable as a clinical predictive marker. Therefore, the aim of this study was 
to identify rapidly determinable predictive biomarkers for the severity of EGFRI-induced 
skin rash, which would be helpful to allow early preventive treatment of the rash while at 
the same time still allowing prediction of EGFRI efficacy early on and facilitate 
optimization of personalized cancer therapy for individual patients. They can also help to 
prevent exposure of patients to substances which are ineffective but still cause 
discomforting side effects. 
 
Since previous work revealed evidence for genetic, pharmacokinetic and cytokine 
markers, the intention of this work was to identify functional biomarkers that are able to 
measure EGFR inhibition variability in the periphery, especially in blood plasma and skin 
cells. Therefore, molecules that interact with, regulate or functionally modulate EGFR 
inhibition were selected and their levels determined in plasma samples from patients 
treated with an EGFRI by enzyme-linked immunosorbent assay (ELISA) and it was 
checked for correlations with the development of EGFRI-induced skin toxicity. The EGFRI 
cetuximab, the EGFR ligand amphiregulin (AREG) and the growth factors hepatocyte 
growth factor (HGF) and 25-OH-vitamin D were selected as candidates following these 
criteria. 
Since miRNAs have recently been shown to be very important in the response to cancer 
therapy, investigating the suitability of specific mature or precursor miRNA molecules as 
functional, epigenetic biomarkers for the development of EGFRI-induced skin toxicity was 
of special interest. Therefore, next generation sequencing (NGS) was performed in 
keratinocyte and fibroblast cultures from healthy donors to compare miRNA profiles 
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between cells previously identified as rather erlotinib-sensitive and those identified as 
rather erlotinib-insensitive.  
Results show that plasma levels of the EGFRI cetuximab were not significantly associated 
with development of EGFRI-induced rash.  
While the investigated candidates AREG and 25-OH-vitamin D also failed to show a 
significant correlation with the rash, the plasma concentration of the MET ligand HGF was 
significantly inversely correlated with severity of EGFRI-induced skin rash. This inverse 
correlation was also seen with overall survival (OS) in patients who developed EGFRI-
induced rash but not in patients with no rash. HGF seems to be a promising biomarker, 
whose predictive and/or prognostic value should definitely be validated in a larger and 
well-controlled patient cohort. 
In this study primary human dermal keratinocytes as well as fibroblasts have proven to be 
suitable as in vitro models for studying EGFRI-induced skin rash and associated potential 
biomarkers. Comparison of miRNA profiles between erlotinib-sensitive and rather -
insensitive cells combined with a literature review to identify the miRNAs with the most 
supporting data, led to identification of the precursor miRNAs  mir-146a, mir-31, mir-221, 
mir-520e and mir-944  as most promising predictive biomarkers in keratinocytes, with mir-
146a, mir-520e and mir-944 having known targets and a plausible suggested mechanism 
of action and mir-31 and mir-221 having already been shown to be associated with 
sensitivity to an EGFRI in at least one previously published study. In fibroblasts the 
precursor miRNA mir-34a was identified as the by far most promising predictive biomarker 
with MET reported as direct target and an associated plausible mechanism of action and 
two confirmatory previous studies. Further identified promising miRNAs in fibroblasts were 
mir-382, mir-494, mir-520e and mir-7-1, also with plausible suggested targets.  
 
Overall, the final conclusion of this study is that it might be possible to develop a kind of 
“predictive profile” consisting of several different biomarkers which taken together may 
have a predictive value on individual extent of EGFR inhibition in patients. The results of 
this study suggest that parameters like the plasma concentration of HGF, the expression 
of mir-146a and mir-31 in dermal keratinocytes and the expression of mir-34a in dermal 
fibroblasts might be promising parameters to include in such a predictive profile. However, 
all suggested parameters need to be further confirmed and validated in clinical settings. 
Eventually, such a predictive score might be used in the future to predict the requirement 
for changes in dosage of a specific EGFRI, closer monitoring of therapy efficacy by more 
frequent tumor imaging or maybe even change in therapy away from using an EGFRI or 
at least adding an adjuvant drug to the EGFRI for better efficacy.  
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Chapter I: Introduction 
 
I.1  Personalized drug therapy 
It has been known from the beginning of human medicine that drug efficacy and safety 
varies to a great extent among individual patients. However, it has taken until the late 
1950s to recognize genetic variations as one cause for this variability and to start forming 
the research area of “pharmacogenetics”, which investigates these genetic variations1. 
Differences in the sequences of genes encoding drug target proteins, drug-metabolizing 
enzymes or drug transporters can have an effect on drug efficacy and safety. On top of 
that, there are also indirect effects, meaning that the genetic variation changes proteins 
which function in the biological context of the drug target/metabolizing 
enzyme/transporter, which can also alter the drug response. Such indirect effects make it 
difficult to identify single phenotype-genotype associations in drug response. In addition, 
various none-genetic factors can also influence drug response, adding to the complexity 
of the subject. The overall goal of the research area of pharmacogenetics and one of the 
most important goals of the current field of human medicine in general, is to achieve 
treatment of patients with target-specific drugs at the optimal dose for this patient to reach 
maximal therapeutic benefit with minimal adverse effects, which is called “individualized 
medicine” or “personalized medicine”. 
In this regard it is of uttermost importance to first understand the molecular mechanisms 
behind a disease as well as the pharmacokinetic and pharmacodynamic properties of a 
drug and next to genomics also other approaches like transcriptomics, proteomics, 
epigenetics and metabolomics have to be used to identify and develop individualized 
treatment strategies. After the decades of genetic research, the role of RNA came more 
and more into focus and the importance of gene regulation and RNA modification of gene 
function was recognized, which created the field of epigenetics. 
To date in cancer therapy there are already several targeted agents used, which are 
directed against specific molecular structures, which are found in the tumor of a patient 
but ideally not in his/her normal cells or at least to a lesser extent2. Epidermal growth 
factor receptor inhibitors (EGFRIs) for example target the epidermal growth factor receptor 
(EGFR), which is expressed in almost all cells of the body but which is often over-
expressed or over-activated in tumor cells, especially in non-small cell lung cancer 
(NSCLC), colorectal cancer, pancreatic cancer and head and neck cancer. Unfortunately, 
EGFRIs only seem to work in a subset of patients suffering from EGFR-expressing 
tumors. Today there are some genetic variants (e.g. of EGFR itself or of downstream 
signaling molecules such as KRAS [Kirsten rat sarcoma virus oncogene homolog]) known 
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to be partially predictive for response to EGFRIs in a subgroup of patients. However, there 
are still no methods or characteristics known which could be used to reliably select all 
patients who will benefit from an EGFRI therapy and determine their optimal dosage. 
There is still more research needed to identify the causes for the variability in response to 
EGFRIs among patients. 
 
 
I.2  Epidermal growth factor receptor inhibitors (EGFRIs) 
EGFR is a receptor tyrosine kinase, which is expressed on the surface of almost all cell 
types and regulates fundamental cell functions. Its signaling pathways will be further 
described in chapter I.5. 
Frequently administered inhibitors which are specific for EGFR are the tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib and the monoclonal antibodies (mAbs) cetuximab 
and panitumumab. 
 
 
I.2.1 Tyrosine kinase inhibitors 
TKIs are small-molecular-weight molecules, which enter the cell by passive as well as 
active transport mechanisms. In vitro studies have shown that for uptake of erlotinib and 
gefitinib the active transport plays a much larger role than the passive one3. Erlotinib and 
gefitinib are lipophilic and have been shown in different studies to be substrates of 
different organic cation transporters (OCTs), like hOCT1 (erlotinib)4, hOCT2 (erlotinib)5 
and hOCT3 (gefitinib)3. Efflux of TKIs is mediated by adenosine triphosphate (ATP)-
dependent efflux pumps, such as P-glycoprotein (P-gp, also called ATP-binding cassette 
sub-family B member 1, ABCB1)6. TKIs act by reversibly binding to the intracellular ATP-
binding site and therefore blocking ATP-binding and signal transduction7. 
Erlotinib hydrochloride, International Union of Pure and Applied Chemistry (IUPAC) name 
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (tradename Tarceva) -in 
this thesis referred to as erlotinib- is approved in the European Union (EU) since 
September 20058. This study mainly focuses on erlotinib as representative for the class of 
EGFRIs. Its structural formula is presented in figure 1. Erlotinib is indicated as first-line 
treatment of patients with locally advanced or metastatic NSCLC with EGFR activating 
mutations, for switch maintenance treatment in patients with locally advanced or 
metastatic NSCLC with EGFR activating mutations and stable disease after first-line 
chemotherapy and for treatment of patients with locally advanced or metastatic NSCLC 
after failure of at least one prior chemotherapy regimen. It is also indicated in combination 
with gemcitabine for treatment of patients with metastatic pancreatic cancer.  
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Gefitinib, IUPAC name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-
ylpropoxy)quinazolin-4-amine;hydrochloride (tradename Iressa) is approved in the EU 
since June 20098. Its structural formula is presented in figure 1. It is indicated for the 
treatment of adult patients with locally advanced or metastatic NSCLC with activating 
mutations of EGFR. 
Treatment with erlotinib and gefitinib leads to dramatic antitumor activity in a subset of 
NSCLC patients: for patients with activating EGFR mutations in the tumor the initial 
response rate was shown to be approximately 75% (reviewed by Stewart et al. 20159). 
The frequency of EGFR mutations is 10-30 %, depending on the studied populations. The 
majority of initially responsive patients will eventually acquire resistance because of an 
acquired T790M mutation in exon 20 of EGFR or other still largely unknown mechanisms. 
However, resistance to EGFRIs will not be subject of this thesis. 
 
 
 
 
Figure 1 Structural formulas of tyrosine kinase inhibitors erlotinib and gefitinib 
A) Structural formula of erlotinib, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine. 
B) Structural formula of gefitinib, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-
ylpropoxy)quinazolin-4-amine. Source: National Center for Biotechnology Information. PubChem 
Compound Database; CID=176870 and CID=123631, https://pubchem.ncbi.nlm.nih.gov/compound. 
 
 
I.2.2 Monoclonal antibodies 
The anti-EGFR mAbs act by irreversibly binding to the extracellular domain of EGFR and 
inhibiting ligand binding. Several randomized clinical trials demonstrated the effectiveness 
of the mAbs cetuximab and panitumumab in combination with fluorouracil (5-FU) and 
either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) in patients with metastatic colorectal 
cancer (mCRC) and wild-type (WT) RAS (rat sarcoma)10-13. 
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Cetuximab (tradename Erbitux) is a chimeric monoclonal IgG1 antibody produced in a 
mammalian cell line (Sp2/0, mouse spleen) by recombinant deoxyribonucleic acid (DNA) 
technology. It is approved in the EU since June 20048. It is indicated for the treatment of 
patients with EGFR-expressing, RAS WT mCRC in combination with FOLFOX or FOLFIRI 
or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy. 
Panitumumab (tradename Vectibix) is a fully human monoclonal IgG2 antibody produced 
in a mammalian cell line (CHO, Chinese hamster ovary) by recombinant DNA technology. 
It is approved in the EU since December 2007 (first conditional marketing authorization, 
full authorization granted in January 2015)8. It is indicated for the treatment of adult 
patients with WT RAS mCRC in first-line in combination with FOLFOX or FOLFIRI, in 
second-line in combination with FOLFIRI for patients who have received first-line 
fluoropyrimidine-based chemotherapy (excluding irinotecan) or as monotherapy after 
failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. 
 
 
I.2.3 Newer epidermal growth factor receptor inhibitors 
Next to erlotinib, gefitinib, cetuximab and panitumumab there are additional EGFRIs also 
approved for clinical use, which either target mutant EGFR instead of WT or have 
additional targets next to EGFR and were therefore not studied here. 
The TKI lapatinib (tradename Tyverb) targets EGFR and human epidermal growth factor 
receptor 2 (HER2)14 and is indicated for the treatment of adult patients with breast cancer, 
whose tumors overexpress HER2. It is used in combination with capecitabine, 
trastuzumab or an aromatase inhibitor depending on the disease stage, expression of 
hormone receptor and previous treatment regimens8. The TKI afatinib (Tradename Giotrif) 
targets EGFR, HER2 and HER415 and is indicated as monotherapy for the treatment of 
EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating 
EGFR mutation(s); and for the treatment of locally advanced or metastatic NSCLC of 
squamous histology progressing on or after platinum-based chemotherapy8.  
The mAb pertuzumab (tradename Perjeta) targets HER2 and prevents dimerization with 
EGFR16 and is indicated for use in combination with trastuzumab and docetaxel in adult 
patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, 
who have not received previous anti-HER2 therapy or chemotherapy for their metastatic 
disease and for use in combination with trastuzumab and chemotherapy for the 
neoadjuvant treatment of adult patients with HER2-positive, locally advanced, 
inflammatory, or early stage breast cancer at high risk of recurrence8. 
The mAb necitumumab (tradename Portrazza) targets EGFR17 and in combination with 
gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients 
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with locally advanced or metastatic EGFR expressing squamous NSCLC who have not 
received prior chemotherapy for this condition8. This antibody was approved in February 
2016 in Germany, after patient enrolment for the Dermatoxgen study and is therefore not 
studied here.  
Recently, also EGFRIs have become available which specifically target mutant EGFR, 
such as the TKI osimertinib (tradename Tagrisso), which is indicated for the treatment of 
adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. 
 
 
I.3  Predictive and prognostic biomarkers 
In targeted cancer therapy it often takes some time (several weeks) until it can be clearly 
seen, e.g. by tumor imaging, whether the treatment is working sufficiently. In late stages of 
a tumor disease or for especially aggressive types by the time the possible insufficiency of 
a therapy is detected by such imaging techniques, it might be too late for the patients to 
optimize drug dosing or initiate an alternative treatment strategy. Therefore, it is of high 
value to have so called biomarkers available, which can predict therapy efficacy and 
patient outcome early on and facilitate optimization of personalized cancer therapy for 
individual patients. They can also help to prevent exposure of patients to substances 
which are ineffective but still cause discomforting side effects.  
A biomarker is a clinical or biologic parameter which can be objectively measured and 
which provides information about disease outcome18,19. The World Organization of Health 
(WHO) defines a biomarker as “[…] any substance, structure or process that can be 
measured in the body or its products and influences or predicts the incidence of outcome 
or disease”20. A biomarker can be a single variable or a combination of different 
measurements, e.g. a signature consisting of expression values of various genes. One 
example of a biomarker already used in the clinics is the expression of the HER2 receptor 
in breast cancer cells. High expression of this receptor suggests a high success rate of 
treatment with the anti-HER2 antibody trastuzumab and would indicate that anthracycline-
based adjuvant chemotherapy might be supportive21,22. 
 
Biomarkers can be divided into predictive and prognostic ones. A predictive biomarker 
allows for an in-advance evaluation of the efficacy of a therapy, e.g. an EGFRI therapy. In 
contrast, a prognostic biomarker allows for an in-advance evaluation of the outcome of a 
disease for a patient independent of the treatment19.  
 
For efficacy of EGFRIs the straightest potential biomarker might be EGFR expression on 
the surface of tumor cells. Unfortunately, there was no clear association found between 
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EGFR expression and response to EGFRIs, as shown for cetuximab in colorectal cancer23 
and squamous cell cancer of the head and neck24 and for gefitinib in NSCLC25. Further 
potential therapy-associated predictive biomarkers for EGFRIs could be genetic variants 
of the EGFR gene or of other genes encoding proteins involved in the EGFR signaling 
network. In NSCLC driver mutations of EGFR (e.g. deletions in exon 19 or the missense 
mutation L858R in exon 21) are known positive predictive biomarkers for efficacy of 
erlotinib and gefitinib26,27. In metastatic colorectal cancer mutations in exons 2/3/4 of the 
GTPases (guanosine triphosphate) KRAS and NRAS are known negative biomarkers for 
efficacy of cetuximab and panitumumab28. The predictive role of EGFR inhibition reactivity 
might not be fully discriminable from the prognostic role. In older studies a small number 
of patients with skin rash, who were later diagnosed with KRAS mutations, had a better 
course of disease if treated with an EGFRI29. This points to an additional prognostic role of 
skin rash as reaction to EGFRI effects outside the tumor. Overall, in none of the numerous 
conducted studies mutation status of EGFR or RAS genes was sufficient to predict EGFRI 
efficacy for all patients (see for example the study by Lièvre et al. where 68 % of non-
responders to cetuximab had WT KRAS29). Hence, new biomarkers are still needed. 
 
Various serum/plasma proteins like growth factors which influence EGFR signaling might 
be suitable predictive biomarkers. Especially ligands of the EGFR could be promising in 
this regard. In addition, in recent years gene regulatory molecules, such as miRNAs have 
been in the focus of research in several research areas. MiRNAs are also conceivable as 
potential predictive biomarkers for efficacy of EGFRIs. 
 
 
I.4  EGFRI-induced skin toxicity 
The most common adverse drug reactions observed during therapy with all approved 
EGFRIs are diarrhea and skin toxicities. Diarrhea is observed in around 17% of patients 
treated with cetuximab30. In patients treated with erlotinib the incidence of diarrhea is very 
variable, ranging from 18 % to 68 % across different phase III clinical studies (reviewed by 
Hirsh et al. 201431). Diarrhea is a rather unspecific side effect, which was not found to 
have a strong correlation with patients’ outcome32. Mild to moderate forms are commonly 
treated with loperamide, an opioid which acts locally in the colon, to decrease its dose-
limiting properties. For more severe forms temporary discontinuation of EGFRI treatment 
is recommended. 
Skin toxicities typically induced by EGFRIs include nail changes (e.g. paronychia or 
pyogenic inflammation or cracking of nails and cuticles)33, xerosis and pruritus, hair 
changes (e.g. alopecia or increased growth or change in texture) and papulopustular 
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(acneiform) rash34,35. An example for the EGFRI-induced papulopustular rash is presented 
in figure 2. Incidences of the dermatologic side effects range from 14 % for paronychia to 
80 % for papulopustular rash. Reported numbers slightly differ across clinical studies 
depending on study population, applied EGFRI, system used for toxicity grading, tumor 
types etc. 
 
 
 
Figure 2 Papulopustular rash induced by an epidermal growth factor receptor inhibitor 
Papulopustular (acneiform) rash on the back of a patient treated with the epidermal growth factor 
receptor inhibitor (EGFRI) erlotinib. Picture by Prof. Dr. Ralf Gutzmer, Medical School Hannover, 
Department of Dermatology, Allergology and Venereology, adapted from Hichert et al.36. 
 
 
The described skin toxicities are typically observed for all approved EGFRIs and seem to 
be a class effect of this group of inhibitors. Interestingly, occurrence and severity of the 
EGFRI-induced skin toxicity have been shown in numerous independent studies to be 
positively correlated with patients’ progression-free and overall survival (PFS and OS)37-39. 
The molecular mechanism behind the development of EGFRI-induced skin toxicity is not 
fully elucidated today but is of high interest with regard to the identification of biomarkers 
predictive for efficacy and safety of EGFRIs. 
In the clinics health care professionals already use the occurrence of EGFRI-induced skin 
rash as clinical marker for the efficacy of EGFRI tumor therapy and in case that no rash 
develops, they often try to increase the dosage of the inhibitor until rash development is 
obtained40,41. 
However, in many cases EGFRI-induced skin toxicities also lead to substantial physical 
discomfort for the patients, limit their daily activities and have a severe psychological 
impact, resulting in dose reduction or discontinuation of EGFRI treatment. Since the skin 
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toxicities are such disturbing side effects for the patients, they are often treated with 
various topical or systemic medications. A systematic review performed by Brown and 
colleagues in 2016 reported on the most commonly recommended treatment strategies for 
EGFRI-induced rash, taking into account 59 articles including recommendations from 
expert opinions, randomized-controlled trials and case report studies42. The most 
commonly recommended treatments are topical antibiotics and corticosteroids for mild 
rash, oral antibiotics, corticosteroids and antihistamines for moderate to severe rash and 
delay or dose reduction of EGFRI for very severe rash. Hence, due to medications 
severity of EGFRI-induced skin toxicity may be suppressed, rendering it unsuitable as 
predictive marker. On top of that, EGFRI-induced skin rash usually takes two to three 
weeks to reach its maximal manifestation after initiation of therapy or in some cases even 
longer43. Rapidly determinable predictive biomarkers for the severity of EGFRI-induced 
skin rash would allow to start early with preventive treatment of the rash and still also 
allow prediction of efficacy of EGFRI therapy. Such biomarkers might indicate whether 
clinicians should intensify therapy and monitoring, e.g. by more frequent tumor imaging. 
 
 
I.5  EGFR and its signaling pathways 
The EGFR belongs to the erythroblastic leukemia viral oncogene homolog (ErbB) family of 
receptor tyrosine kinases and is also called ErbB1 or HER1. The other three ErbB 
receptors are ErbB2 (HER2, Neu), ErbB3 (HER3) and ErbB4 (HER4)44. EGFR is a 170 
kDa transmembrane glycoprotein, which possesses an extracellular domain with a ligand-
binding cleft and a dimerization loop, a single transmembrane domain and an intracellular 
kinase domain which also contains an ATP-binding site (depicted in figure 3)45,46. 
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Figure 3 Crystal structure of the epidermal growth factor receptor 
EGFR possesses an extracellular domain with a ligand-binding cleft for interaction with one of 
seven possible ligands, which activates the receptor. There is also a dimerization loop (dashed 
circle) in the extracellular domain, which is needed to form a dimer with another EGFR monomer 
(homodimer) or with one of the other three ErbB receptors (heterodimer). Following the single 
transmembrane domain there is also an intracellular kinase domain which contains an ATP-binding 
site and is activated via cross-phosphorylation of the two receptor monomers following ligand-
binding and dimerization. Adapted from Tebbutt et al.46, originally published by Yarden and Pines45. 
Abbreviations: ATP, adenosine triphosphate; EGFR, epidermal growth factor receptor; ErbB, 
erythroblastic leukemia viral oncogene homolog. 
 
 
EGFR regulates fundamental cell functions, like survival, proliferation and migration, via 
numerous signaling pathways, including the MAPK cascade (RAS/RAF/MAPKK/MAPK), 
the phospholipase C (PLCγ/PKC), the Akt (PI3K/Akt) and the STAT3 pathways. These 
pathways are depicted in figure 4 and are further described in sections I.5.1 to I.5.4, 
including explanations of abbreviations of involved proteins. 
In mammals a variety of EGFR ligands exist, which can bind to the receptor and activate 
its down-stream signaling cascades. Next to epidermal growth factor (EGF) there are six 
additional ligands known. In distinct cell types and contexts different combinations and 
amounts of the various ligands are expressed, facilitating fine-tuned regulation and 
specificity of EGFR signaling47. Moreover, each ligand has its own binding characteristics 
leading to distinct homo- or hetero-dimerization of ErbB receptors 48. 
Dimerization leads to autophosphorylation of the receptor at specific tyrosine residues 
(cross-phosphorylation by the two monomers), which then recruit various signal 
transducer proteins, leading to the activation of numerous signaling cascades49. 
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I.5.1 MAPK pathway 
One of the best characterized signaling cascades induced via EGFR is the mitogen-
activated protein kinase (MAPK) cascade. MAPKs are enzymes which covalently attach 
phosphate to specific serines and threonines of certain target proteins44. Upon 
autophosphorylation of EGFR following ligand binding, a complex of adaptor proteins 
(growth factor receptor-bound protein 2 [Grb2], son of sevenless [SOS] and sometimes 
also Shc) binds to the phosphorylated tyrosine residues of EGFR50. A subsequent 
conformational change of the guanine nucleotide exchange factor SOS facilitates 
recruitment of the GTPase RAS (RAS-GDP). SOS induces the release of guanosine 
diphosphate (GDP) from RAS, which facilitates binding of guanosine triphosphate (GTP) 
to RAS. This activated form of RAS (RAS-GTP) in turn activates the protein kinase rapidly 
accelerated fibrosarcoma (RAF) by phosphorylation. RAF subsequently phosphorylates 
various other protein kinases, known as MAPK kinases (MAPKK) or MKKs, namely e.g. 
MKK4, MKK7 and MEK1/2. These proteins again phosphorylate further downstream 
proteins. MKK4 and MKK7 primarily phosphorylate c-Jun amino-terminal kinase (JNK) 
while MEK1/2 preferably targets extracellular receptor-regulated kinase (ERK)1/251. The 
MAPKs JNK and ERK1/2 themselves phosphorylate specific transcription factors, which 
act in the nucleus. A prominent target of JNK is c-Jun, which is part of a complex (AP-1), 
which binds to specific DNA sequences and alters expression of the respective genes52. 
 
 
I.5.2 PI3K/Akt pathway 
Another prominent signaling cascade activated by EGFR is the PI3K/Akt pathway. 
Phosphoinositide 3-kinase (PI3K) binds to activated (autophosphorylated) EGFR and can 
then phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to yield 
phosphatidylinositol-3,4,5-trisphosphate (PIP3)50,53. PIP3 mediates translocation of the 
serine/threonine kinase Akt to the plasma membrane, where it is activated via 
phosphorylation. Activated Akt can in turn activate different effector proteins, like 
mechanistic target of rapamycin (mTOR), which can become part of different complexes, 
which have functions at various cell organelles and on gene transcription and 
translation54,55.  
 
 
I.5.3 STAT3 pathway 
EGFR can also activate transcription factor signal transducer and activator of transcription 
3 (STAT3). Upon ligand-mediated kinase activation and autophosphorylation of EGFR, 
STAT3 is recruited from the cytosol to phosphorylated tyrosines of EGFR (Y1068 and 
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Y1086) via its SH2 domain and is itself phosphorylated at a tyrosine residue (Y705)56. 
This phosphorylation leads to dimerization of STAT3 and translocation to the nucleus, 
where the STAT3 dimers can bind to their specific target DNA sequences and enhance 
gene expression leading to increased proliferation and survival of the cell. 
 
 
I.5.4 PLCγ/PKC pathway 
The last prominent signaling pathway which can be activated by EGFR is the 
phospholipase Cγ (PLCγ) pathway. PLCγ directly interacts with activated EGFR and 
hydrolyzes PIP2 to inositol 1,3,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG)50. IP3 
further acts on the membrane of intracellular calcium reservoirs and provokes release of 
calcium ions (Ca2+)57. DAG on the other hand mediates activation of protein kinase C 
(PKC), which itself is able to initiate several signaling cascades to finally alter proliferation 
and inflammatory responses. These numerous cascades cannot be further covered within 
the scope of this thesis. 
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Figure 4 Epidermal growth factor receptor signaling pathways 
When one of the seven known EGFR ligands EGF, HB-EGF, TGFα, BTC, AREG, EREG, or EPNG 
(grey) binds to EGFR, receptor homodimers or heterodimers (with HER1, HER2 or HER3) form, 
leading to autophosphorylation (red P) of EGFR at specific tyrosine residues. Different signaling 
cascades are initiated. Green: PI3K/Akt pathway; blue: STAT3 pathway; orange: MAPK pathway; 
brown: PLCγ pathway; red: effector proteins/transcription factors which alter gene transcription. 
Abbreviations: AREG, amphiregulin, BTC, betacellulin; DAG, 1,2-diacylglycerol; EGF, epidermal 
growth factor; EGFR, epidermal growth factor receptor; EPNG, epigen; EREG, epiregulin; ERK, 
extracellular signal-regulated kinase; GDP, guanosine diphosphate; Grb2, growth factor receptor-
bound protein 2; GTP, guanosine triphosphate; HB-EGF, heparin-binding EGF-like growth factor; 
HER, human epidermal growth factor receptor; JNK, c-Jun amino-terminal kinase; K, tyrosine; 
MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; mTOR, mechanistic target of 
rapamycin; P, phosphate; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-
bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PKC, protein kinase C; PLCγ, 
phospholipase Cγ; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma; SOS, son of 
sevenless; STAT3, signal transducer and activator of transcription 3; TGFα, transforming growth 
factor α. 
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I.6  EGFR signaling in skin 
The human skin is composed of three layers: the hypodermis, the dermis and the 
outermost epidermis58,59. The dermis and the epidermis are separated by the basement 
membrane. The structure is depicted in figure 5. 
 
The hypodermis is made up of loose connective tissue and fat. 
The dermis mainly consists of fibroblasts, which produce collagen, elastin and structural 
proteoglycans to produce a tough and supportive cell matrix and also of 
immunocompetent mast cells and macrophages. The dermis also contains blood and 
lymphatic vessels, nerve fibers, sweat and sebaceous glands and hair roots. Dermal 
fibroblasts are derived from mesenchymal stem cells and are not fully differentiated 
cells60. Unlike other fibroblast cell types, dermal fibroblasts are far less likely to 
differentiate, which makes them popular cell models in all kinds of different research 
areas. 
The epidermis mainly consists of keratinocytes and there are four distinct epidermal layers 
with characteristic physical appearances and functions (reviewed in Lacouture 200658). 
From inside to outside there are the stratum basale (mainly keratinocyte stem cells, also 
melanocytes and Merkel cells), stratum spinosum (mainly differentiating keratinocytes, 
also immune cells like Langerhans cells), stratum granulosum (mainly keratinocytes who 
start to flatten and whose cytoplasm appears granular) and stratum corneum 
(keratinocytes become non-viable, cornified cells known as corneocytes). The later 
functions as protective barrier for the body and consists of structural proteins like 
involucrin and loricrin. Keratinocyte stem cells are present in the stratum basale and allow 
the epidermis to constantly renew61. These stem cells generate keratinocytes which exit 
the basal layer, stop growing and instead differentiate and migrate towards the skin 
surface, where they finally lose their nucleus and fuse to squamous sheets before being 
shed from the surface. The epidermis is completely renewed within around 48 days62. 
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Figure 5 Structure of human skin 
The human skin consists of three layers: the hypodermis, the dermis and the outermost epidermis. 
Dermis and epidermis are separated by the basement membrane. The hypodermis is mainly 
composed of lose connective and adipose tissue. The dermis is mainly composed of fibroblasts, 
which produce collagen, elastin and structural proteoglycans to produce a tough and supportive 
cell matrix and it also contains structures like blood and lymphatic vessels and hair roots. The 
epidermis mainly contains keratinocytes and is composed of four distinct layers: stratum basale, 
stratum spinosum, stratum granulosum and stratum corneum. EGFR is mainly expressed in the 
basal cell layer and the directly adjacent layers of the stratum spinosum. Figure adapted from 
Lacouture 200658. 
Abbreviations: EGFR, epidermal growth factor receptor. 
 
 
The proliferation, differentiation and migration of keratinocytes are highly regulated by 
numerous growth factors and cytokines. EGFR is mainly present in the basal cell layer 
and the directly adjacent layers of the stratum spinosum and EGFR signaling has been 
shown to be especially important in this regulation63. EGFR knockout mice lacking EGFR 
especially in the epidermis (EGFRΔep) show a phenotype of impaired epidermal 
stratification, skin inflammation and hair follicle abnormalities64. In adult EGFRΔep mice 
elevated numbers of keratin 1-positive suprabasal layers of cells were detected, indicating 
epidermal hyperplasia. In addition, the terminal differentiation marker loricrin, which 
should normally mainly be found in the stratum corneum, was also detected in the basal 
layer. Taken together, EGFRΔep mice show deregulated growth and differentiation of 
keratinocytes and therefore impaired stratification of the epidermis. 
During treatment with an EGFRI, EGFR signaling is also blocked in epidermal cells, 
resulting in growth arrest of basal keratinocytes and premature differentiation. However, 
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so far it has not been elucidated which specific pathways of the various EGFR-triggered 
pathways and which signaling proteins in particular are involved in keratinocytes. 
Decreased EGFR signaling also leads to increased production of pro-inflammatory 
cytokines (via various pathways which under normal conditions are probably blocked via 
pathways involving active EGFR). Among other cytokines, increased levels of CCL2, 
CCL5 and CXCL10 have been found upon EGFRI treatment in skin biopsies from patients 
as well as in cultured keratinocytes and mice58,64. These cytokines cause vasodilation and 
edema and recruit immune cells like dendritic cells, neutrophils and T lymphocytes which 
release enzymes causing loss of intercellular attachments of keratinocytes and apoptosis 
of epidermal cells. These cellular processes cause the typical clinical manifestations of 
EGFRI-induced skin toxicities. 
 
 
I.7  Criteria for selection of biomarker candidates 
The criteria for selection of molecules as biomarker candidates for this study were existing 
literature data about an effect on the function of EGFRIs or on the regulation of EGFR 
itself as well as known expression/function in skin cells. 
 
The EGFR ligand amphiregulin (AREG) is particularly interesting with regard to EGFRI-
induced skin rash because of its pivotal role in skin homeostasis 65. It was found to be the 
most abundant EGFR ligand present in cultured human keratinocytes with over 19 times 
more messenger RNA (mRNA) and over seven times more soluble protein than any of the 
other ligands 47. In the same study neutralization of AREG with specific antibodies 
resulted in significant inhibition of keratinocyte proliferation and decreased 
phosphorylation of ERK, which was not the case for antibodies against the other ligands, 
illustrating the importance of AREG in normal keratinocyte growth. In addition, Rittié and 
colleagues have shown that induction of AREG (by retinoids) leads to activation of EGFR 
and an increase in proliferation of human keratinocytes, which in turn can lead to 
hyperplasia of the epidermis 66. Ishikawa et al. previously also observed a significant 
correlation between high serum concentrations of AREG and poor response to gefitinib in 
patients with NSCLC67. Because of these observations it is conceivable that AREG could 
be involved in the development of EGFRI-induced skin rash and the plasma/serum 
concentration of AREG might serve as a reliable prognostic or maybe even a predictive 
biomarker specific for the efficacy of EGFRI therapy. 
 
The cytokine hepatocyte growth factor (HGF) has also been shown to influence the 
function of EGFRIs. It is a direct ligand of the receptor tyrosine kinase MET but has been 
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found to induce resistance to EGFRIs and is therefore thought to be able to influence 
EGFR signaling indirectly, via cross-talk of signaling pathways 68. Activation of the MET 
receptor can in turn activate the PI3K/Akt, RAS/RAF/MAPK, STAT3/JNK and PLCγ1 
pathways (reviewed in 69). HGF/MET signaling mediates disruption of cadherin-based 
contacts between cells resulting in cell motility and can also induce proliferation and 
survival of cells 70-72. A synergistic effect of MET and EGFR activation on cell proliferation 
and motility of NSCLC cells has been found, as well as a synergistic effect of MET and 
EGFR inhibition on apoptosis 73. This suggests a cross-talk between the two pathways. In 
addition, Hammond and colleagues found a high degree of overlap of effector molecules 
which were phosphorylated (indicating activation) by EGF and HGF 74. 
The role of dysregulated HGF/MET signaling in tumorigenesis and especially in invasive 
growth and metastasis has been intensively studied 75-78. However, little is known about 
the influence of HGF on EGFRI therapy and its role in the development of EGFRI-induced 
skin rash. First associations of serum levels of HGF with EGFRI-induced skin toxicity have 
been found in a small cohort (n = 103) of metastatic colorectal cancer patients (inverse 
correlation) by Takahashi and colleagues in 2015 79. Therefore, HGF was selected as 
biomarker candidate for EGFRI efficacy here. 
 
Interesting literature data with regard to a role in EGFR regulation has also been found for 
vitamin D. A putative vitamin D responsive element (VDRE) has  
been found in the EGFR promoter region (GGGTCCAGAGGGGCA), which has high 
sequence similarity to a known functional VDRE in the human osteocalcin gene 
(GGGTGAACGGGGGCA) and was shown to bind vitamin D in electrophoretic mobility 
shift assays 80-82. Another VDRE has been found in intron 1 of the EGFR gene 
(AGTTGAATAAGTTGA) and its functionality was confirmed in gene reporter analyses in 
ovarian cancer cells83. 
An increasing effect of the main metabolite of vitamin D, called cholecalcitriol 
(1α,25(OH)2D3) on EGFR mRNA levels has been observed in osteoblast-like cells80 and a 
decreasing effect in some breast cancer cells82. These results from previous studies 
concerning the effect of 1α,25(OH)2D3 on EGFR suggest that vitamin D might also play a 
role in cancer therapy involving EGFRIs. 
There are two types of vitamin D, vitamin D2 (ergocalciferol) and D3 (cholecalciferol). 
Vitamin D3 is mainly (85%) produced in the skin from 7-dehydrocholesterol by ultraviolet-B 
light and gets transported to the liver where it is hydroxylated to cholecalcidiol (also called 
25-hydroxyvitamin D3, 25(OH)D3 or 25-OH-vitamin D3) by 25-hydroxylases. The 25(OH)D3 
is the storage form of vitamin D3. It is transported to the kidney and is further hydroxylated 
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by 25-hydroxyvitamin D3-1α-hydroxylase to yield the hormonally active metabolite 
cholecalcitriol (1α,25(OH)2D3). 
In this context it is also interesting that the enzyme 25(OH)D3-1α-hydroxylase is not just 
expressed in the kidney but also at several extrarenal tissues, including skin (basal 
keratinocytes and hair follicles)84. Therefore, local conversion of 25(OH)D3 into the active 
metabolite 1α,25(OH)2D3 is possible in skin cells and it has been shown in vitro as well as 
in vivo that human keratinocytes can produce substantial amounts of active 
1α,25(OH)2D385,86  Therefore, it is conceivable that vitamin D might has an influence on 
EGFR signaling in skin cells and could affect the development of EGFRI-induced skin 
rash and was chosen as biomarker candidate in this study. 
 
 
I.8  Epigenetics and functional gene regulation in association with EGFRI 
efficacy 
MiRNAs are short RNA molecules, which do not encode proteins but can regulate gene 
expression at the post-transcriptional level. They play a role in nearly every biological 
pathway87. 
 
 
I.8.1 MiRNA biogenesis 
MiRNA biogenesis is depicted in figure 6. MiRNA molecules are 19 to 25 nucleotides (nt) 
long and can bind to partially complementary sequences in the 3’ untranslated region 
(UTR) of mRNA molecules. They are transcribed as primary transcripts called pri-miRNAs 
and then excised by the RNase Drosha to produce so called pre-miRNAs, which are 
hairpin-containing miRNA precursors with a length of 60 to 110 nt88. The pre-miRNA 
molecules are exported to the cytoplasm and subsequently processed to yield mature 
duplex miRNA molecules. One of the two strands of these duplex miRNA molecules - the 
guide strand - is loaded into the RNA-induced silencing complex. The other strand - the 
passenger strand - can also be incorporated but at a lower frequency89,90. It is currently 
unclear at which point of the miRNA biogenesis pathway regulation is most important and 
has the greatest influence on miRNA-mediated epigenetic regulation. Therefore, in 
addition to the mature miRNA molecules, the precursor miRNAs will be included in the 
analyses in this study as well. 
Upon binding of their target mRNA molecules (with partially complementary sequence in 
the 3’ UTR), miRNAs can either mechanically block translation or facilitate mRNA 
degradation. The identification of targets of individual miRNAs has been the subject of 
innumerable studies and it has been learned that the impact of certain miRNAs on certain 
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target mRNAs can differ substantially under different conditions, like cell and tissue type, 
developmental stage and stress (including treatment with pharmaceutical substances). 
 
 
 
Figure 6 MiRNA biogenesis 
MiRNAs are transcribed as primary transcripts called pri-miRNAs. These transcripts are excised by 
the RNase Drosha and its cofactor DGCR8 and hairpin-containing pre-miRNAs are produced 
(length: 60 to 110 nt). Pre-miRNAs are exported to the cytoplasm by exportin-5 and processed by 
Dicer to yield mature duplex miRNAs. One of the two strands (length: 19 to 25 nt) is loaded into 
RISC. Upon binding of their target mRNA molecules with partially complementary sequence in the 
3’ UTR, miRNAs can either mechanically block translation or facilitate mRNA degradation. 
Abbreviations: miRNA, micro ribonucleic acid; mRNA, messenger ribonucleic acid; nt, nucleotides; 
RISC, ribonucleic acid-induced silencing complex; UTR, untranslated region. 
 
 
The database miRBase, which provides a searchable online repository for published 
miRNA sequences (Griffiths-Jones laboratory, Faculty of Life Sciences, University of 
Manchester, UK)91,92, contains 28645 entries of hairpin precursor miRNAs, which express 
35828 mature miRNA products and are found in 223 different species (data of version 21, 
released in June 2014). 
Each distinct miRNA has a name/identifier. The first three letters indicate the organism, 
e.g. hsa for human or mmu for mouse. Since in this thesis only human miRNAs are 
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discussed, the “hsa” will be omitted when naming the miRNAs. The mature miRNA is 
designated miR-x in the miRBase database and in the majority of publications, with x 
being a unique sequential number. On the other hand, mir-x refers to the miRNA gene as 
well as to the predicted stem-loop portion of the primary transcript (hairpin miRNA). 
Different precursor sequences and genomic loci which express identical mature miRNA 
sequences are named in the form hsa-mir-x-1 and hsa-mir-x-2. Lettered suffixes denote 
closely related mature sequences, e.g. hsa-miR-34a and hsa-miR-34b. If there are two 
~22nt sequences miRNAs which originate from the same predicted precursor, the 
predominantly expressed mature miRNA receives the name of the form miR-x while the 
other miRNA produced from the opposite arm of the precursor is named miR-x*. In case 
that it is unclear which product is the more abundant one, names like miR-x-5p (from the 
5' arm) and miR-x-3p (from the 3' arm) are assigned. 
 
 
I.8.2 MiRNAs as biomarkers 
Numerous studies indicate that the deregulation of miRNA biogenesis and activity plays 
an important role in development and progression of cancer. Such deregulation can for 
example occur through genomic alterations like deletions93 or mutations (e.g. collected in 
the database SomamiR94) or through aberrant miRNA processing95. 
 
Several miRNAs have also been found to drive cancer development, maintenance or 
metastasis by regulating EGFR signaling pathways. In addition, certain miRNAs were 
shown to increase resistance to EGFRIs. MiR-21 for example targets negative regulators 
of EGFR pathways, namely PTEN, Pdcd4 and Spry96. MiR-34 is known to target the 
receptor tyrosine kinase MET as well as cell-cycle related proteins96. It can inhibit invasive 
growth induced by MET, which was shown in breast97, lung98 and colon99 cancer. In 
hepatocellular cancer cells, treatment with miR-34a together with the MET inhibitor 
SU11274 led to decreased cell proliferation and induction of apoptosis. In addition, 
administration of miR-34 to mice with adenocarcinomas, showing mutations in the Kras 
and p53 genes and resistance to previous therapy, reduced lung tumor initiation and 
progression100. In certain tumors miR-7 was found downregulated and studies showed 
that it can directly target EGFR and some of its downstream proteins and under normal 
conditions negatively regulates EGFR signaling, thereby inhibiting tumorigenesis and 
metastasis. In colorectal cancer patients, low expression of miR-7 was an independent 
prognostic factor for poor survival101. Interestingly, in KRAS mutant, cetuximab resistant 
colorectal cancer cell lines, miR-7 also enhanced susceptibility to cetuximab. In addition, 
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in a different study about head and neck cancer, miR-7 rendered erlotinib-resistant cells 
susceptible to growth inhibition by erlotinib102.  
These results suggest miRNAs as promising targets in cancer therapy, either as direct 
anti-cancer agents or as supportive treatment to enhance efficacy of other anti-cancer 
drugs, e.g. EGFRIs and also indicate that miRNAs might be promising candidates as 
biomarkers, not just as prognostic ones for cancer outcome but also as predictive ones for 
efficacy of certain therapies, especially with EGFRIs. 
 
Since single miRNAs typically have various target genes, they can be seen as kind of 
master regulators of gene expression and they might be more stable biomarkers for 
efficacy of certain drugs than their target mRNAs or proteins90. 
It is hypothesized that in tumor tissues miRNA profiles are probably highly variable and 
subject to constant changes as the tumor grows and develops. In healthy peripheral 
tissues, e.g. in the skin, miRNA profiles might be more stable and therefore more suitable 
to find reliable biomarkers. Those networks of miRNAs which are essential for cell survival 
and functioning will most likely stay intact, even in tumor cells. Hence, those miRNAs with 
essential functions for successful EGFR signaling in skin cells will probably also be 
comparably expressed in tumor cells which are dependent on EGFR. Therefore, it is 
suggested that miRNA biomarkers predictive for EGFRI efficacy might be identifiable in 
skin cells. 
Since to date very little data about potential candidates for such miRNA biomarkers from 
skin cells exists in the literature, we decided to perform a screening of miRNA profiles in 
skin cells with different phenotypes of in vitro sensitivity towards erlotinib, in order to 
identify suitable candidate miRNA biomarkers for efficacy of EGFRIs in this study. 
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Chapter II: Previous work and aim of the project 
 
II.1  Previous work of the research group 
Based on data from the Dermatoxgen study (described in chapter III.2.1.1) the following 
results have been obtained and published prior to this work: 
 
Fuerst et al. 2012103 
A possible immunological role for EGFRIs in addition to direct antagonistic downstream 
effects was investigated by analyzing different polymorphisms in HLA genes. A 
significantly lower incidence of skin rash was found in patients carrying the HLA-A*02:01 
or HLA-A*03:01 alleles; however, no association with worse survival was observed. 
 
Parmar et al. 2013104 
A significant association between the EGFR 497 G/A variant and the occurrence of skin 
toxicity was observed (common 497 G/G genotype: significantly more often skin toxicity 
than with at least one A-allele). In addition, the EGFR -216/-191 GC haplotype and the 
PIK3CA haplotype H4 were correlated with decreased occurrence of skin toxicity.  
 
Hasheminasab et al. 2015105 
To identify genomic variants in the EGFR pathway and in cytokines predisposing to skin 
toxicity, EGFR and inflammatory pathway genes were analyzed by deep sequencing. 
1437 single nucleotide polymorphisms (SNPs) were found in the target region. Three 
SNPs in EGFR intron 1 were found exclusively in patients without skin rash and an EGFR 
intron 23 SNP was associated with skin rash, OS and interleukin-8 plasma concentrations.  
 
Paul et al. 2014106 
Potential protein biomarkers measured in serum samples of the Dermatoxgen patients 
were examined. It was shown that low serum concentrations of interleukin-8 were 
associated with increased severity of EGFRI-induced skin rash and prolonged OS. 
 
Steffens et al. 2016107 
As marker for individual drug metabolism the metabolic ratio of erlotinib/O-desmethyl-
erlotinib in serum from Dermatoxgen patients was found to be correlated with severity of 
skin rash and PFS as well as OS.  
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II.2  Aim of the project 
The occurrence and severity of the typical skin toxicity which is induced as an adverse 
reaction by EGFRIs have been shown to be correlated with prolonged OS and PFS of 
patients37-39. However, since the rash is a disturbing side effect for the patients, it is often 
treated with topical or systemic medication (corticosteroids, antibiotics, antihistamines)42. 
Hence, its severity may be suppressed, rendering it unsuitable as a clinical predictive 
marker in EGFRI therapy. Therefore, rapidly determinable predictive biomarkers for the 
severity of EGFRI-induced skin rash would be helpful to allow early preventive treatment 
of the rash while at the same time still allowing prediction of EGFRI efficacy. Such 
biomarkers might indicate whether clinicians should intensify therapy and monitoring (e.g. 
by more frequent tumor imaging).  
Since previous work revealed evidence for genetic, pharmacokinetic and cytokine 
markers, the intention to my work was to identify functional biomarkers that are able to 
measure EGFR inhibition variability in the periphery, especially in blood plasma and skin 
cells. Therefore, molecules that interact with, regulate or functionally modulate EGFR 
inhibition were selected and determined in plasma or in keratinocyte and fibroblast culture. 
Since miRNAs have recently been shown to be important not just in mechanisms leading 
to the development of cancer but also in the response to cancer therapy, investigating the 
suitability of specific mature or precursor miRNA molecules as predictive biomarkers for 
the development of EGFRI-induced skin toxicity was of special interest. Suitable 
biomarkers should be easily and rapidly measurable and would save valuable time in 
determining the efficacy and safety of an EGFRI therapy for an individual patient. 
Since it has not been elucidated so far, which specific EGFR-triggered pathways and 
which signaling molecules in particular are the ones involved in the function of EGFRIs in 
keratinocytes or fibroblasts, characterization of the respective cell models with regard to 
phenotypes was also an important intermediate aim of this work. 
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Chapter III: Material and methods 
 
III.1  Material 
 
III.1.1 Instruments 
Instruments used in this study are listed by their field of application in table 1, including the 
suppliers. 
 
Table 1 Instruments used in this study, listed by field of application 
Instrument Supplier 
ELISAs  
Safire² microplate reader Tecan, Männedorf, Switzerland 
Thermomixer comfort MTP Eppendorf, Hamburg, Germany 
Cell culture  
Centrifuge 5702 R Eppendorf, Hamburg, Germany 
CO2 Incubator Binder, Tuttlingen, Germany 
Inverse light microscope Axiovert 
40C 
Zeiss, Oberkochen, Germany 
Laminar flow cabinet Herasafe Heraeus, Kendro, Hanau, Germany 
Gel electrophoreses  
Criterion™ gel chamber Bio-Rad, Hercules, USA 
PowerPac™ Universal Bio-Rad, Hercules, USA 
Western blots and 
phospho-kinase arrays 
 
Trans-Blot® SD Semi-Dry 
Transfer Cell 
Bio-Rad, Hercules, USA 
Imaging system Stella 3200 Raytest, Straubenhardt, Germany 
miRNA preparations  
Avanti J-26 XP Centrifuge Beckman Coulter, Krefeld, Germany 
Intelli-Mixer RM-2 L, Rotator and Vortex ELMI, Riga, Latvia 
Diana II digital CCD imaging system 
(height adjustable UV table) 
Raytest, Staubenhardt, Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5804 Eppendorf, Hamburg, Germany 
Mastercycler gradient Eppendorf, Hamburg, Germany 
Qubit® 2.0 Fluorometer Invitrogen™, Life Technologies, Carlsbad, 
USA 
Next generation sequencing  
2100 Bioanalyzer Agilent Technologies, Santa Clara, USA 
MiSeq® Sequencer Illumina®, San Diego, USA 
qRT-PCR  
LightCycler® 480 Roche Diagnostics, Mannheim, Germany 
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III.1.2 Kits 
All kits used in this study are listed by their field of application in table 2, including the 
suppliers. 
 
Table 2 Kits used in this study, listed by field of application 
Kit Supplier 
Cell culture  
Coating Matrix Kit Life Technologies, Carlsbad, USA (now 
Thermo Fisher Scientific) 
ELISAs  
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, Waltham, USA 
Cetuximab (Erbitux®) PK ELISA  Somru BioScience, Charlottetown, 
Canada 
Human Amphiregulin ELISA Kit Sigma-Aldrich, St. Louis, USA 
Human HGF Quantikine® ELISA Kit R&D systems™, Minneapolis, USA 
25-OH-Vitamin-D-ELISA  EUROIMMUN Medizinische 
Labordiagnostika AG, Lübeck, Germany 
Phospho-Erk1 (pThr202 / pTyr204) + Erk2 
(pTyr185/187) and pan-Erk1 / 2 ELISA Kit 
Sigma-Aldrich, St. Louis, USA 
Human/Mouse/Rat Phospho-c-Jun (S63) 
Cell-Based ELISA Kit 
R&D systems™, Minneapolis, USA 
Human Phospho-EGF R/ErbB1 (Y1068) 
Cell-Based ELISA 
R&D systems™, Minneapolis, USA 
Phospho-JNK (Thr183/Tyr185) Cell-Based 
ELISA Kit, human/mouse/rat 
PromoKine, PromoCell, Heidelberg, 
Germany 
Western blots and 
phospho-kinase arrays 
 
Proteome Profiler™ Human Phospho-
Kinase Array Kit 
R&D systems™, Minneapolis, USA 
miRNA preparations  
Qubit® RNA HS Assay Kit Life Technologies, Carlsbad, USA (now 
Thermo Fisher Scientific) 
NEBNext® Multiplex Small RNA Library 
Prep Set for Illumina® (Set 1) 
New England BioLabs, Ipswich, USA 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
Next generation sequencing  
Qubit® dsDNA HS Assay Kit Life Technologies, Carlsbad, USA (now 
Thermo Fisher Scientific) 
Agilent High Sensitivity DNA Kit Agilent Technologies, Santa Clara, USA 
MiSeq® Reagent Kit v2 (50 cycles) Illumina®, San Diego, USA 
qRT-PCR  
miScript II RT Kit Qiagen, Hilden, Germany 
miScript SYBR Green PCR Kit Qiagen, Hilden, Germany 
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III.1.3 Chemicals 
Chemicals used in this study are listed by their field of application in table 3, including the 
suppliers. 
 
Table 3 Chemicals used in this study, listed by field of application 
Chemical Supplier 
Various applications  
Dulbecco’s PBS w/o Magnesium, w/o 
Calcium, sterile 
Biowest, Nuaillé, France 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
Ethanol for molecular biology Merck, Darmstadt, Germany 
Erlotinib hydrochloride Santa Cruz Biotechnology, Dallas, USA 
Recombinant Human EGF Peprotech, Rocky Hill, USA 
Phospho-stop easypack phosphatase 
inhibitor cocktail tablets 
Roche Diagnostics, Mannheim, Germany 
Complete Ultra Tablets, mini easypack 
protease inhibitor cocktail tablets 
Roche Diagnostics, Mannheim, Germany 
Nuclease-free water Ambion, Life Technologies, Carlsbad, 
USA, (now Thermo Fisher Scientific) 
Cell isolation and culture  
Deoxyribonuclease I from bovine 
pancreas (DNase) 
Sigma-Aldrich, St. Louis, USA 
Trypsin from bovine pancreas Sigma-Aldrich, St. Louis, USA 
VLE-RPMI 1640 liquid medium (very low 
endotoxin) 
Biochrom, Merck, Berlin, Germany 
Fibroblast Growth Medium 2 including 
0.02 ml/ml fetal calf serum, 1 ng/ml FGF, 
5 µg/ml insulin 
PromoCell, Heidelberg, Germany 
EpiLife™ medium Gibco, Life Technologies, Carlsbad, USA 
(now Thermo Fisher Scientific) 
Human Keratinocyte Growth Supplement 
(HKGS), sterile 
Gibco, Life Technologies, Carlsbad, USA 
(now Thermo Fisher Scientific) 
Penicillin-Streptomycin solution 100x, 
sterile 
Biowest, Nuaillé, France 
Amphotericin B solution 250 mg/ml, sterile Sigma-Aldrich, St. Louis, USA 
FBS Superior Biochrom, Merck, Berlin, Germany 
TrypLE Express, no phenol red Gibco, Life Technologies, Carlsbad, USA 
(now Thermo Fisher Scientific) 
Trypan Blue solution Sigma-Aldrich, St. Louis, USA 
Cell-based phospho-ELISAs  
Formaldehyde solution Sigma-Aldrich, St. Louis, USA 
Gel electrophoreses for Western blots  
Laemmli Sample Buffer Bio-Rad, Hercules, USA 
β-mercaptoethanol Sigma-Aldrich, St. Louis, USA 
Precision Plus Protein WesternC 
Standards 
Bio-Rad, Hercules, USA 
10 x Tris/Glycerin/SDS (TGS) Buffer Bio-Rad, Hercules, USA 
Gel electrophoreses for miRNA  
 
 
 
41 
 
preparation 
Rotiphorese® 10x TBE Buffer Carl Roth, Karlsruhe, Germany 
Ethidium bromide aqueous solution 
10 mg/ml 
Sigma-Aldrich, St. Louis, USA 
Western blots   
10 x Tris/Glycerin Buffer Bio-Rad, Hercules, USA 
SDS solution 10 % Bio-Rad, Hercules, USA 
PVDF Membranes for Western Blotting Thermo Fisher Scientific, Waltham, USA 
Methanol  
Blotting Grade Blocker, Non Fat Dry Milk Bio-Rad, Hercules, USA 
10 x Tris Buffered Saline (TBS) Bio-Rad, Hercules, USA 
10 % Tween 20 Bio-Rad, Hercules, USA 
SuperSignal™ West Femto Maximum 
Sesitivity Substrate (Substrate A and B) 
Thermo Fisher Scientific, Waltham, USA 
miRNA preparations  
Wasserstoffperoxid 30 % (hydrogen 
peroxide) 
Carl Roth, Karlsruhe, Germany 
PeqGold TriFast™ Peqlab, VWR international, Erlangen, 
Germany 
Chloroform Sigma-Aldrich, St. Louis, USA 
2-Propanol Sigma-Aldrich, St. Louis, USA 
Sodium acetate (≥ 99%, p.a.) ACS Carl Roth, Karlsruhe, Germany 
Next generation sequencing  
Sodium hydroxide (ultra) Fluka Analytical, Sigma-Aldrich Chemie, 
Steinheim, Germany 
 
 
III.1.4 Gels 
Gels used for gel electrophoreses in this study are listed in table 4. 
 
Table 4 Gels used for gel electrophoreses in this study listed by field of application 
Gel Supplier 
Western blots  
Criterion™ Tris-HCl Gel (10–20% 
polyacrylamide gel, 12+2 well, 45 μl) 
Bio-Rad, Hercules, USA 
miRNA preparations  
Criterion™ TBE Gel (10% polyacrylamide 
gel, 18-well) 
Bio-Rad, Hercules, USA 
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III.1.5 Antibodies 
Antibodies used for Western blots in this study are listed in table 5. 
 
Table 5 Antibodies used for Western blots in this study 
Antibody Source Size Supplier Dilution 
used 
Primary     
anti-CK10 mouse 60 kDa Abcam, Cambridge, UK 1:1000 
anti-CK14 mouse 50 kDa Abcam, Cambridge, UK 1:100 
anti-involucrin mouse 120 kDa Abcam, Cambridge, UK 1:1000 
Secondary     
anti-mouse IgG 
poly-HRP 0.5 
mg/ml 
goat not 
specified 
Thermo Fisher Scientific, 
Waltham, USA 
1:20000 
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III.1.6 Primers 
All primers used for quantitative real-time polymerase chain reaction (qRT-PCR) in this 
study were ordered from Qiagen, Hilden, Germany and are listed in table 6. 
 
Table 6 Primer assays used in this study with respective target sequence (all supplied 
by Qiagen, Hilden, Germany) 
Primer assay Target 
(mir=stem loop, 
miR=mature) 
Hs_mir-7-1_PR_1 miScript Precursor Assay (MP00003500) hsa-mir-7-1 
Hs_mir-17_PR_1 miScript Precursor Assay (MP00001064) hsa-mir-17 
Hs_mir-30b_PR_1 miScript Precursor Assay (MP00001827) hsa-mir-30b 
Hs_mir-31_PR_1 miScript Precursor Assay (MP00008757) hsa-mir-31 
Hs_mir-34a_PR_1 miScript Precursor Assay (MP00002044) hsa-mir-34a 
Hs_mir-138-2_PR_1 miScript Precursor Assay (MP00000889) hsa-mir-138-2 
Hs_mir-146a_PR_1 miScript Precursor Assay (MP00000938) hsa-mir-146a 
Hs_mir-191_PR_1 miScript Precursor Assay (MP00001211) hsa-mir-191  
Hs_mir-200c_PR_1 miScript Precursor Assay (MP00001414) hsa-mir-200c 
Hs_mir-221_PR_1 miScript Precursor Assay (MP00001617) hsa-mir-221 
Hs_mir-382_PR_1 miScript Precursor Assay (MP00002177) hsa-mir-382  
Hs_mir-484_PR_1 miScript Precursor Assay (MP00002338) hsa-mir-484  
Hs_mir-494_PR_1 miScript Precursor Assay (MP00002408) hsa-mir-494  
Hs_mir-520e_PR_1 miScript Precursor Assay (MP00002716) hsa-mir-520e 
Hs_mir-944_PR_1 miScript Precursor Assay (MP00003801) hsa-mir-944  
Hs_miR-7-1*_1 miScript Primer Assay (MS00010535) hsa-miR-7-1-3p 
Hs_miR-31*_1 miScript Primer Assay (MS00009415) hsa-miR-31-3p 
Hs_miR-34a_1 miScript Primer Assay (MS00003318 ) hsa-miR-34a-5p 
Hs_miR-146a_1 miScript Primer Assay (MS00003535) hsa-mir-146a-5p 
Hs_miR-200c_1 miScript Primer Assay (MS00003752) hsa-miR-200c-3p 
Hs_miR-3182_1 miScript Primer Assay (MS00020909) hsa-miR-3182  
Hs_miR-4455_1 miScript Primer Assay (MS00041181) hsa-miR-4455  
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III.1.7 Special labware 
Special labware used in this study is listed by field of application in table 7, including the 
suppliers. 
 
Table 7 Special labware used in this study, listed by field of application 
Special labware Supplier 
Cell-based phospho-ELISAs  
Cell culture microplate, 96 well, PS; F-
bottom, µClear®, black, Cellstar®, TC 
Greiner Bio-One, Kremsmünster, Austria 
Cell culture  
Neubauer counting chamber 0.1 mm 
depth 
LO Laboroptik, Lancing, UK 
Tissue culture flasks 75 TPP, Trasadingen, Switzerland 
6-well tissue culture test plates TPP, Trasadingen, Switzerland 
miRNA preparations  
cell scrapers 30 cm, sterile TPP, Trasadingen, Switzerland 
Qubit® assay tubes, 500 µl Thermo Fisher Scientific, Waltham, USA 
Non-stick RNase-free 1.5 and 2 ml 
microfuge tubes 
Ambion, Life Technologies, Carlsbad, 
USA, (now Thermo Fisher Scientific) 
Spin-X centrifuge tube filter 0.45 µm 
cellulose acetate RNase/DNase free 
Corning Incorporated, Corning, USA 
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III.1.8 Software 
Software used in this study is listed by field of application in table 8, including suppliers. 
 
Table 8 Software used in this study, listed by field of application 
Software Supplier 
Various applications  
Excel™ 2010 Microsoft, Washington, USA 
Word 2010 Microsoft, Washington, USA 
Powerpoint™ 2010 Microsoft, Washington, USA 
Gimp 2.8.10 The Gimp-Team, www.gimp.org 
R v3.2.5 R Foundation for Statistical Computing, 
Vienna, Austria 
Linear and Nonlinear Mixed Effects 
Models (lnme) package for the R 
environment 
Pinheiro J et al. (2016)108  
ELISAs  
Magellan™ v 6.6 Tecan, Männedorf, Switzerland 
XFluor4 v 4.51 for Microsoft Excel™ Tecan, Männedorf, Switzerland 
Western blots and 
phospho-kinase arrays 
 
AIDA Image Analyzer Raytest, Straubenhardt, Germany 
Next generation sequencing  
2100 Expert Software (Bioanalyzer) Agilent Technologies, Santa Clara, USA 
Illumina® Experiment Manager 1.6 Illumina®, San Diego, USA 
Cutadapt 1.9 Marcel Martin 2011109 
Bowtie 1.0.1 John Hopkins University, Baltimore, USA 
Langmead 2009110 
DESeq 2, package for the R environment Love 2014111 
qRT-PCR  
LightCycler® 480 software release 1.5.0 Roche Diagnostics Mannheim, Germany 
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III.1.9 Databases 
Databases used in this study are listed by field of application in table 9. 
 
Table 9 Databases used in this study, listed by field of application 
Database Operator Website 
Next generation sequencing   
miRBase Griffiths-Jones lab, 
Faculty of Life 
Sciences, University 
of Manchester91,92 
http://www.mirbase.org 
PubChem Compound Database  National Center for 
Biotechnology 
Information 
https://pubchem.ncbi.nlm.
nih.gov/compound 
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III.2  Methods 
An overview of the methods which were used in the two parts of this work - the 
investigation of plasma biomarkers in patient samples from the Dermatoxgen cohort and 
the identification of epigenetic biomarkers in an in vitro cell model of keratinocytes and 
fibroblasts – is presented in figure 7. Details for each method are provided in the following 
chapters. 
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Figure 7 Overview of methods used for this study 
* Since the EGFR-ELISA was found not sensitive enough, a lysate based assay was tried for 
ERK1/2. [1] Somru Bioscience cetuximab ELISA user manual, [2] Sarstedt product catalogue. 
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III.2.1 Clinical study (investigations with patient plasma) 
 
III.2.1.1 Dermatoxgen study 
The Dermatoxgen study is a prospective, multicenter study which was conducted to 
investigate pharmacogenetic factors of skin toxicity induced by EGFRIs. For the patient 
case recruitment phase, the study received financial support by the Wilhelm Sander 
Stiftung (grant numbers: 2008.017.01 and 2008.017.2). The patient cohort included 
patients who received treatment with an EGFRI for cancer of different solid tumor types 
(pancreatic, colon, head and neck or lung cancer). Patients were included before they 
were first-time treated with an EGFRI (erlotinib, gefitinib, cetuximab or panitumumab). 
Written informed consent was obtained from all patients and the study was reviewed by 
the ethical boards of Ulm University and the Ludwig-Maximilians-University of Munich. 
Patients were recruited during the active recruitment period (2008-2014) at four different 
study sites, namely the Departments of Internal Medicine I (Prof. Dr. Thomas Seufferlein) 
and II (Prof. Dr. Christian Schumann, Dr. Stefan Rüdiger) at Ulm University, a 
hematology-oncology practice (Hämato-Onkologische Schwerpunkt-Praxis) in Ulm (Dr. 
Volker Kächele) and the Department of Internal Medicine III at the Klinikum Grosshadern, 
Ludwig-Maximilians-University of Munich (Prof. Dr. Stefan Böck, Prof. Dr. Volker 
Heinemann). 
 
Clinical assessment – performed by the clinicians at the study sites listed above 
Over the first four weeks of EGFRI treatment, the patients visited a physician once a week 
and the occurrence and severity of dermal adverse effects as well as diarrhea were 
documented together with any conducted treatments. The severity of skin toxicity was 
graded according to the Common Toxicity Criteria for Adverse Events of the American 
National Cancer Institute (NCI CTCAE version 3.0, 2006)112. 
 
Rash/desquamation 
Grade 1: Macular or papular eruption or erythema without associated symptoms  
Grade 2: Macular or papular eruption or erythema with pruritus or other associated 
symptoms; localized desquamation or other lesions covering < 50% of body 
surface area  
Grade 3: Severe, generalized erythroderma or macular, papular or vesicular eruption; 
desquamation covering ≥ 50% body surface area  
Grade 4: Generalized exfoliative, ulcerative, or bullous dermatitis 
 
 
General patient parameters were also determined including age, gender, body mass index 
(BMI) and smoking status. In addition, doses of administered EGFRIs and all other 
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medication were documented. At the fifth visit (four weeks after initiation of EGFRI 
therapy) a blood sample was drawn from each patient for genetic analyses and serum and 
plasma samples were generated at the respective study site. Blood samples were drawn 
directly before application of the next scheduled dose of the respective EGFRI. Follow-up 
visits were conducted at three, six and twelve months after start date of treatment to 
document PFS and OS of patients. 
 
Patients enrolled in the study were diagnosed with either of the following tumor types: 
pancreatic, colon, head and neck or non-small cell lung cancer. EGFRIs were 
administered in combination with different chemotherapeutic agents. Doses and 
application schemes of EGFRIs are listed in table 10. 
 
 
Table 10 EGFRI dosages and application schemes used in the Dermatoxgen study 
EGFRI Initial dose Application scheme dose 
erlotinib - daily 50, 100 or 150 mg 
gefitinib - daily 150 or 250 mg 
cetuximab 250, 400, 450 or 
500 mg/m² 
weekly (250 mg/m²) or bi-
weekly (500 mg/m²) 
250 or 500 mg/m² 
depending on application 
scheme 
panitumumab - bi-weekly (6 mg/kg body 
weight) or every three 
weeks (9 mg/kg body 
weight) 
6 or 9 mg/kg body weight 
depending on application 
scheme 
 
 
III.2.1.2 Enzyme-linked immunosorbent assays (ELISAs) with patient plasma 
An ELISA is an antibody-based detection assay for the quantitative measurement of a 
target substance. In this study different ELISA kits were used to quantify cetuximab, 
calcidiol, HGF and AREG in plasma samples of patients from the Dermatoxgen study. 
These ELISAs employ the quantitative sandwich immunoassay technique. 
 
Procedure 
ELISAs were conducted according to the respective manufacturer’s instructions. 
A capture antibody specific for the respective target protein had been pre-coated on a 96-
well plate by the manufacturer. Plasma samples were added to the wells and the target 
protein was bound by the immobilized antibody. Furthermore, different known 
concentrations of the target protein were added to some wells, so called standards. To 
some wells only buffer was added, so called blanks. After a washing step, a detection 
antibody was added which was specific for the target protein. The detection antibody was 
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either directly linked to an enzyme or it was biotinylated and in an additional step 
streptavidin was added which was in turn linked to an enzyme and bound to the biotin. 
After an additional washing step, a substrate solution was added and the enzyme 
catalyzed a reaction leading to color development. The amount of color is proportional to 
the amount of target protein present. A stop solution was applied and the intensity of the 
color was read with a microplate reader. Absorbance was also measured at a reference 
wavelength to correct for optical imperfections in the plate. 
 
Analysis 
Absorbance values measured at the reference wavelength were subtracted from the 
absorbance values measured at the target wavelength to correct for optical imperfections 
in the plate. If blanks had been included in the experiment their readings were also 
subtracted from the sample and standard readings to correct for unspecific signals 
originating from the reagents not the target protein. If replicates had been measured the 
mean absorbance was calculated for each set. A standard curve was plotted with 
standard concentration on the x-axis and measured absorbance on the y-axis. A four or 
five parameter curve fit was drawn. The concentration of target protein within the plasma 
samples could be calculated by inserting the measured absorbance values in the equation 
of the standard curve. The calculations were performed with the programs Magellan™, 
XFluor4 and R, as specified in the following table 11. 
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Table 11 Characteristics of the different protein ELISAs used in this study 
Target protein  Cetuximab Calcidiol (25-OH-vitamin D) Amphiregulin (AREG) Hepatocyte growth factor (HGF) 
ELISA kit Cetuximab (Erbitux®) PK ELISA, 
Somru BioScience 
25-OH-Vitamin-D-ELISA, 
EUROIMMUN Medizinische 
Labordiagnostika AG 
Human Amphiregulin ELISA Kit, 
SIGMA-ALDRICH 
Quantikine® ELISA Human HGF, 
R&D systems 
Replicates (samples) Duplicates Duplicates Duplicates Duplicates 
Concentrations of 
standards [ng/ml] 
156, 312, 625, 1250, 2500, 5000, 
7500, 10000 
0, 4, 10, 25, 60, 120 16.46, 49.38, 148.1, 444.4, 1333, 
4000 
125, 250, 500, 1000, 2000, 4000, 
8000 
Capture antibody Monoclonal anti-cetuximab 
antibody 
Monoclonal antibody specific for 
cholecalcidiol and ergocalcidiol 
Anti-amphiregulin antibody Monoclonal anti-HGF antibody 
Detection antibody Polyclonal anti-cetuximab antibody 
linked to an enzyme 
Enzyme-linked streptavidin Biotinylated anti-amphiregulin 
antibody 
Polyclonal anti-HGF antibody linked 
to an enzyme 
Enzyme Not specified Peroxidase Horseradish peroxidase linked to 
streptavidin 
Horseradish peroxidase 
Substrate 3,3',5,5'-tetramethylbenzidine (TMB) 
Target wavelength 450 nm 
Reference wavelength 650 nm 640 nm 540 nm 540 nm 
Curve fit 4-parameter curve fit 
Calculations Absorbance was measured using the program Magellan™. All 
calculations including subtraction of reference absorbance, calculation of 
mean values from duplicates, plotting of standard curves, drawing of 
curve fits and determination of target protein concentrations were 
performed automatically by the software Magellan™. 
Absorbance was measured using the program XFluor4. Subtraction of 
reference absorbance and calculation of mean values from duplicates 
was conducted in MS-Office Excel™. Plotting of standard curves, 
drawing of curve fits and calculation of target protein concentrations were 
conducted with the lnme package in the R environment for statistical 
techniques. 
Assay specialities 
  
Unlabeled calcidiol in the samples 
and biotin-labeled calcidiol 
specifically added to the wells 
compete for binding sites of the 
capture antibodies. 
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III.2.2 Cell model (experiments with cells from healthy human donors) 
 
III.2.2.1 Isolation of primary human keratinocytes 
Primary adult human keratinocytes were isolated from excess skin obtained from plastic 
surgery at the University Women’s Clinic Bonn (Universitätsfrauenklinik). The skin was 
kindly provided by the working group of Prof. Dr. med. Dr. ès sci. Thomas Bieber at the 
Dermatology and Allergology Department (Klinik und Poliklinik für Dermatologie und 
Allergologie). Within the same group, Dr. Kazumasa Iwamoto and Tim Stroich prepared a 
0.4 mm split-thickness skin using an electric dermatome and washed the skin two times in 
phosphate buffered saline (PBS). 
 
The subsequent protocol was adapted from the one published by Aasen and Belmonte in 
2010113. The skin was incubated in 0.5 % trypsin in PBS with 1 % antibiotics and 
antimycotics (penicillin-streptomycin and amphotericin B) at 37 °C for 1 h with the 
epidermis facing up. The epidermis was peeled off from the dermis using forceps and the 
epidermis was cut into small pieces of approx. 1 cm². The pieces were transferred to a 
centrifuge tube containing 50 ml VLE-RPMI 1640 cell culture medium with 10 % fetal 
bovine serum, 1 % antibiotics and antimycotics and 100 U/ml DNase I. The solution was 
thoroughly resuspended and filtered through a cell strainer. The cells were washed two 
times with VLE-RPMI 1640 medium using centrifugation at 300 x g for 10 min each. The 
cells were counted in a Neubauer counting chamber and seeded at 4 x 105 cells per well 
of a 6-well plate in 2 ml EpiLife™ cell culture medium. This serum-free medium has a 
defined concentration of calcium chloride (60 µM) which slows down differentiation of 
keratinocytes while at the same time removing contamination of other cell types such as 
fibroblasts, because they do not grow well under these conditions. Prior to use, the 6-well 
plates were coated with type I collagen by adding 800 µl dilution medium and 8 µl coating 
matrix per well and incubating the plates at 22 °C for 30 min. Coating of the culture plates 
is important for maximum yield with initial seeding of cells but was found to be 
unnecessary during subsequent passages. After cell seeding the medium had to be 
changed after 3 days and subsequently every 2 to 3 days. Under these culture conditions 
it took several days before healthy colonies of cells were visible. Cells were not allowed to 
become more than 75 % confluent to prevent differentiation. Cell aliquots were frozen at a 
concentration of 1 to 1.5 x 106/ml in freezing medium (90 % fetal bovine serum + 10 % 
dimethyl sulfoxide [DMSO]). 
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III.2.2.2 Culturing of cells 
All cell culture work was carried out under a sterile laminar flow hood. 
 
In this project primary adult human epidermal keratinocytes and dermal fibroblasts were 
used for in vitro studies. Keratinocytes were obtained as described in section III.2.2.1 
Fibroblasts were obtained from healthy tissue by dermal excision from patients at the 
Clinical Pharmacology Department of the University Medicine Göttingen (kindly provided 
by Dr. med. Markus Schirmer). 
 
Cell stocks were stored in liquid nitrogen. Prior to any experiments, in our laboratory all 
cell cultures were routinely tested for contaminations with Mycoplasma. 
The medium used for culturing of keratinocytes was EpiLife™ supplemented with Human 
Keratinocyte Growth Supplement and for fibroblasts Basal Fibroblast Growth Medium 2 
supplemented with 0.02 ml/ml fetal calf serum, 5 µg/ml Insulin and 0.001 µg/ml fibroblast 
growth factor (FGF). Both types of media were also supplemented with penicillin-
streptomycin (x 1) and in addition the keratinocyte medium contained 250 ng/ml 
amphotericin B as an antimycotic. All cells were grown at 37 °C and 5 % CO2. The 
medium was changed every 2 to 3 days and cells were passaged every 7 to 10 days. 
 
For passaging, the medium was aspirated and the cells were washed with 10 ml PBS per 
flask. The cells were then incubated with 1 ml of the recombinant enzyme TrypLE Express 
for 5 min to detach them from the culture flask. 10 ml of fresh medium were added and the 
cells were transferred to 50 ml centrifuge tubes and centrifuged at 600 x g (keratinocytes) 
or 300 x g (fibroblasts) and room temperature (RT) for 5 min. The supernatant was 
discarded, the pellet resuspended in 10 ml PBS and centrifuged again as before. The 
supernatant was discarded and cells resuspended in 1 ml fresh medium. Living cells were 
counted by mixing 10 µl of cell suspension with 10 µl trypan blue, applying it to a 
Neubauer counting chamber and counting all cells which were able to exclude the blue 
dye indicating they were alive. Cells were seeded into fresh 75 cm² culture flasks at 
concentrations between 2 x 105 and 4 x 105 cells per flask.  
 
 
III.2.2.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed to achieve separation of denatured proteins according to their 
electrophoretic mobility, which is determined by their molecular weight. To exclude an 
influence of the proteins’ secondary and tertiary structures on the separation, proteins are 
denatured by applying heat (95 °C) which leads to destruction of hydrogen bonds and 
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disulfide bonds are reduced by using ß-mercaptoethanol. To ensure a similar relation 
between charge and size for each of the proteins, they are treated with SDS, which covers 
them and provides a negative charge. In an electric field the negatively charged proteins 
migrate through the polyacrylamide gel towards the anode. Small polypeptides migrate 
faster than larger ones resulting in separation of the proteins. This was necessary for later 
Western blot analyses. 
 
Procedure 
Cell lysates were prepared exactly as described in section III.2.2.6 (also using the lysis 
buffer from the Erk1/2 ELISA kit) but without any prior in vitro treatment. The 
concentration of total protein in the cell lysates was determined by a bicinchoninic acid 
assay as described by the manufacturer. To the total protein solution a mixture of Laemmli 
Buffer and ß-mercaptoethanol (1:20) was added to yield a concentration of 0.4 µg/µl. The 
Laemmli Buffer reduces disulfide bonds. The proteins were then denatured at 95 °C for 5 
min. The samples were cooled on ice for 1 min and 20 µl were loaded per wells of a 
ready-to-use 10-20 % tris-HCl gel. As a marker 10 µl of Precision Plus Protein WesternC 
Standards was added to one well. The gel chamber was filled with 1 x tris/glycerin/SDS 
(TGS) buffer containing 0.1 % SDS and the electrophoresis was run at 100 V for 20 min 
(stacking phase) followed by 200 V for 30 min.  
 
 
III.2.2.4 Western blot (tank-blot procedure) 
After electrophoretic separation the proteins were transferred to a polyvinylidene fluoride 
(PVDF)-membrane to allow for detection of certain proteins by specific antibodies. Protein 
transfer is achieved by placing a PVDF-membrane next to the gel containing the 
separated proteins and applying an electric field. The cathode has to be next to the gel 
and the anode next to the membrane allowing for the negatively charged proteins to 
migrate towards the anode and thereby being blotted onto the membrane. After protein 
transfer the free protein binding sites on the membrane have to be blocked, e. g. by 
incubating it in skim milk solution. The proteins of interest can then be detected by 
incubation with specific primary antibodies, followed by incubation with a secondary 
antibody coupled to an enzyme and subsequent addition of a chemiluminescent substrate 
and detection with an appropriate imaging system. 
 
Procedure 
A PVDF-membrane was incubated in methanol for 1 min for activation and then 
equilibrated in transfer buffer (150 ml 10 x tris-glycerin, 150 ml methanol, 1.5 ml 10 % 
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SDS). A complex was formed, consisting of the membrane and the protein gel with a filter 
paper and sponge on each side, which was then soaked in transfer buffer and blotting 
was performed in a blotting tank in transfer buffer for 60 min with a constant electric 
current of 350 mA. A cooling pack (-20 °C) was included in the tank during the run. The 
membrane was then blocked by incubation with 5% skim milk in wash buffer (tris buffered 
saline with 10% Tween 20 (1:200); TBS-T) for 1 h. The membrane was cut into three 
strips so it could be incubated with three different primary antibodies. The size of the 
target proteins was taken into account and the membrane was cut at the appropriate 
places with the help of the protein standard which had been run with the gel. The 
membrane strips were incubated overnight at 4 °C with gentle shaking with a primary 
antibody solution against the respective protein of interest diluted in TBS-T. For dilution 
factors for specific antibodies see table 5. On the next day the membranes were washed 
three times for 10 sec and then three times for 10 min each with TBS-T and then 
incubated with an HRP-conjugated secondary antibody solution diluted in 5% skim milk in 
TBS-T for 1 h at RT. The membranes were washed again as before and incubated with a 
chemiluminescent substrate (reagent A + reagent B 1:1) for 5 min. The protein bands 
were visualized with a chemiluminescent imaging system (CCD camera). Exposure time 
was varied for optimization of signal visualization. 
 
 
III.2.2.5 Human phospho-kinase array 
To investigate the influence of in vitro incubation with erlotinib and stimulation with EGF 
on the different EGFR signaling pathways in keratinocytes and fibroblasts, Proteome 
Profiler™ Human Phospho-Kinase Arrays were conducted with cell lysates. With this 
array relative levels of phosphorylation of 43 kinase phosphorylation sites and two related 
total proteins of EGFR signaling pathways are detected simultaneously. Higher amounts 
of phosphorylation correspond to stronger signaling activity and therefore indicate which 
pathways are most important in the different cell types. 
 
Procedure 
Primary adult human dermal keratinocytes and fibroblasts were cultured as described in 
section III.2.2.2. For each experiment three different treatment conditions were applied. 
Each treatment was carried out in duplicate. Therefore, six 75 cm² cell culture flasks were 
used per experiment. The cells were cultured to 75 % confluency. The cells were washed 
with PBS and starved for 2 h, meaning that the complete culture medium was replaced by 
supplement-free medium to reduce the presence of growth factors which could influence 
or mask the effect of erlotinib or EGF on the cells. Subsequently, to two flasks 10 µl of 10 
 
 
 
57 
 
mM erlotinib hydrochloride dissolved in 100 % DMSO were added resulting in a final 
erlotinib concentration of 10 µM and 0.1 % DMSO in the medium. Since DMSO can be 
harmful for cells, 10 µl of 100 % DMSO were added to the other four flasks (final 
concentration 0.1 %) to create equal DMSO conditions and rule out that possible effects 
seen later on are due to DMSO. All cells were incubated for 2 h and then stimulated with 
EGF. For stimulation, EGF was added to the erlotinib-containing flasks and two of the 
other flasks at a final concentration of 4 nM. All cells were incubated for 5 min. An 
overview of cell treatments is given in table 12. The concentrations of the substances 
were chosen according to previous experiments conducted by other members of our 
research group prior to my work. 
 
 
Table 12 Incubation and stimulation conditions for cells in human phospho-kinase arrays 
Abbreviated name of 
sample 
2 h incubation 5 min stimulation 
no treatment 
(negative control) 
medium with DMSO - 
EGF medium with DMSO 4 nM EGF 
erlotinib + EGF medium with 10 µM erlotinib in 
DMSO 
4 nM EGF 
 
 
After stimulation with EGF, the cells were detached from the flasks and counted as 
described before. Cells from the two flasks with equal treatment conditions were pooled. 
Cell lysates were prepared by solubilizing the cells at 1 x 107 cells/ml in the lysis buffer 
provided with the kit. The cells were properly resuspended and rocked gently at 4 °C for 
40 min. The samples were centrifuged at 14000 x g and 4 °C for 5 min to sort out the cell 
debris from the protein lysates. The supernatants were transferred to clean tubes and 
further used in the assay. The total protein concentration in the lysates was determined by 
bicinchoninic acid assay. 
 
In the phospho-kinase array kit nitrocellulose membranes are provided on which capture 
and control antibodies have been spotted in duplicate. A list of all target proteins of the 
capture antibodies with their relevant phosphorylation sites is given in table 13. 
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Table 13 Target proteins of the capture antibodies spotted on the nitrocellulose 
membranes of the Proteome Profiler™ Human Phospho-Kinase Arrays and their 
phosphorylation sites relevant for the array 
Target Phosphorylation 
site 
 Target Phosphorylation 
site 
p38α T180/Y182  STAT2 Y689 
ERK1/2 T202/Y204,  STAT5a Y694 
T185/Y187  p70 S6  
Kinase 
T421/S424 
JNK 1/2/3 T183/Y185,    
T221/Y223  RSK1/2/3 S380/S386/S377 
GSK-3α/β S21/S9  eNOS S1177 
p53 S392  Fyn Y420 
EGFR Y1086  Yes Y426 
MSK1/2 S376/S360  Fgr Y412 
AMPKα1 T183  STAT6 Y641 
Akt 1/2/3 S473  STAT5b Y699 
Akt 1/2/3 T308  STAT3 Y705 
p53 S46  p27 T198 
TOR S2448  PLC-γ1 Y783 
CREB S133  Hck Y411 
HSP27 S78/S82  Chk-2 T68 
AMPKα2 T172  FAK Y397 
β-Catenin -  PDGF Rβ Y751 
p70 S6  T389  STAT5a/b Y694/Y699 
Kinase  STAT3 S727 
p53 S15  WNK1 T60 
c-Jun S63  PYK2 Y402 
Src Y419  PRAS40 T246 
Lyn Y397  HSP60 - 
Lck Y394    
 
 
All reagents were brought to RT before use and prepared according to the manufacturer’s 
instructions. Samples were kept on ice prior to use. The phospho-kinase array is divided 
into two membranes (A and B) to decrease cross-reactivity and increase sensitivity. The 
membranes were placed into an 8-well multi-dish. Membrane A and B were placed in 
separate wells and 1 ml blocking buffer (1 x Array Buffer 1) was added to each well. The 
dish was incubated for 1 h at RT on a rocking platform shaker. After incubation the 
blocking buffer was aspirated. The cell lysate samples were prepared by using 200 µg of 
total protein and diluting it with blocking buffer to a final volume of 2 ml. 1 ml was then 
added to each membrane (A and B). A separate set of membranes A and B was used for 
each sample (no treatment, EGF and erlotinib + EGF; for treatment conditions see table 
12). The membranes were incubated overnight at 4 °C on a rocking platform shaker. 
Each membrane set was placed in a separate plastic container (A and B together in one 
container) and washed three times with 10 ml of 1 x Wash Buffer. During each washing 
step the membranes were incubated on a rocking platform shaker for 10 min. For each A 
membrane 20 µl of reconstituted Detection Antibody Cocktail A were added to 1 ml of 1 x 
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Array Buffer 2/3 and 1 ml of the mixture was added to each A membrane in the 8-well 
dish. The same was done for all B membranes but with reconstituted Detection Antibody 
Cocktail B instead of A. All membranes were incubated for 2 h at RT on a rocking platform 
shaker. The membranes were washed as before but this time corresponding A and B 
membranes were washed in separate containers to avoid cross-reactivity of the detection 
antibodies. 
Streptavidin-HRP was diluted with 1 x Array buffer 2/3 using the dilution factor on the label 
and 1 ml was added to each membrane in the 8-well dish. The membranes were 
incubated for 30 min at RT on a rocking platform shaker. The membranes were washed 
as before but this time corresponding A and B membranes were washed in the same 
container again. 
Excess buffer was drained from the membranes and they were placed on the lid of one of 
the wash containers. 1 ml of Chemi Reagent Mix was added to each set of membranes (A 
and B) and incubated for 1 min. The Chemi Reagent Mix was removed again and signals 
were detected using a chemiluminescent imaging system (CCD camera). 
 
Analysis 
The image analysis software AIDA was used to determine the pixel density for each spot 
on the membranes corresponding to the amount of the respective phosphorylated protein 
present in the sample. The signal values were exported to a spreadsheet program 
(Excel™). The average pixel density was calculated for each set of duplicate spots. The 
pixel density at a clear area of the membrane was used as a background value and 
subtracted from all sample values. The amounts of the different phosphorylated proteins 
were compared between the different samples (no treatment, EGF and erlotinib + EGF). 
 
 
III.2.2.6 Cell-based and lysate-based phospho-ELISAs 
Cell-based or lysate-based phospho-ELISAs were used to measure the relative amount of 
certain phosphorylated proteins in human primary fibroblasts or keratinocytes under 
different in vitro treatment conditions. For each protein to be analyzed there is an antibody 
specific for the phosphorylated protein and also a different antibody specific for the whole 
protein regardless of the phosphorylation status (pan-protein). Hence, the amount of 
phosphorylated protein present can be normalized to the total amount of that protein. 
 
Procedure 
For the cell-based ELISAs, cells were seeded into 96-well plates at a concentration of 1 x 
105 cells/ml. 100 µl of cell suspension were used per well. The cells were grown overnight 
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and then starved for either 2 or 20 h. The cells were then incubated with 5 or 10 µM 
erlotinib for 2 h and subsequently stimulated with 4 or 40 nM EGF for 5 min. For each 
experiment three different in vitro treatment conditions were used: no treatment, EGF and 
erlotinib + EGF (for details see table 12). All samples and conditions were used in 
triplicates on the plates. 
 
After stimulation the cells were fixed and permeabilized in the wells by replacing the 
culture medium with 100 µl of 4 % formaldehyde in 1 x PBS or Fixing Solution provided 
with the kit respectively and incubating them for 30 min at RT. For the lysate-based 
ELISAs instead of growing the cells directly in the 96-well plates they are grown in 75 cm² 
culture flasks as usual and after the desired treatment cell lysates are prepared and then 
used for the ELISA. In this study a phospho-Erk1/2 and pan-Erk1/2 ELISA was used as a 
lysate-based phospho-ELISA. These cell lysates were prepared exactly as described for 
the human phospho-kinase array in section III.2.2.5. The only changes in procedure were 
the use of the lysis buffer provided with this ELISA kit, which was mixed 1:2 with sterile 
water containing phosphatase and protease inhibitors (tablets dissolved according to 
protocol provided by the manufacturer) and cells were solubilized at a concentration of 4 x 
106 cells/ml. 
Primary anti-phospho- and anti-pan-antibody solution were added to each well. 
Depending on the assay, the primary antibody specific for the phospho-protein and the 
one specific for the pan-protein were either added to the same well or to separate ones. In 
the c-Jun and the EGFR assays the primary antibodies are derived from different species 
enabling the use of two different secondary antibodies without cross-reactivity. The two 
secondary antibodies are labeled with different enzymes and two spectrally distinct 
fluorogenic substrates can be used for detection. Therefore the measurement of phospho- 
and pan-protein could be performed in the same well. In the JNK assay the 
measurements were performed in separate wells. The cells were incubated with the 
primary antibodies overnight at 4 °C or for 2 h at RT, depending on the assay. Negative 
controls were also included, for which blocking buffer was added to the wells instead of 
primary antibody solutions. The cells were washed again and 50 µl of each secondary 
antibody solution were added per well and incubated for 2 or 3 h at RT. 
The cells were washed again with 1 x wash buffer or PBS and substrate solution was 
added to each well (c-Jun and EGFR assays: 75 µl of the first substrate; JNK assay: 100 
µl of substrate). Incubation times varied from 30 to 60 min depending on the intensity of 
the developing signal (rosy color). Incubation was conducted at RT and in the dark. For 
the c-Jun and EGFR assays 75 µl of the second substrate were then added to each well 
and incubated for further 30 min at RT in the dark.  
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Subsequently, for the c-Jun and EGFR assays fluorescence was measured with 
excitation at a wavelength of 540 nm and emission at 600 nm representing the amount of 
phosphorylated target protein in the cells and subsequently with excitation at 360 nm and 
emission at 450 nm representing the amount of total target protein. 
For the JNK assay after incubation with the substrate 50 µl of stop solution were added to 
each well and absorbance was measured at 450 nm with a microplate reader. The 
specific conditions for the different ELISA kits are presented in table 14. The programs 
XFluor4 and Excel™ were used for data collection and analysis. 
 
Analysis 
Depending on the assay type, mean absorbance or fluorescence values of the negative 
controls (no primary antibodies used) were calculated from the triplicate measurements 
and subtracted from each sample reading to correct for unspecific reactivity of the 
secondary antibodies.  
Following this correction, for the c-Jun and EGFR assays the amount of phosphorylated 
target protein was normalized to the amount of total target protein by dividing the 
phospho-value by the pan-value. From the normalized triplicate values the mean was 
calculated for each sample. 
For the JNK assay following the negative control correction, first the mean absorbance 
values were calculated for each triplicate set of sample readings. Afterwards the amount 
of phosphorylated target protein was normalized to the amount of total target protein by 
dividing the mean phospho-value by its corresponding mean pan-value for each sample. 
Normalized amounts of phospho-protein were compared between the different in vitro 
treatment conditions for each sample. 
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Table 14 Characteristics of the cell-based and lysate-based phospho-ELISAs used in this study 
Target protein  Phosphorylated c-Jun (S63) Phosphorylated JNK 
(Thr183/Tyr185) 
Phosphorylated EGFR (Y1068) Phosphorylated Erk1 (T202/Y204) 
and Erk2 (T185/187)  
ELISA kit Human/Mouse/Rat Phospho-c-Jun 
(S63) Cell-Based ELISA Kit 
Phospho-JNK (Thr183/Tyr185) 
Cell-Based ELISA Kit, 
human/mouse/rat 
Human Phospho-EGF R/ErbB1 
(Y1068) Cell-Based ELISA 
Phospho-Erk1 (pThr202 / pTyr204) 
+ Erk2 (pTyr185/187) and pan-Erk1 
/ 2 ELISA Kit 
Starvation time 2 h 20 h 2 h 2 h 
Erlotinib 
concentration for 
incubation 
5 µM 5 µM 10 µM 5 µM 
EGF concentration for 
stimulation 
4 nM 4 nM 40 nM 40 nM 
Conditions for 
blocking 
1 h, RT 1 h, 37 °C 1 h, RT No blocking 
Primary antibodies Rabbit anti-phospho-c-Jun (S63) Mouse anti-phospho-JNK 
(Thr183/Tyr185) 
Mouse anti-phospho-EGFR 
(Y1068) 
Rabbit anti-phospho-
Erk1(T202/Y204)/Erk2(T185/Y187) 
Mouse anti-c-Jun Mouse anti-JNK Goat anti-EGFR Anti-pan-Erk1/2 
Phospho- and pan-
protein measured in 
one well or separate? 
One well Separate wells One well Separate wells 
Secondary antibodies HRP-conjugated goat anti-rabbit 
IgG 
HRP-conjugated anti-mouse IgG 
HRP-conjugated donkey anti-
mouse IgG 
HRP-conjugated anti-rabbit IgG 
AP-conjugated goat anti-mouse IgG AP-conjugated donkey anti-goat 
IgG 
HRP-Streptavidin 
Substrates Fluorogenic substrate for HRP 3,3',5,5'-tetramethylbenzidine 
(TMB) 
Fluorogenic substrate for HRP 3,3',5,5'-tetramethylbenzidine 
(TMB) Fluorogenic substrate for AP Fluorogenic substrate for AP 
Incubation conditions Primary antibodies: 16 h, 4 °C 
Secondary antibodies: 2 h, RT 
Primary antibodies: 2h, RT 
Secondary antibodies: 3 h, RT 
Primary antibodies: 16 h, 4 °C 
Secondary antibodies: 2 h, RT 
Primary antibodies: 1 h, RT 
Secondary antibodies: 1 h, RT 
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III.2.2.7 Isolation of total RNA 
Total RNA was isolated from primary human dermal keratinocytes and fibroblasts by the 
guanidinium thiocyanate-phenol-chloroform extraction method developed by Chomczyński 
and Sacchi in 1987114. The chaotropic salt guanidine isothiocyanate is used to lyse the 
cells and denature proteins, which also leads to the inactivation of RNases. The aqueous 
samples containing the lysed cells are mixed with phenol and chloroform and centrifuged. 
This results in the formation of three phases. The proteins and hydrophobic lipids partition 
into the lower organic phase while the RNA remains in the upper aqueous phase and the 
DNA is found in the interphase. The aqueous phase contains the whole range of cellular 
RNAs including small RNAs. The RNA is precipitated with 2-propanol, washed with 
ethanol and dissolved in nuclease-free H2O. 
 
Procedure 
To avoid contamination with RNases, gloves were worn at all times during isolation of 
RNA and tubes used for preparation of reagents were rinsed with 3 % H2O2 and ultrapure 
water. 
 
For isolation of RNA cells were cultured in 6-well plates to a confluency of approx. 75 %. 
On the day of RNA isolation cells were starved for 2 h and then incubated for 2 h either 
with medium containing 5 µM erlotinib in DMSO or with medium only containing DMSO 
followed by stimulation with 4 nM EGF for 5 min. For an overview on the in vitro treatment 
conditions see table 12. Each condition was applied to four separate wells. 
 
After stimulation the culture medium was aspirated and wells were washed with 2 ml PBS 
each. 1 ml of peqGOLD TriFast™ containing guanidine isothiocyanate and phenol was 
added to each well and incubated for 5 min at RT. The cells were detached from the 
plates with cell scrapers and the cell solutions were transferred to microcentrifuge tubes. 
200 µl of chloroform were added per tube, vigorously shaken for 15 sec and incubated for 
5 min at RT. The samples were centrifuged at 12000 x g and 4 °C for 10 min. The upper 
aqueous phase was transferred to fresh tubes and 500 µl of 2-propanol were added per 
tube. The samples were incubated for 10 min on ice and then centrifuged at 12000 x g 
and 4 °C for 10 min. The supernatants were discarded and the pellets washed with 500 µl 
of 75 % ethanol each. The samples were centrifuged at 12000 x g and 4 °C for 5 min. The 
pellets were left to dry and dissolved in nuclease-free water. Replicate samples were 
pooled and the concentration of total RNA was measured with a fluorometer as described 
in section III.2.2.8. The total RNA samples were stored at -80 °C until further use. 
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III.2.2.8 Quantification of total RNA and DNA 
The concentration of total RNA and complementary DNA (cDNA) produced during library 
preparation for next generation sequencing (NGS) was determined with a fluorometer and 
specific RNA and dsDNA high sensitivity assays designed by the manufacturer of the 
instrument. The assays contained an advanced RNA- or dsDNA-selective dye, which only 
fluoresced when bound to their target. Each assay contained two standard samples. From 
the fluorescence values of these standards the instrument generated a standard curve 
and applied a curve-fitting algorithm (modified Hill plot) to obtain a line from which 
concentration values could be calculated for the samples. In a special thin-walled tube 1 µl 
of sample was mixed with 199 µl of the reagent and incubated for 2 min at RT. 
Fluorescence was then measured. 
 
 
III.2.2.9 Library preparation for next generation sequencing (NGS) 
In order to determine miRNA profiles of cells by NGS on the Illumina® platform, RNA 
transcripts have to be converted into barcoded cDNA libraries. The workflow consists of 3’ 
adapter ligation, hybridization of the reverse transcription primer, 5’ adapter ligation, 
reverse transcription, polymerase chain reaction (PCR) amplification and purification of 
the PCR amplified cDNA. During PCR amplification there is also a different index primer 
used for each sample to individually label each sample, allowing for multiplexing in later 
NGS runs. The maximal number of samples which can be included in one sequencing run 
is twelve. In addition, the cDNA originating from miRNA transcripts as opposed to other 
types of RNA has to be isolated by size selection on a poly acrylamide gel. 
 
Procedure 
All steps were conducted according to the manufacturer’s instructions. Between 400 and 
900 ng of total RNA were used per sample. 
 
For 3’ adaptor ligation 6 µl of input RNA (diluted with variable volumes of nuclease-free 
H2O for equal amounts of input RNA among samples) were mixed with 1 µl of 3’ adaptor, 
incubated for 2 min at 70 °C and transferred to ice. 10 µl of 2 x 3’ ligation reaction buffer 
and 3 µl of 3’ ligation enzyme mix were added and incubated for 1 h at 25 °C. 
To prevent adaptor-dimer formation, the reverse transcription primer was hybridized to the 
excess of 3’ adaptor resulting in double-stranded DNA molecules which are not substrates 
for the ligase used for 5’ adaptor ligation in the next step. For this hybridization 4.5 µl H2O 
and 1 µl reverse transcription primer were added to the samples, heated for 5 min at 
75 °C, transferred to 37 °C for 15 min and then incubated for 15 min at 25 °C. 
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For 5’ adaptor ligation the 5’ adaptor was denatured by incubating it at 70 °C for 2 min. 
Then 1 µl of denatured 5’ adaptor, 1 µl of 10 x 5’ ligation reaction buffer and 2.5 ml of 5’ 
ligation enzyme mix were added to the ligation mixture from before and the samples were 
incubated for 1 h at 25 °C. 
 
Reverse transcription was performed by adding 8 µl of first strand synthesis reaction 
buffer, 1 µl of murine RNase inhibitor and 1 µl of ProtoScript II Reverse Transcriptase to 
the adaptor-ligated RNA from before and incubating the samples for 1 h at 50 °C. 
 
PCR amplification was performed by adding 50 µl of LongAmp Taq 2 x master mix, 2.5 µl 
of SR Primer for Illumina®, 5 µl of H2O and 2.5 µl of one of twelve different indexed PCR 
primers to each cDNA sample and running the PCR reaction under the conditions listed in 
table 15. 
 
 
Table 15 PCR cycling conditions used for amplification of cDNA transcripts during library 
preparation for next generation sequencing on the Illumina® platform 
Cycle step Temperature Time Number of cycles 
Initial denaturation 94 °C 30 sec 1 
Denaturation 
Annealing 
Extension 
94 °C 
62 °C 
70 °C 
15 sec 
30 sec 
15 sec 
 
14 
Final extension 70 °C 5 min 1 
Hold 4 °C until further use  
 
 
The amplified cDNA was purified by use of a PCR purification kit with columns for DNA 
binding according to the manufacturer’s instructions. The PCR reaction mixture was mixed 
with 5 volumes of Buffer PB containing a pH indicator. If the samples turned purple 10 µl 
of 3 M sodium acetate with pH 5.0 were added. The yellow color indicated a pH of ≤ 7.5 
which was needed for optimal DNA binding to the columns. To elute the DNA from the 
columns, 30 µl of nuclease-free H2O were added to each column and the samples were 
incubated for 1 min at RT and then centrifuged again for 1 min. The cDNA samples were 
stored at -20 °C until further use. 
 
The purified cDNA was size selected on a 10 % polyacrylamide gel to isolate the adapter-
ligated constructs originating from miRNA transcripts as opposed to other types of RNA. 
For all subsequent steps tubes with low DNA and RNA binding properties were used (non-
stick tubes). 
 
 
 
66 
 
The wells of the ready-to-use gel were rinsed with 1 x TBE buffer and the gel was run 
without samples at 100 V for 20 min to remove residual gel pieces and salts from the 
wells. All twelve samples from one library preparation set were pooled (4 µl per sample) 
and 10 µl of 6 x loading dye were added. A small part of 5 µl of the mixture was added to 
one well of the gel for later cutting under UV-light (“cutting sample”). The rest of the 
mixture was distributed evenly into three wells of the gel. 5 µl of the marker Quick-Load 
pBR322 DNA-MspI Digest were added to two wells, one close to the “small cutting” 
sample and one close to the other samples. The gel was run at 100 V for 1.5 h. 
Subsequently, the gel was incubated with 50 ml of ultrapure H2O containing 4 µl of the 
nucleic acid stain ethidium bromide for 5 min in the dark to allow the stain to intercalate 
into the DNA allowing for fluorescent detection of DNA bands on the gel. The gel was 
rinsed with 50 ml of ultrapure H2O and the part of the gel containing the “cutting sample” 
was cut off from the rest of the gel and placed on a UV-light table. The marker served to 
identify the 140 bp DNA band representing the adapter-ligated constructs derived from the 
21 nucleotide-long miRNA transcripts. The band was cut out under UV-light. The “cutting 
sample” part of the gel was placed next to the rest of the gel again and the 140 bp band 
was cut out from the three sample lanes (without UV-light, meaning without seeing the 
bands) at the same height as from the “cutting sample”. This way UV-light was not used 
on the samples which could have altered the cDNA and affected further analyses. 
Each piece of gel was transferred to a 500 µl sample tube with small holes placed in a 
larger tube to serve as a strainer to shred the gel pieces. The samples were centrifuged in 
the strainers at 16,000 x g for 2 min. Each gel sample was mixed with 250 ml of gel 
elution buffer and rotated end-to-end for 2 h with shaking. The samples were centrifuged 
at 14,000 x g for 2 min in gel filtration columns and 1 µl of linear acrylamide, 25 µl of 3 M 
sodium acetate pH 5 and 750 µl of 100 % ethanol were added. The samples were 
vortexed and incubated at -80 °C for 45 min to precipitate the DNA. The samples were 
centrifuged at 14,000 x g and 4°C for 30 min and the resulting pellets were washed with 
400 µl of 80 % ethanol. After another centrifugation step as before the supernatants were 
discarded again and the pellets were left to dry before dissolving them in 6 µl of TE buffer 
each and pooling all three samples. The DNA concentration was measured as described 
in section III.2.2.8. 
 
 
III.2.2.10 Quality control and quantification of library cDNA 
The purified and size-selected cDNA libraries for NGS were quantified and purity and size 
of the cDNA molecules were checked on microfluidic chips with a bioanalyzer. A high 
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sensitivity DNA kit developed by the manufacturer of the instrument was used which 
covered a range of 50 – 7000 bp. 
With the bioanalyzer the sample components are electrophoretically separated according 
to their size. There is a fluorescent dye which intercalates into the DNA and whose 
fluorescence signals are translated into gel-like images and electropherograms. The 
usage of a DNA ladder and two markers allows for sizing of the cDNA samples.  
 
Procedure 
Dye-concentrate was added to a gel matrix vial (15 µl). The gel-dye mix was vortexed, 
applied to a spin filter and centrifuged at 2,300 x g for 10 min. A volume of 9 µl of the mix 
was loaded onto a high sensitivity DNA microfluidic chip and distributed evenly along all 
wells by leaving the chip in the chip priming station with the plunger pressed down for 1 
min. Gel-dye mix was loaded onto three more wells of the chip (9 µl each) and 5 µl of 
marker solution were added to the remaining twelve wells. The well designated to the 
ladder was filled with 1 µl of high sensitivity DNA ladder. Into the eleven sample wells 1 µl 
of sample or H2O (for unused wells) were added and the chip was vortexed at 2400 rpm 
for 1 min. The chip was run on the bioanalyzer. 
 
Analysis 
The quality of the run was checked by examining the amount, size and shape of the DNA 
ladder and marker peaks. The size, concentration and molarity of the sample components 
were determined by the bioanalyzer software. The peak for the correctly adapter-ligated, 
size-selected cDNA constructs was expected at 147 bp. The peak at this size was further 
examined with regard to its shape. A stand-alone, well-resolved peak represents a pure 
sample. A representative electropherogram for a keratinocyte library is presented in figure 
8. 
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Figure 8 Example of an electropherogram and gel-like image for a keratinocyte barcoded 
cDNA library used in a bioanalyzer analysis 
The size, quantity and purity of cDNA library constructs generated for next generation sequencing 
were analyzed on a microfluidic high sensitivity DNA chip with a bioanalyzer. Here an example 
electropherogram for a keratinocyte library is shown. A high sensitivity DNA ladder was used for 
size determination. The peak for correctly adapter-ligated, size-selected cDNA constructs is 
expected at 147 bp. To each sample and the ladder well there were also two markers added which 
are shown in green and purple here. Abbreviations: bp, base pairs; FU, fluorescence units. 
 
 
If the peak at 147 bp was the highest one and the molarity was at least 3 nM the sample 
was considered pure enough and suitable for NGS. 
 
 
III.2.2.11 Next generation sequencing (NGS) 
NGS was conducted on the Illumina® platform which uses sequencing by synthesis 
chemistry. In comparison to capillary electrophoresis sequencing, in NGS there is not just 
one DNA fragment sequenced at a time but millions of fragments in parallel. 
A specifically prepared cDNA library is loaded onto a flow cell which contains a lawn of 
oligonucleotides complementary to the library adapters. The library fragments are 
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captured on the flow cell as depicted in step 1 of figure 9 and bridge amplification results 
in the generation of clonal clusters as depicted in step 2 of figure 9. During the actual 
sequencing process a DNA polymerase catalyzes the incorporation of 
deoxyribonucleotide triphosphates (dNTPs) into DNA strands complementary to the cDNA 
fragments captured on the flow cell (see step 3 of figure 9). The dNTPs are labeled with 
fluorescent dyes (each of the four different dNTPs with a different dye) and bound to 
reversible terminators. The terminators allow for single sequential cycles of DNA 
synthesis. During each cycle the incorporated nucleotides are identified by fluorophore 
excitation and the signal is recorded as depicted in step 4 of figure 9. 
 
 
 
Figure 9 NGS method on the Illumina® platform 
On the Illumina® platform sequencing by synthesis chemistry is used for next generation 
sequencing. 1. Adapter-ligated fragments of a cDNA library are captured on the surface of a flow 
cell by capture oligonucleotides complementary to the adapters (cDNA fragments shown in grey, 
capture oligonucleotides in green and adapters in orange and yellow). 2. Clonal clusters are 
generated from the fragments by bridge amplification. 3. A DNA polymerase catalyzes the 
incorporation of fluorescently labeled dNTPs during synthesis of DNA strands complementary to 
the fragments of the clusters (dNTPs shown as circles in blue, green, red and yellow, each 
corresponding to one of the 4 possible bases contained; adenosine (A), cytidine (C), guanosine 
(G), thymidine (T)). The dNTPs are linked to reversible terminators allowing for single sequential 
cycles of DNA synthesis. 4. During each cycle of dNTP incorporation the incorporated base is 
identified for each cluster by fluorophore excitation and the signal is recorded. Figure modified from 
the MiSeq® user manual form Illumina®. 
Abbreviations: cDNA, complementary deoxyribonucleic acid; dNTP, deoxyribonucleotide 
triphosphate; NGS, next generation sequencing. 
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The determined sequencing reads can be aligned to a reference genome to allow 
identification of known sequences and in case of miRNA profiling the identified miRNAs 
can be counted for each sample. De-multiplexing is achieved by sorting the sequencing 
reads according to the attached indices. 
 
Procedure 
For NGS the library sample had to be denatured. A stock of 1.0 N NaOH was freshly 
diluted to a concentration of 0.2 N with ultra-pure H2O. The cDNA library sample was 
diluted to a concentration of 3 nM with TE buffer (from the library preparation kit) and 10 µl 
were mixed with 10 µl of 0.2 N NaOH for denaturation. The sample solution was vortexed, 
centrifuged at 300 x g for 1 min and incubated for 5 min at RT. A volume of 980 µl HT1 
Buffer was added to the sample. Subsequently, 500 µl of the resulting solution were mixed 
with 500 µl of HT1 Buffer for further dilution. Final concentrations in the sample were 15 
pM cDNA and 1 mM NaOH. Finally, 600 µl of the resulting solution were loaded onto the 
sequencing cartridge purchased from the manufacturer of the sequencer. The cartridge 
contained all reagents necessary for the sequencing run. 
A fresh flow cell was cleaned with 100 % ethanol and ultra-pure H2O and inserted into the 
sequencer. The cartridge and wash buffer were also loaded onto the sequencer. The 
sequencing run was performed with the program for small RNA and 36 cycles. 
 
Analysis 
After the sequencing run the MiSeq® Reporter software was used to generate fastq-files 
containing the determined sequence reads. For each of the twelve samples included in 
one sequencing run a separate file was generated. Some of the sequence reads still 
contained parts of the 3’ adapters ligated to the RNA transcripts during library preparation. 
These adapter sequences had to be trimmed to allow proper alignment to reference 
genomes. Adapter trimming was performed with the program cutadapt. Reads which were 
shorter than 15 bp after adapter trimming were discarded to minimize false positive 
alignment results. 
After adapter trimming, the sequencing reads were aligned to reference genomes using 
the program bowtie. First the reads were aligned to the whole human genome. Only those 
reads successfully aligned were used for further analysis. The reads were then aligned to 
published mature or precursor (hairpin) miRNAs collected in the miRBase data base. In 
figure 10 the alignment success is depicted, which also shows how well the library 
preparation and sequencing worked. The figure shows representative results from one 
sequencing run. For each sample contained in the run, the total number of reads is set to 
100 %.  
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Figure 10 Alignment success for reads determined by NGS from a keratinocyte library 
Representative results from sequencing run 2. After NGS performed with a cDNA library from 
keratinocytes (size-selected for miRNA), the determined reads were aligned to the whole human 
genome. Successfully aligned reads were then aligned to two different miRBase databases 
containing either published precursor (hairpin) or mature miRNAs. For each individual sample the 
number of total reads is set to 100 % (purple). Reads aligned to the human genome (green), 
hairpin miRNA (red) and mature miRNA (blue) are shown in % of total reads. Abbreviations: HK, 
human keratinocytes; NGS, next generation sequencing. 
 
 
In table 16 the alignment success is summarized for each sequencing run. The aligned 
reads in % are given as a range for each run, considering all twelve samples within each 
run respectively. 
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Table 16 Alignment success of reads determined by NGS for all sequencing runs 
(keratinocytes and fibroblasts) 
After NGS performed with cDNA libraries from keratinocytes or fibroblasts (size-selected for 
miRNA), the determined reads were aligned to the whole human genome. Successfully aligned 
reads were then aligned to two different miRBase databases containing either published precursor 
(hairpin) or mature miRNAs. For each sequencing run the number of total reads is given as a range 
(considering all twelve samples of that run). Reads aligned to the human genome are given as % of 
total reads. Reads aligned to hairpin miRNA or mature miRNA are given in % of reads aligned to 
the human genome. Abbreviations: FB, fibroblasts; HK, human keratinocytes; NGS, next 
generation sequencing. 
Sequencing 
run 
Samples included Total 
reads 
Human 
[% of total 
reads] 
miRNA 
hairpin 
[% of human] 
miRNA 
mature 
[% of human] 
Run 1, 
keratinocytes 
HK1, HK2, HK3, HK4 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
56270 - 
132828 
87 - 90 14 - 38 6 - 13 
Run 2, 
keratinocytes 
HK1, HK2, HK3, HK4 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
173456 - 
433721  
87 - 91 14 - 39 6 - 12 
Run 3, 
keratinocytes 
HK5, HK6, HK7, HK8 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
879837 - 
2274129 
92 - 95 30 - 54 13 - 24 
Run 4, 
keratinocytes 
HK9, HK10, HK11, HK12 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
189470 - 
526177 
76 - 78 40 - 58 14 - 22 
Run 5, 
fibroblasts 
FB57, FB64, FB99, FB136 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
1104763 - 
2701038 
92 - 95 24 - 39 14 - 26 
Run 6, 
fibroblasts 
FB76, FB79, FB80, FB93 
(each with incubation: 
none, EGF, and 
erlotinib+EGF) 
728592 - 
2317572 
92 - 94 18 - 43 10 - 26 
 
 
For each sample a list of identified mature and hairpin miRNAs was transferred to the 
spreadsheet program Excel™ and all reads were counted. 
The package DESeq2 for use with the statistical software environment R was used to 
normalize the read counts and determine specific mature or hairpin miRNAs which were 
differentially expressed between two groups of samples (e.g. untreated erlotinib-sensitive 
versus untreated erlotinib-insensitive cells). 
 
Some of the differentially expressed miRNAs identified with the DESeq2 program were 
chosen for further analysis. Those miRNAs which were significantly differentially 
expressed in the two groups of erlotinib-sensitive and -insensitive cells with a p-value < 
0.05 and a fold change ≥ 1.50 (up-regulated) or ≤ 0.66 (down-regulated) respectively, 
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were regarded as especially interesting. For a better overview, the overlap of significantly 
differentially expressed miRNAs (p < 0.05) between erlotinib-sensitive and -insensitive 
cells across all three different in vitro treatment groups (no treatment, EGF and EGF + 
erlotinib) was determined. Venn diagrams were prepared to visualize which specific 
miRNAs were significantly differentially expressed in all three treatment groups and 
therefore represent a “baseline” difference between erlotinib-sensitive and -insensitive 
cells (see figure 11). It was also determined, which miRNAs were only significantly 
differentially expressed in cells treated with erlotinib and therefore represent a difference 
in response to erlotinib in the sensitive as compared to the -insensitive cells. Numbers in 
overlapping parts of the Venn diagram circles represent the numbers of specific miRNAs 
which were significantly differentially expressed (p < 0.05) in both or all three treatment 
groups, respectively. 
 
 
 
 
Figure 11 Example of a Venn diagram used to visualize the overlap of differentially 
expressed miRNAs in erlotinib-sensitive as compared to -insensitive cells 
between different in vitro treatments 
Numbers in overlapping parts of the circles represent the numbers of specific miRNAs which were 
significantly differentially expressed (p < 0.05) in both or all three treatment groups, respectively. 
 
 
For the “overlap” miRNAs from all three treatment groups and the “erlotinib only” miRNAs 
a structured literature search was conducted (but with non-strict criteria) and publications 
concerning their roles in cancer and cancer therapy, association with EGFR or similar 
tyrosine kinases and erlotinib or other EGFRIs and specific functions in keratinocytes, 
fibroblasts and skin homeostasis were reviewed. Those miRNAs for which a role in the 
aforementioned areas had already been suggested in previous studies were chosen, to 
strengthen the evidence for them as suitable candidate miRNAs. Their differential 
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expression in erlotinib-sensitive versus -insensitive samples was validated using qRT-
PCR. The results of the literature search are presented in the appendix (table 38). Since 
pre-experiments had shown that greater differences in expression could be identified for 
precursor (hairpin) miRNAs than for mature miRNAs, in NGS as well as qRT-PCR, mainly 
Precursor Assays were chosen for analyses. Only for the most interesting miRNAs also 
the mature forms were tested. Those miRNAs whose expression was analyzed in 
keratinocytes by PCR were also investigated in fibroblasts and vice versa to determine 
potential differences in those two cell types. 
 
 
III.2.2.12 MiRNA expression analysis by quantitative real time polymerase chain 
reaction (qRT-PCR) 
Differential expression of candidate mature and precursor miRNA molecules determined 
by NGS was further analyzed using qRT-PCR with the miScript PCR system by Qiagen 
(Hilden, Germany). This system enables specific quantification of multiple mature as well 
as precursor miRNAs from a single cDNA preparation. Total RNA is used as starting 
material. Messenger RNA (mRNA) is reverse transcribed into cDNA using oligo-
deoxythymine (oligo-dT) and random primers. Mature miRNA, precursor miRNA and other 
noncoding RNA are not polyadenylated in nature, so the enzyme poly(A) polymerase has 
to be used for polyadenylation before reverse transcription, in order for the oligo-dT 
primers to be able to bind. The oligo-dT primers have a degenerate anchor at the 3’ end 
and a universal tag sequence at the 5’ end to ensure that later on only cDNA from miRNA 
and no genomic DNA is detected. 
For detection of specific mature and precursor miRNAs, qRT-PCR was performed with 
miScript Primer Assays and Precursor Assays each including a forward primer specific for 
the respective miRNA and a universal reverse primer. The DNA double strand dye SYBR 
Green was also needed for the quantification. Upon binding to the amplified PCR 
products, SYBR Green increases its fluorescence up to 1000-fold. A thermal cycler 
equipped with fluorescence detection modules can be used to monitor fluorescence 
during log-linear phase of PCR amplification. The measured fluorescence reflects the 
amount of amplified product in each cycle. The crossing point (CP) is the point at which 
there is enough PCR product accumulated to give a fluorescent signal above background. 
CP values correlate with the amount of PCR template and therefore are the basis for 
quantification. If there is a large amount of template at the start of the PCR reaction, 
relatively few amplification cycles will be needed for the fluorescent signal to rise above 
background. Hence, a low or early CP will be measured. In contrast, if a small amount of 
template is present, a high or late CP will be measured.  
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In order to correct for sample-to-sample variations, the amount of target miRNA has to be 
normalized by also quantifying the amount of an endogenous reference RNA within each 
sample. Here the small nuclear RNA (snRNA) RNU6B was used as reference RNA. 
 
Procedure 
Total RNA was isolated as described in section III.2.2.7. All reactions were set up on ice 
to prevent degradation of RNA. For reverse transcription a master mix was prepared using 
the reagents listed below. The amount of water added depended on the volume of 
template RNA which had to be added in the subsequent step (250 ng of template RNA 
were used per reaction). 
 
Reagent      Volume per reaction 
5x miScript HiFlex Buffer    4 µl 
10x miScript Nucleics Mix    2 µl 
miScript Reverse Transcriptase Mix  2 µl 
RNase-free water     variable 
Template RNA 250 ng (not added 
directly but in the subsequent step!)  variable 
 
Total volume      20 µl 
 
To each reaction (tube) the appropriate volume of template RNA was added 
(corresponding to 250 ng RNA) and the mixture was incubated at 37 °C for 60 min 
followed by 95 °C for 5 min to inactivate the transcriptase. As negative controls one 
sample containing no reverse transcriptase and one sample containing 5 µl H2O instead 
of the template RNA were included. 
 
For qRT-PCR the cDNA samples from the previous step were diluted 1:10 with RNase-
free water. A master mix was prepared using the reagents listed below. 
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Reagent      Volume per reaction 
2x QuantiTect SYBR Green 
Master Mix       12.5 µl 
10x miScript Universal Primer   2.5 µl 
10x miScript Primer 
or Precursor Assay     2.5 µl 
RNase-free water     variable 
cDNA 17 ng (not added directly 
but in the subsequent step!)    variable 
 
Total volume      25 µl 
 
Twenty-five (25) µl of the master mix were used per well of a 96-well plate and the 
appropriate volume of diluted cDNA was added to each well (corresponding to 17 ng 
cDNA). The plate was sealed with heat-sealing film and centrifuged at 1000 x g and RT 
for 1 min to remove bubbles. The following PCR program was run on a LightCycler® 480 
(Roche Diagnostics, Mannheim, Germany). 
 
 
Table 17 PCR program run in this study 
Step Cycles Temperature Time 
Initial activation step 
(for HotStarTaq DNA Polymerase) 
1 95 °C 15 min 
Amplification 
Denaturation 
Annealing 
Extension 
45  
94 °C 
55 °C 
70 °C 
 
15 s 
30 s 
30 s 
 
 
Analysis 
For analysis, relative expression (RE) levels (fold-changes) were calculated from CP 
values with the function RE = 2-∆∆CP. In this equation ∆CP is the difference between the 
sample’s CP value obtained for the target RNA and the sample’s CP value obtained for 
the reference RNA RNU6B. In turn, ∆∆CP is the difference between the afore-mentioned 
normalized value and the CP value of the control sample (e.g. erlotinib sensitive cells as 
compared to erlotinib-insensitive cells). All CP values were calculated from duplicate 
replicates. Analyses were performed with the LightCycler® 480 software and Microsoft 
Excel™.  
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III.2.3 Statistical analysis 
Plasma biomarker analyses in patient samples from the Dermatoxgen study 
First of all, the concentrations of the plasma analytes cetuximab, AREG, HGF and 25-OH-
vitamin D were tested for association with the multinomial end-point maximal (max) skin 
rash and max diarrhoea using analysis of variance (ANOVA) and the Jonckheere-Terpstra 
linear trend test. In case the endpoints were dichotomized, associations were calculated 
by Student’s t-test. The hypothesis was that the plasma concentrations would correlate 
with the occurrence and grade of EGFRI-induced skin rash in patients. 
The influence of covariates such as tumor type, tumor stage, age and BMI had previously 
been analysed by multiple regression and had been excluded as published by Steffens et 
al. 107 and were excluded again for the data sub set used here. 
 
The above mentioned plasma proteins were also tested for association with the end-
points OS and PFS. Therefore, survival distributions between different patient groups 
were compared using Kaplan-Meier analysis. OS times were restricted with an upper limit 
= 360 days. Data from patients lost to follow-up were censored at the day last known 
alive. Due to the nature of our censored data, the non-parametric log-rank test was used. 
All p-values are reported as nominal p-values and p-values < 0.05 were regarded as 
significant. Since some of the survivor functions do not fall below a survival portion of 0.5, 
median OS and 95 % confidence intervals cannot be calculated. Therefore, mean OS 
times with standard error (SE) are provided for comparisons. OS data was found to be 
more expressive than PFS data in this study, meaning that differences in survival times 
between the different analysed patient groups were more profound. Therefore, only OS 
data is presented throughout this thesis. 
 
All statistical analyses were performed with R v3.2.5 including the libraries coin v1.1-2 and 
survival 2.39-5 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Epigenetic biomarker analyses in the human skin cell model 
Following miRNA profiling by NGS the package DESeq2 for use with the statistical 
software environment R was used to normalize the detected miRNA read counts and 
determine specific mature or hairpin miRNAs which were differentially expressed between 
two groups of samples (e.g. untreated erlotinib-sensitive versus untreated erlotinib-
insensitive cells). 
The package uses shrinkage estimation for dispersions and fold changes to determine 
stable estimates for differential miRNA expression. The fold change as logarithm of the 
basis 2 (log2 fold change) is given with its standard error (log fold change standard error, 
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lfcSE). The program performs a hypothesis test (Wald test) to check whether there is 
enough evidence to reject the null hypothesis, stating that the effect is only due to 
experimental variability and not due to the treatment or differential characteristics of the 
sample groups. The result of the Wald test together with the corresponding p-value is also 
listed by the program. In addition, DESeq2 uses Benjamini-Hochberg adjustment (false 
discovery rate) to calculate adjusted p-values, taking into account that if multiple testing is 
performed, the significance level has to be corrected stepwise (more strict with each test) 
to prevent detection of an increasing amount of false positives. 
 
Mean differences in miRNA expression determined in qRT-PCR experiments are 
presented together with standard error of the mean (SEM) in bar diagrams (error bars), as 
calculated with the program Excel™. One-sided, unpaired Student’s t-test was used to 
test these differences for significance.  
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Chapter IV: Results 
 
IV.1 Patient samples from the Dermatoxgen study 
 
IV.1.1 Patient characteristics 
The aim of this study was to identify biomarkers for the occurrence and severity of EGFRI-
induced skin toxicity. Samples from 248 patients of the Dermatoxgen cohort were used for 
the analyses in this thesis. Clinical parameters were determined prior to this work at the 
respective study sites. Characteristics of the patients whose plasma samples were used 
for this work are listed in table 18. 
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Table 18 Characteristics of patients from the Dermatoxgen study 
All Dermatoxgen patients whose clinical data and plasma samples were analyzed within this thesis 
are included in this table. 
Characteristics Category Count 
(Total: n = 248) 
% 
Sex female 92 37.1 
  male 156 62.9 
Age median* [years] (range) 
 
68.5 (31-87) 
 BMI median* [kg/m²] (range)   24.7 (14.2-48.9)   
Smoking status* never 90 36.3 
 
former 122 49.2 
 
present 29 11.7 
  unknown 7 2.8 
Tumor* lung cancer 143 57.7 
 
colon cancer 
(KRAS WT) 46 18.5 
 
head and neck 
cancer 10 4.0 
 
pancreatic cancer 49 19.8 
Metastasis* yes 123 49.6 
 no 68 27.4 
 unknown 57 23.0 
EGFRI applied during 
observation period erlotinib 150 60.5 
 
gefitinib 13 5.2 
 
cetuximab 74 29.8 
 
panitumumab 11 4.4 
Maximal skin rash during 
observation period 
(grade after NCI-CTCAE)112 0 53 21.4 
 
1 93 37.5 
 
2 90 36.3 
  3 12 4.8 
Maximal diarrhea during observation 
period (grade after NCI-CTCAE)112 0 156 62.9 
 
1 60 24.2 
 
2 24 9.7 
 
3 7 2.8 
 
4 1 0.4 
* at beginning of observation period 
 
Abbreviations: BMI, body mass indexr; EGFRI, epidermal growth factor receptor inhibitor; NCI-
CTCAE, National Cancer Institute - Common Terminology Criteria for Adverse Events; WT, 
wild type. 
 
 
 
 
 
81 
 
There were 92 (37.1 %) female and 156 (62.9 %) male patients analyzed with a median 
age of 68.5 years (range 31 – 87 years). The majority of patients were diagnosed with 
lung cancer (57.7 %) but there were also patients included diagnosed with pancreatic 
(19.8 %), colon (18.5 %) and head and neck (4.0 %) cancer. In accordance with the 
indications of the single EGFRIs, the majority of patients were treated with erlotinib (60.5 
%), followed by cetuximab (29.8 %), gefitinib (5.2 %) and panitumumab (4.4 %). BMI and 
smoking status of the patients were also considered. 
Since skin rash is the main form of skin toxicity induced by treatment with an EGFRI, the 
maximal grade of skin rash developed during the observation period was used as 
measure for skin toxicity in all analyses. Within the patient population described here, 53 
patients (21.4 %) developed no skin rash, while 93 (37.5 %) showed grade 1, 90 (36.3 %) 
grade 2 and twelve (4.8 %) even grade 3 skin rash. 
Diarrhea is also a common adverse effect of EGFRIs, which was not shown to stably 
correlate with treatment efficacy or OS in previous studies32. Within the patient population 
described here, 156 patients (62.9 %) showed no diarrhea, while 60 patients (24.2 %) had 
grade 1, 24 (9.7 %) grade 2, seven (2.8 %) grade 3 and one patient (0.4 %) even grade 4 
diarrhea. 
 
 
IV.1.2 Correlation between plasma concentrations of cetuximab and skin rash and 
survival  
As shown in a publication by our research group, there is an association between a 
metabolic ratio of erlotinib and occurrence of skin rash as well as OS of patients 107. The 
calculations performed by Michael Steffens showed that patients with a low ratio of 
erlotinib serum concentration divided by serum concentration of the metabolite O-
desmethyl-erlotinb developed lower grades of EGFRI-induced skin rash and had shorter 
OS times. In this work it was investigated whether a correlation between plasma 
concentrations of cetuximab and development of skin rash and survival time could be 
identified. Following erlotinib, cetuximab was the next most frequently used EGFRI in the 
Dermatoxgen study cohort. For the patients who received this EGFRI, the plasma 
concentrations of cetuximab were determined by a specific ELISA. The correlation 
between the concentration of cetuximab and the occurrence and severity of EGFRI-
induced skin rash were investigated. The results are depicted in figure 12. 
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Figure 12 Correlation between plasma concentration of cetuximab and EGFRI-induced 
skin rash 
The concentration of cetuximab was determined in plasma of patients from the Dermatoxgen study 
by ELISA. n = 54. A) Cetuximab concentration plotted against the occurrence of skin rash during 
the observation period (0 = no rash, 1 = rash); Welch Two-Sample t-Test, p-value = 0.159. B) 
Cetuximab concentration plotted against the max grade of skin rash developed during observation 
period; ANOVA, p-value = 0.526. 
Abbreviations: ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; EGFRI, 
epidermal growth factor receptor inhibitor; max, maximal; n. number [of patients]. 
 
 
The plasma concentration of cetuximab was not significantly correlated with the 
occurrence (p-value = 0.159) or the grades (p-value = 0.526) of EGFRI-induced skin rash. 
The association with OS of the patients was also analyzed, as depicted in figure 13. 
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Figure 13 Association between plasma concentration of cetuximab and overall survival 
Patients from the Dermatoxgen study were followed-up for 360 days after initiation of the EGFRI 
therapy. The proportion of patients still alive is plotted over the observation period in the Kaplan-
Meier plots. Patients are grouped according to their plasma conc. of cetuximab. A) Dichotomized, 
mean OS of patients with low cetuximab conc. 270 days (SE: 20.4), for patients with high 
cetuximab conc. 333 days (SE: 12.6); log rank test, p-value = 0.027; B) Quartered, mean OS for 
group 1 279 days (SE: 25.9), group 2 261 days (SE: 29.6), group 3 326 days (SE: 22.5), group 4 
340 days (SE: 10.0); log rank test, p-value = 0.110. OS times are restricted with an upper limit = 
360 days. 
Abbreviations: conc., concentration; EGFRI, epidermal growth factor receptor inhibitor; OS, overall 
survival; SE, standard error; #, number of patients.  
 
 
The plasma concentration of cetuximab was significantly associated with OS when 
patients were dichotomized (p-value = 0.027). When patients were sorted into four groups 
according to the plasma concentration of cetuximab, the association between the 
cetuximab concentration and OS was not significant (p-value = 0.110). 
 
 
IV.1.3 Correlation between plasma concentrations of growth factors AREG and 
HGF and skin rash and survival 
Following the analysis of serum/plasma concentrations of EGFRIs themselves, the 
plasma concentrations of the selected biomarker candidates EGFR ligand AREG and 
MET ligand HGF were determined as well. The correlation between the plasma 
concentrations of AREG and HGF and EGFRI-induced skin rash are shown in figure 14. 
Figure 14 B and D have similarly also been published in the article published by the 
author of this thesis [Hichert et al. 2017]115. 
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Figure 14 Correlation between plasma concentrations of AREG and HGF and EGFRI-
induced skin rash 
The concentrations of AREG and HGF were determined in plasma of patients from the 
Dermatoxgen study by ELISA (AREG n = 190; HGF n = 197). A) AREG concentration plotted 
against the occurrence of skin rash during the observation period (0 = no rash, 1 = rash); Welch 
Two-Sample t-Test, p-value = 0.18. B) AREG concentration plotted against the max grade of skin 
rash developed during observation period; Linear Trend Test, p-value = 0.0763. C) HGF 
concentration plotted against the occurrence of skin rash during the observation period (0 = no 
rash, 1 = rash); Welch Two-Sample t-Test, p-value = 0.0769. D) HGF concentration plotted against 
the max grade of skin rash developed during observation period; Linear Trend Test, p-value = 
0.00124. For better visualization, in Figures C) and D) the plots are also presented without the 
outliers. In these cases outliers were still used for the calculations but excluded during plotting. 
Abbreviations: AREG, amphiregulin; ELISA, enzyme-linked immunosorbent assay; EGFRI, 
epidermal growth factor receptor inhibitor; HGF, hepatocyte growth factor; max, maximal; n, 
number [of patients]. 
 
 
The plasma concentration of AREG was not significantly correlated with the occurrence 
(p-value = 0.18) or the grade (p-value = 0.0763) of EGFRI-induced skin rash. The plasma 
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concentration of HGF was not significantly correlated with skin rash when only looking at 
the occurrence (skin rash yes/no; p-value = 0.0769) but when considering the grade of the 
developed skin rash (grades 0 to 3) the correlation was significant (p-value = 0.00124). 
The association with OS of the patients was also analyzed, as depicted in figure 15. 
Figure 15 has similarly also been published in the article published by the author of this 
thesis [Hichert et al. 2017]115. 
 
 
 
Figure 15 Association between plasma concentrations of AREG and HGF and overall 
survival 
Patients from the Dermatoxgen study were followed-up for 360 days after initiation of the EGFRI 
therapy. The proportion of patients still alive is plotted over the observation period in the Kaplan-
Meier plots. Patients are grouped according to their plasma concentration of A) AREG, 
dichotomized, mean OS for patients with low AREG conc. 252 days (SE: 12.5), for patients with 
high AREG conc. 255 days (SE: 12.6); log rank test, p-value = 0.86 and B) HGF, dichotomized, 
mean OS for patients with low HGF conc. 290 days (SE: 10.5), for patients with high HGF conc. 
210 days (SE: 12.4); log rank test, p-value = 2 x 10-5. OS times are restricted with an upper limit = 
360 days. 
Abbreviations: AREG, amphiregulin; conc., concentration; EGFRI, epidermal growth factor receptor 
inhibitor; HGF, hepatocyte growth factor; OS, overall survival; SE, standard error; #, number of 
patients. 
 
 
The plasma concentration of AREG was not significantly correlated with OS of the 
patients (p-value = 0.86) while the association of the plasma concentration of HGF with 
OS was significant (p-value = 2 x 10-5), with a mean of 290 days for patients with low HGF 
levels and 210 days for patients with high levels. 
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The survival curve for the plasma concentration of HGF was further divided according to 
the type of tumor the patients were suffering from. Separate survival curves were drawn 
for patients with bronchial, colon, head and neck, and pancreatic cancer respectively, 
which are presented in figure 16. 
 
 
 
 
87 
 
 
 
Figure 16 Association between the plasma concentration of HGF and overall survival 
separated according to tumor type 
Patients from the Dermatoxgen study were followed-up for 360 days after initiation of the EGFRI 
therapy. The proportion of patients still alive is plotted over the observation period in the Kaplan-
Meier plots. Patients are grouped according to their plasma conc. of HGF. A) Patients with lung 
cancer, mean OS for patients with low HGF conc. 282 days (SE: 14.0), for patients with high HGF 
conc. 200 days (SE: 16.2); log rank test, p-value = 0.0018. B) Patients with colon cancer, mean 
OS for patients with low HGF conc. 320 days (SE: 21.7), for patients with high HGF conc. 324 days 
(SE: 23.2); log rank test, p-value = 0.63. C) Patients with head and neck cancer, mean OS for 
patients with low HGF conc. 212 days (SE: 56.5), for patients with high HGF conc. 287 days (SE: 
31.1); log rank test, p-value = 0.59. D) Patients with pancreatic cancer, mean OS for patients with 
low HGF conc. 287 days (SE: 19.9), for patients with high HGF conc. 160 days (SE: 22.7); log rank 
test, p-value = 0.00014. OS times are restricted with an upper limit = 360 days. 
Abbreviations: concentration; EGFRI, epidermal growth factor receptor inhibitor; HGF, hepatocyte 
growth factor; OS, overall survival; SE, standard error; #, number of patients. 
 
 
lung cancer colon cancer 
head and neck cancer pancreatic cancer 
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When sorting patients according to their tumor type, the significant association between 
the plasma concentration of HGF and OS observed in figure 15 can only be shown for 
lung (p-value = 0.0018) and pancreatic (p-value = 0.00014) but not for colon (p-value = 
0.63) and head and neck (p-value = 0.59) cancer. 
 
We then subdivided the patient cohort into two groups, according to whether they had 
developed an EGFRI-induced skin rash or not. This allowed investigating whether the 
increased OS in patients with low plasma concentrations of HGF was specific for patients 
with EGFRI-induced skin rash or rather a general observation for all patients. Results are 
depicted in figure 17. Figure 17 has similarly also been published in the article published 
by the author of this thesis [Hichert et al. 2017]115. 
 
 
 
Figure 17 Association between plasma concentration of HGF and overall survival in 
patients with or without skin rash 
Patients from the Dermatoxgen study were followed-up for 360 days after initiation of the EGFRI 
therapy. The proportion of patients still alive is plotted over the observation period in the Kaplan-
Meier plots. Patients are grouped according to their plasma concentration of HGF. A) Patients who 
did not develop EGFRI-induced skin rash; log rank test, p-value = 0.56; mean OS for patients with 
low HGF conc. 193 days (SE: 22.5), for patients with high HGF conc. 164 days (SE: 23.6). B) 
Patients who developed EGFRI-induced skin rash (grades 1 to 3); log rank test, p-value = 0.0075; 
mean OS for patients with low HGF conc. 299 days (SE: 11.2), for patients with high HGF conc. 
240 days (SE: 14.5). OS times are restricted with an upper limit = 360 days. 
Abbreviations: conc., concentration; EGFRI, epidermal growth factor receptor inhibitor; HGF, 
hepatocyte growth factor; OS, overall survival; SE, standard error; #, number of patients. 
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The association between increased OS in patients and low plasma concentrations of HGF 
was only significant in the subgroup of patients with skin rash (p-value = 0.0075) but not 
for the ones without rash (p-value = 0.56). In the subgroup of patients with skin rash, the 
mean OS time was 299 days (SE: 11.2) for patients with low HGF levels (≤ 1220 pg/ml) 
and 240 days (SE: 14.5) for patients with high levels (> 1220 pg/ml). 
 
 
IV.1.4 Correlation between plasma concentrations of 25-OH-vitamin D and skin 
rash, survival and metastasis 
Following the analyses regarding the plasma concentrations of the EGFRI cetuximab, the 
EGFR ligand AREG and the MET ligand HGF, the role of the plasma concentration of the 
selected biomarker candidate 25-OH-vitamin D with regard to EGFRI-induced skin rash 
and OS was also investigated. The results are depicted in figures 18 and 19. Figure 18 B 
has similarly also been published in the article published by the author of this thesis 
[Hichert et al. 2017]115. 
 
 
 
Figure 18 Correlation between plasma concentration of 25-OH-vitamin D and EGFRI-
induced skin rash 
The concentration of 25-OH-vitamin D was determined in plasma of patients from the Dermatoxgen 
study by ELISA. n = 211. A) 25-OH-vitamin D concentration plotted against the occurrence of skin 
rash during the observation period (0 = no rash, 1 = rash); Welch Two-Sample t-Test, p-value = 
0.251. B) 25-OH-vitamin D concentration plotted against the max grade of skin rash developed 
during observation period; ANOVA, p-value = 0.415.  
Abbreviations: ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; EGFRI, 
epidermal growth factor receptor inhibitor; max, maximal; n, number [of patients]. 
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The plasma concentration of 25-OH-vitamin D was not significantly correlated with the 
occurrence (p-value = 0.251) or the grade (p-value = 0.415) of EGFRI-induced skin rash. 
The association with OS of the patients was also analyzed, as depicted in figure 19. 
 
 
 
Figure 19 Association between plasma concentration of 25-OH-vitamin D and overall 
survival 
Patients from the Dermatoxgen study were followed-up for 360 days after initiation of the EGFRI 
therapy. The proportion of patients still alive is plotted over the observation period in the Kaplan-
Meier plots. Patients are grouped according to their plasma conc. of 25-OH-vitamin D. 
Dichotomized, mean OS of patients with low 25-OH-vitamin D conc. 243 days (SE: 12.0), for 
patients with high 25-OH-vitamin D conc. 255 days (SE: 11.6); Log rank test, p-value = 0.67. OS 
times are restricted with an upper limit = 360 days. 
Abbreviations: conc., concentration; EGFRI, epidermal growth factor receptor inhibitor; OS, overall 
survival; SE, standard error; #, number of patients.  
 
 
25-OH-vitamin D is the storage form of vitamin D and measurement of its plasma 
concentration is most suitable to detect vitamin D status. In our study the plasma levels 
varied between 0.3 and 84.0 ng/ml (median: 19.7 ng/ml; mean: 21.3 ng/ml). In the 
literature there is no standardized cut-off value defining vitamin D sufficiency and 
deficiency. However, most studies suggest that plasma levels of ≥ 20 ng/ml are sufficient 
for calcidiol to have a beneficial effect on health, e.g. with regard to bone mineral density 
and cancer-related as well as all-cause mortality116,117. Therefore, in our study we defined 
25-OH-vitamin D levels ≤ 20 ng/ml as low and > 20 ng/ml as high levels. When comparing 
OS times between patients with low and those with high 25-OH-vitamin D levels, there 
was no significant difference (p-value = 0.67). 
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As a control for the quality of the Dermatoxgen plasma samples and the correct 
conduction of the assays, the association of the plasma concentration of 25-OH-vitamin D 
with metastasis was also investigated. A significant association had previously been 
shown in various studies118,119. The result is shown in figure 20. 
 
 
 
 
Figure 20 Correlation between plasma concentration of 25-OH-vitamin D and metastasis 
The concentration of 25-OH-vitamin D was determined in plasma of patients from the Dermatoxgen 
study by ELISA. n = 207. The concentration is plotted against the presence of metastases at the 
beginning of the observation period (0 = no metastasis, 1 = metastasis); Welch Two-Sample t-Test, 
p-value = 0.0109. 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; n, number [of patients]. 
 
 
The plasma concentration of 25-OH-vitamin D was significantly correlated with metastasis 
(p-value = 0.0109). Patients who showed metastases at the beginning of the observation 
period had lower plasma concentrations of 25-OH-vitamin D than those who showed no 
metastases. 
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IV.2 Epigenetic biomarker analyses in the human skin cell model 
To enable epigenetic analyses and investigations of functional biomarkers, a major aim of 
this study was the establishment of a suitable cell model for in vitro studies of molecular 
mechanisms underlying and influencing EGFRI-induced skin toxicity. Primary human 
epidermal keratinocytes and primary human dermal fibroblasts from healthy donors were 
isolated, brought into culture and evaluated for their suitability as such a cell model. 
 
 
IV.2.1 Keratinocytes 
 
IV.2.1.1 Establishment of primary epidermal keratinocytes 
As described in section I.6 the main type of skin cells involved in the development of 
EGFRI-induced skin toxicity are epidermal keratinocytes. Therefore, these cells were 
chosen for the investigation aiming at finding a suitable cell model. Primary epidermal 
keratinocytes were isolated from twelve healthy human donors and brought into culture. 
The cells had to be monitored closely during sub-culturing by visual examination to ensure 
that the right cell type was cultured and that the keratinocytes did not differentiate too far 
prior to any experiments. Figure 21 illustrates the formation of mainly pure epidermal 
keratinocyte clusters. At passage (p) 0 there are different cell types present in the sample 
(Figure 21 A) including keratinocytes, fibroblasts and melanocytes. Due to the application 
of optimal culture conditions for keratinocytes, the other cell types die during subculturing 
making the keratinocyte clusters purer over time (Figure 21 B and C). Only then further 
analyses of only the keratinocytes are possible. 
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Figure 21 Isolation and cultivation of primary human epidermal keratinocytes 
The cells were obtained from healthy excess skin removed during plastic surgery. A) Three days after 
isolation, cells in passage 0. Different types of cells are present distinguishable by their shapes (elongated: 
fibroblasts, stellar: melanocytes, small and polygonal: keratinocytes, round: dead or damaged cells). B) Ten 
days after isolation, cells in passage 1; clusters of keratinocytes are forming. C) 25 days after isolation, cells 
in passage 5; mainly keratinocytes remaining in the culture. 
 
 
In addition to visual identification by cell morphology, the presence of certain keratinocyte 
marker proteins (CK10, CK14 and involucrin) was also checked using Western blotting, 
which is shown in Figure 22. 
 
 
 
 
Figure 22 Detection of keratinocyte marker proteins in human keratinocytes by Western 
blot 
Primary human keratinocytes were isolated from healthy excess skin removed during plastic 
surgery. The keratinocyte marker proteins CK14 (50 kDa), CK10 (60 kDa) and involucrin (120 kDa) 
were detected by Western blot. Cells were in passage 3 to 6. Abbreviations: CK, cytokeratin; HK, 
human keratinocytes; kDa, kilo Dalton. 
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The cytokeratins CK10 and CK14 were detected in all twelve keratinocyte samples, while 
the signal for CK10 was stronger than for CK14. Involucrin, which is mainly found in the 
two outer epidermal layers, was not detected in any of the twelve samples. No controls 
were available for the assay, since for commercially available primary keratinocytes no 
information about differentiation status was provided. Therefore, results have to be 
interpreted with caution (refer to chapter IV.2.1). Specificity of the assays was at least 
confirmed by inclusion of lanes with either no primary or no secondary antibody. 
 
 
IV.2.1.2 Effect of erlotinib on EGFR signaling in keratinocytes in vitro 
To further evaluate the suitability of epidermal keratinocytes as cell model for studying 
EGFRI-induced skin toxicity, the in vitro effect of incubation with the EGFRI erlotinib was 
investigated. The relative phosphorylation levels of different kinase phosphorylation sites 
and related proteins involved in EGFR signaling cascades were compared between 
keratinocytes incubated with erlotinib and stimulated with EGF (Figure 23 C) and 
keratinocytes only stimulated with EGF (Figure 23 B). Concentrations were chosen 
analogous to the ones established for other methods (e.g. Western blotting) by other 
members of this research group prior to this work and were found to be suitable also for 
this method. Phosphorylation indicates activation. As a control untreated keratinocytes 
were also included (Figure 23 A). Human phospho kinase arrays were conducted and 
three separate experiments were performed with different cell samples (HK3 p6, HK4 p5, 
HK4 p8). Figures 23 and 24 show representative results for HK4 p8.  
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Figure 23 In vitro effect of erlotinib on phosphorylation of proteins involved in EGFR 
signaling in keratinocytes 
Human phospho kinase arrays were conducted with keratinocyte cell lysates of HK4 p8. Some 
sections of the membranes after chemiluminescent visualization of the phosphorylated proteins are 
shown. A) No treatment. B) Stimulated with 4 nM EGF for 5 min. C) Incubated with 10 µM erlotinib 
for 2 h then stimulated with 4 nM EGF for 5 min. A stronger signal (pixel density) corresponds to 
higher amounts of phosphorylated protein present and stronger signaling activity. Abbreviations: 
EGF, epidermal growth factor; HK, human keratinocytes; p, passage. 
 
. 
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Figure 24 Quantification of in vitro effect of erlotinib on phosphorylation of proteins involved in EGFR signaling in keratinocytes 
Human phospho kinase arrays were conducted with keratinocyte cell lysates of HK4 p8. The mean pixel density after chemiluminescent visualization of the 45 different 
phosphorylated proteins is shown. Light blue: no treatment. Dark blue: stimulated with 4 nM EGF for 5 min. Green: incubated with 10 µM erlotinib for 2 h then stimulated with 
4 nM EGF for 5 min. A stronger signal (pixel density) corresponds to higher amounts of phosphorylated protein present and stronger signaling activity. 
Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HK, human keratinocytes; p, passage. 
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EGF increased phosphorylation of most of the tested proteins involved in EGFR signaling 
cascades while erlotinib decreased the phosphorylation. The strength of the effect was 
different for the various signaling proteins. For quantification of the effects two ratios were 
calculated for each protein as suggested by the manufacturer: 
 
1)  𝐸𝐺𝐹 𝑛𝑜 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 =  
𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑓𝑜𝑟 𝑐𝑒𝑙𝑙𝑠 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝐸𝐺𝐹
𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑓𝑜𝑟 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
⁄  
 
The higher the value for this ratio, the stronger is the stimulating effect of EGF. 
 
2)  𝑒𝑟𝑙𝑜𝑡𝑖𝑛𝑖𝑏 𝐸𝐺𝐹 =  
𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑓𝑜𝑟 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑒𝑟𝑙𝑜𝑡𝑖𝑛𝑖𝑏
𝑎𝑛𝑑 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝐸𝐺𝐹
𝑝𝑖𝑥𝑒𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑖𝑦 𝑓𝑜𝑟 𝑐𝑒𝑙𝑙𝑠 𝑜𝑛𝑙𝑦 𝑠𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝐸𝐺𝐹
⁄  
 
The lower the value for this ratio, the stronger is the inhibitory effect of erlotinib. 
 
The two ratios were calculated for all proteins and all three cell samples (HK3 p6, HK4 p5, 
HK4 p8). The five proteins on which erlotinib had the strongest effect across all 
experiments are listed in table 19 for all cell samples. The values for all other proteins are 
provided in appendix A). 
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Table 19 Mean pixel density for selected proteins from human phospho-kinase arrays of 
three different keratinocyte cell samples 
Human phospho kinase arrays were conducted with three different keratinocyte cell samples (HK3 
p6, HK4 p5, HK4 p8) following three in vitro treatment conditions (no treatment, 4 nM EGF for 5 
min and 10 µM erlotinib for 2 h + 4 nM EGF for 5 min). For clearer comparison of the stimulating 
effect of EGF and the inhibitory effect of erlotinib between the different cell samples, ratios were 
calculated (EGF/no treatment and erlotinib/EGF). Results for the five phosphorylated proteins on 
whose abundance EGF and erlotinib had the biggest effect are listed here. Abbreviations: EGF, 
epidermal growth factor; HK, human keratinocytes; p, passage. 
 
mean pixel density for HK3 p6 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
JNK 1/2/3 4254 13344 4993 3.14 0.37 
EGF R 5884 28853 6687 4.90 0.23 
AMPKα1 1052 4001 2370 3.80 0.59 
c-Jun 20885 35552 11892 1.70 0.33 
Src 1772 35532 2232 20.05 0.06 
 
mean pixel density for HK4 p5 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
JNK 1/2/3 11292 16537 6933 1.46 0.42 
EGF R 13143 38779 18868 2.95 0.49 
AMPKα1 7833 10667 3559 1.36 0.33 
c-Jun 22371 40513 14939 1.81 0.37 
Src 6088 11194 2641 1.84 0.24 
 
mean pixel density for HK4 p8 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
JNK 1/2/3 9328 15247 8401 1.63 0.55   
EGF R 9225 26717 17661 2.90 0.66   
AMPKα1 4752 8422 4465 1.77 0.53   
c-Jun 17372 27373 13679 1.58 0.50   
Src 5823 6115 5262 1.05 0.86   
 
 
In vitro erlotinib seemed to have the strongest inhibitory effect on the phosphorylation of 
the EGFR itself as well as on the MAPK JNK 1/2/3, its downstream transcription factor c-
Jun, the kinase Src and the catalytic subunit of 5’ adenosine monophosphate-activated 
kinase (AMPKα1). 
 
For further analyses of EGFR signaling across more than just the three example 
keratinocyte samples used for the phospho kinase arrays, specific phospho-ELISAs were 
conducted. According to the results from the phospho kinase arrays and considering the 
commercial availability of validated assays, ELISAs for phospho-JNK, phospho-c-Jun and 
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phospho-EGFR were chosen. In order to identify the most suitable assay to detect 
phenotypic differences in the in vitro effect of erlotinib between different cell samples, 
meaning differences in sensitivity towards erlotinib, important criteria were sufficient 
sensitivity, reproducibility and proper functioning of the assay in general. 
 
 
IV.2.1.3 Effect of erlotinib on the phosphorylation of JNK, c-Jun and EGFR in 
keratinocytes in vitro 
The relative amount of phosphorylated target protein, normalized to the amount of total 
target protein, was determined and compared between cells incubated with erlotinib and 
stimulated with EGF, cells only stimulated with EGF and cells left untreated. For better 
comparison between cells from different individuals, again the ratios EGF/no treatment 
and erlotinib/EGF were calculated as explained in the previous section (IV.2.1.2). The 
results for these ratios from the phospho-JNK ELISA are presented in table 20. 
 
 
Table 20 In vitro effect of erlotinib on relative amount of phosphorylated JNK in 
keratinocytes 
Phospho-JNK ELISAs were conducted with six different keratinocyte cell samples following three in 
vitro treatment conditions (no treatment, 4 nM EGF for 5 min and 5 µM erlotinib for 2 h + 4 nM EGF 
for 5 min). The relative amount of phosphorylated JNK was determined in RFUs normalized to total 
protein. For clearer comparison of the stimulating effect of EGF and the inhibitory effect of erlotinib 
between the different cell samples, ratios were calculated (EGF/no treatment and erlotinib/EGF). 
Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; HK, 
human keratinocytes; JNK, c-Jun N-terminal kinase; p, passage; RFUs, relative fluorescence units. 
 
phospho-JNK 
cell sample EGF/no treatment erlotinib/EGF 
HK1 p8 1.1659 0.8503 
HK2 p6 1.4367 0.7884 
HK3 p6 0.9873 0.8569 
HK4 p8 0.9774 0.5563 
HK5 p6 0.5658 1.1855 
HK6 p8 1.0989 1.2762 
 
 
In the phospho-JNK ELISA EGF only increased the relative amount of phosphorylated 
JNK in some cell samples but not all (EGF/no treatment < 1 means the relative amount of 
phosphorylated target protein is higher in untreated samples than in samples stimulated 
with EGF). In addition, erlotinib only decreased the relative amount of phosphorylated JNK 
in some of the cell samples (erlotinib/EGF > 1 means the relative amount of 
phosphorylated target protein is higher in cells incubated with erlotinib than in un-
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incubated samples). Therefore, the phospho-JNK ELISA did not seem to be suitable to 
measure the in vitro effect of erlotinib on human epidermal keratinocytes. Hence, it was 
not used for further analyses. Instead, a phospho-c-Jun ELISA was conducted and tested 
for its suitability for this task. The results are presented in table 21. 
 
 
Table 21 In vitro effect of erlotinib on relative amount of phosphorylated c-Jun in 
keratinocytes 
Phospho-c-Jun ELISAs were conducted with twelve different keratinocyte cell samples following 
three in vitro treatment conditions (no treatment, 4 nM EGF for 5 min and 5 µM erlotinib for 2 h + 4 
nM EGF for 5 min). The relative amount of phosphorylated c-Jun was determined in RFUs 
normalized to total protein. For clearer comparison of the stimulating effect of EGF and the 
inhibitory effect of erlotinib between the different cell samples, ratios were calculated (EGF/no 
treatment and erlotinib/EGF). Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked 
immunosorbent assay; HK, human keratinocytes; p, passage; SD, standard deviation, RFUs, 
relative fluorescence units. 
 
phospho-c-Jun 
cell sample EGF/no treatment erlotinib/EGF 
HK1 p6 1.0958 0.8106 
HK2 p5 1.2098 0.5923 
HK3 p4 1.2044 0.5982 
HK4 p4 1.0994 0.6094 
HK5 p4 1.0790 0.5304 
HK6 p4  1.0089 0.7701 
HK7 p4 1.2341 0.7644 
HK8 p4 1.2578 0.7214 
HK9 p4 1.0820 0.7591 
HK10 p7 1.1824 1.0477 
HK11 p4 1.0568 1.0137 
HK12 p7 1.0779 0.8273 
 
 
Stimulation with EGF increased the relative amount of phosphorylated c-Jun in all tested 
keratinocytes (EGF/no treatment > 1). Prior incubation with erlotinib decreased the relative 
amount of phosphorylated c-Jun in most but not all cell samples (erlotinib/EGF < 1).  
The cell samples HK1, HK2, HK3, HK4, HK5 and HK6 were cultured again and used for a 
second independent experiment (biological duplicates) to investigate the reproducibility of 
the results. Mean ratios and standard deviations (SDs) are given in table 22. 
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Table 22 Reproducibility of results for in vitro effect of erlotinib on keratinocytes from 
phospho-c-Jun ELISA 
Phospho-c-Jun ELISAs were conducted with six different keratinocyte cell samples following three 
in vitro treatment conditions (no treatment, 4 nM EGF for 5 min and 5 µM erlotinib for 2 h + 4 nM 
EGF for 5 min). The relative amount of phosphorylated c-Jun was determined in RFUs normalized 
to total protein. For clearer comparison of the stimulating effect of EGF and the inhibitory effect of 
erlotinib between the different cell samples, ratios were calculated (EGF/no treatment and 
erlotinib/EGF). Results are presented as mean values with SDs from two independent experiments. 
Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; HK, 
human keratinocytes; n, number [of independent experiments]; p, passage; SD, standard deviation, 
RFUs, relative fluorescence units. 
  
phospho-c-Jun 
  
EGF/no treatment erlotinib/EGF 
cell sample n mean SD mean SD 
HK1 p6 2 1.6068 0.7227 0.6256 0.2617 
HK2 p5 2 1.3127 0.1454 0.6032 0.0154 
HK3 p4 2 1.1892 0.0215 0.7182 0.1697 
HK4 p4 2 1.1330 0.0475 0.7758 0.2353 
HK5 p4 2 1.1413 0.0882 0.6947 0.2324 
HK6 p4  2 1.0883 0.1124 0.8407 0.0998 
 
 
Some of the standard deviations calculated for the biological duplicates were quite high. 
Hence, the phospho-c-Jun ELISA did not seem to be suitable to provide stable and 
reproducible results for the in vitro effect of erlotinib on human keratinocytes. Next, a 
phospho-EGFR ELISA was conducted and tested for its suitability for this task. The 
results are presented in table 23. 
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Table 23 In vitro effect of erlotinib on relative amount of phosphorylated EGFR in 
keratinocytes 
Phospho-EGFR ELISAs were conducted with twelve different keratinocyte cell samples following 
three in vitro treatment conditions (no treatment, 40 nM EGF for 5 min and 10 µM erlotinib for 2 h + 
4 nM EGF for 5 min). The relative amount of phosphorylated EGFR was determined in relative 
fluorescence units normalized to total protein. For clearer comparison of the stimulating effect of 
EGF and the inhibitory effect of erlotinib between the different cell samples, ratios were calculated 
(EGF/no treatment and erlotinib/EGF). Abbreviations: EGF, epidermal growth factor; EGFR, 
epidermal growth factor receptor; ELISA, enzyme-linked immunosorbent assay; HK, human 
keratinocytes; p, passage; RFUs, relative fluorescence units. 
 
phospho-EGFR 
cell sample EGF/no treatment erlotinib/EGF 
HK1 p6 1.3538 0.7622 
HK2 p5 1.5424 0.7504 
HK3 p4 1.4562 0.7673 
HK4 p4 1.6011 0.6570 
HK5 p4 1.5005 0.7253 
HK6 p5 1.4800 0.7279 
HK7 p4 1.3491 0.7147 
HK8 p4 1.2517 0.6792 
HK9 p4 1.2783 0.7974 
HK10 p7 1.1858 0.6808 
HK11 p4 1.1649 0.7675 
HK12 p7 1.7210 0.5312 
 
 
Stimulation with EGF increased the amount of phosphorylated EGFR (EGF/no treatment > 
1), while prior incubation with erlotinib decreased it (erlotinib/EGF < 1) in all cell samples. 
Therefore, the phospho-EGFR ELISA seemed to be suitable to measure the in vitro effect 
of erlotinib in human keratinocytes. 
The cell samples HK1, HK2, HK3 and HK 4 were cultured again and used for two 
additional independent experiments (biological triplicates) to investigate the reproducibility 
of the results. Mean ratios and SDs are given in table 24. 
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Table 24 Reproducibility of results for in vitro effect of erlotinib on keratinocytes from 
phospho-EGFR ELISA 
Phospho-EGFR ELISAs were conducted with four different keratinocyte cell samples following 
three in vitro treatment conditions (no treatment, 40 nM EGF for 5 min and 10 µM erlotinib for 2 h + 
4 nM EGF for 5 min). The relative amount of phosphorylated EGFR was determined in RFUs 
normalized to total protein. For clearer comparison of the stimulating effect of EGF and the 
inhibitory effect of erlotinib between the different cell samples, ratios were calculated (EGF/no 
treatment and erlotinib/EGF). Results are presented as mean values with SDs from three 
independent experiments. Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked 
immunosorbent assay; HK, human keratinocytes; n, number [of independent experiments]; p, 
passage; SD, standard deviation, RFUs, relative fluorescence units. 
  
phospho-EGFR 
  
EGF/no treatment erlotinib/EGF 
cell sample n mean SD mean SD 
HK1 p6 3 1.3824 0.0629 0.7911 0.0921 
HK2 p5 3 1.5411 0.0633 0.6990 0.0445 
HK3 p4 3 1.5072 0.0526 0.7190 0.0440 
HK4 p4 3 1.4542 0.1553 0.7107 0.0479 
 
 
The standard deviations calculated for the biological triplicates of the phospho-EGFR 
ELISA were much lower than for the phospho-c-Jun ELISA. The phospho-EGFR ELISA 
seemed to be the most suitable among the tested assays to detect differences in the in 
vitro effect of erlotinib (sensitivity towards erlotinib) on human epidermal keratinocytes. 
Therefore, the results from the phospho-EGFR ELISA (table 23) were used to group the 
keratinocyte cell samples according to their sensitivity towards erlotinib for further 
analyses. A low erlotinib/EGF ratio means higher sensitivity towards erlotinib. This 
grouping is depicted in figure 25. 
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Figure 25 Keratinocytes grouped into rather erlotinib-sensitive and -insensitive 
The results from phospho-EGFR ELISAs, which were conducted with twelve different keratinocyte 
cell samples following in vitro treatment with erlotinib (10 µM, 2 h) and subsequent stimulation with 
EGF (40 nM, 5 min) or stimulation with EGF alone, were used to calculate an erlotinib/EGF ratio for 
each cell sample. Cell samples were grouped into rather erlotinib-sensitive and erlotinib-insensitive 
according to the ratio. A smaller ratio means higher sensitivity towards erlotinib. 
Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ELISA, 
enzyme-linked immunosorbent assay; HK, human keratinocytes. 
 
 
For all twelve keratinocyte samples the miRNA profiles were determined and compared 
between the six rather erlotinib-sensitive and the six rather erlotinib-insensitive samples. 
 
 
IV.2.1.4 MiRNA profiles of erlotinib-sensitive versus erlotinib-insensitive 
keratinocytes 
In order to assess epigenetic effects of erlotinib in keratinocytes, total RNA was isolated 
from the epidermal keratinocyte samples and barcoded cDNA libraries were prepared for 
NGS. Mature as well as precursor (hairpin) miRNAs which were differentially expressed 
between the six rather erlotinib-sensitive and the six rather erlotinib-insensitive cell 
samples (both determined in vitro by the EGFR-ELISA, see previous section) were 
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identified with the program DESeq2. Both, mature as well as precursor miRNAs were 
investigated since they mark different time points in post-transcriptional gene regulation 
and it is currently unknown the amounts of which are more important in influencing EGFR 
inhibition or development of EGFRI-induced skin rash. It was also checked whether prior 
incubation with erlotinib + EGF or EGF alone had an influence on the list of differentially 
expressed miRNAs. Those miRNAs with a p-value < 0.05 and a fold change of ≥ 1.50 (up-
regulated) or ≤ 0.66 (down-regulated) respectively, were considered interesting and are 
listed in table 25 for cells with no treatment. 
 
 
Table 25 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive keratinocytes (no treatment) 
Differentially expressed precursor and mature miRNAs in rather erlotinib-sensitive as compared to -
insensitive keratinocytes (n = 6 in each group) were determined by NGS and the program DESeq2. 
In vitro sensitivity towards erlotinib was previously determined by EGFR-ELISA. miRNAs with a p-
value < 0.05 and a fold change of ≥ 1.50 (up-regulated) or ≤ 0.66 (down-regulated) respectively, 
are listed. The fold change as logarithm of the basis 2 (log2 fold change) is given with its standard 
error (lfcSE, log fold change standard error). The result of the statistic Wald test (stat) together with 
the corresponding p-value is also listed. 
 
erlotinib-sensitive vs. -insensitive 
treatment: none 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-1273c -0.5966 0.2028 0.6613 -2.9422 3.26E-03 
hsa-mir-3911 -0.6772 0.2376 0.6254 -2.8500 4.37E-03 
hsa-mir-95 0.7409 0.2936 1.6712 2.5232 1.16E-02 
hsa-mir-611 -0.6297 0.2619 0.6463 -2.4040 1.62E-02 
hsa-mir-5189 -0.6949 0.2966 0.6177 -2.3428 1.91E-02 
hsa-mir-146a -0.6348 0.2968 0.6440 -2.1390 3.24E-02 
hsa-mir-4451 -0.6823 0.3296 0.6232 -2.0696 3.85E-02 
hsa-mir-485 -0.6806 0.3347 0.6239 -2.0332 4.20E-02 
hsa-mir-4695 -0.6271 0.3145 0.6475 -1.9944 4.61E-02 
hsa-mir-1973 -0.6392 0.3250 0.6421 -1.9669 4.92E-02 
            
mature miRNA           
hsa-miR-31-3p -0.7517 0.2781 0.5939 -2.7035 6.86E-03 
hsa-miR-4451 -0.6517 0.2603 0.6365 -2.5036 1.23E-02 
hsa-miR-224-5p 0.6182 0.2592 1.5349 2.3849 1.71E-02 
 
 
In the erlotinib-sensitive keratinocytes nine precursor and two mature miRNAs were 
significantly down-regulated while one precursor and one mature miRNA were 
significantly up-regulated when compared to erlotinib-insensitive cells. Fold changes 
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ranged between 1.53 and 1.67 (0.66 and 0.59 for down-regulation, respectively). The 
differentially expressed miRNAs differed in cells incubated with EGF or erlotinib 
(respective lists presented in appendix A). 
 
Reproducibility of the sequencing results was confirmed by repeating the sequencing run 
with the same barcoded cDNA library including the samples HK1, HK2, HK3 and HK4. 
The list of differentially expressed miRNAs differed but the most significantly differentially 
expressed ones were still identified. 
 
For a better overview, those miRNAs which were significantly differentially expressed (p < 
0.05) under all three different in vitro treatments were determined, as depicted in figure 
26. These miRNAs are referred to as “overlap miRNAs”. 
 
 
 
 
Figure 26 Overlap of differentially expressed miRNAs in erlotinib-sensitive as compared to 
-insensitive keratinocytes between different in vitro treatments 
Significantly differentially expressed precursor (left) and mature (right) miRNAs in rather erlotinib-
sensitive as compared to -insensitive keratinocytes (n = 6 in each group). MiRNA expression was 
determined by NGS. Cells were either incubated with 4 nM EGF (dark blue circle) or 4 nM EGF 
plus 5 µM erlotinib (green circle) or left untreated (light blue circle) prior to sequencing. Numbers in 
overlapping parts of the circles represent the numbers of specific miRNAs which were significantly 
differentially expressed (p < 0.05) in both or all three treatment groups, respectively. 
Abbreviations: EGF, epidermal growth factor; miRNA, micro ribonucleic acid; NGS, next generation 
sequencing. 
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Those miRNAs which were significantly differentially expressed in rather erlotinib-sensitive 
as compared to -insensitive keratinocytes regardless of the in vitro treatment were 
considered especially interesting. They represent a “baseline” difference between the 
erlotinib-sensitive and -insensitive cells, which is independent of stimulation with EGF or 
incubation with erlotinib. There was no overlap of mature miRNAs in all three treatment 
groups. There was one overlap of precursor miRNAs, which was found to be mir-146a. 
 
Those miRNAs which were only significantly differentially expressed in cells incubated 
with erlotinib and not in the other treatment groups were also considered especially 
interesting. They represent a difference in response to erlotinib in erlotinib-sensitive as 
compared to -insensitive keratinocytes. There were 19 different miRNA precursors and 13 
mature miRNAs only significantly differentially expressed in cells incubated with erlotinib. 
For these miRNAs a thorough literature search was conducted to select those miRNAs 
which had already been found to be involved in response to EGFRIs in previous studies, 
which strengthened the evidence for these candidate miRNAs. Further analysis of all 
miRNAs would have exceeded the timeframe of this thesis. An overview table of the 
results of this literature search can be found in Appendix A). Based on the literature 
search, expression of the following precursor and mature miRNAs in erlotinib-sensitive as 
compared to -insensitive keratinocytes was verified using qRT-PCR: mir-146a, miR-146a-
5p, mir-31, miR-31-3p, mir-138-2, mir-221, mir-520e, and mir-944. In addition, the 
following miRNAs identified from the equivalent literature search for candidate miRNAs in 
fibroblasts (refer to Appendix B) were also tested in keratinocytes to compare their roles in 
the two cell types: mir-34a, miR-34a-5p, mir-17, mir-30b, mir-382, mir-494, mir-7-1, miR-7-
1-3p. 
In general, in PCR analyses the differences in expression between cell samples grouped 
as erlotinib-sensitive and those grouped as erlotinib-insensitive were not significant for 
any miRNAs as tested with Student’s t-test (except for mir-944 with p-value = 0.02). 
Figure 27 shows a comparison of ∆CP values for expression of miRNAs in untreated 
erlotinib-sensitive keratinocytes and untreated erlotinib-insensitive keratinocytes. 
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Figure 27 Comparison of miRNA expression in untreated erlotinib-sensitive and erlotinib-
insensitive keratinocytes determined by qRT-PCR 
∆CP values representing expression of different miRNAs in untreated keratinocytes as determined 
by qRT-PCR. Dark red: Mean ∆CP values of erlotinib-sensitive cell samples as determined by 
ELISAs (n = 6). Light red: Mean ∆CP values of erlotinib-insensitive cell samples (n = 6). MiRNAs 
were selected due to results from NGS and a literature search. Error bars represent SEM.* 
represents a significant difference (p-value < 0.05, Student’s t-test). 
Abbreviations: ∆CP, delta crossing point; ELISA, enzyme-linked immunosorbent assay; NGS, next 
generation sequencing; qRT-PCR, quantitative real-time polymerase chain reaction; SEM, 
standard error of the mean. 
 
 
Upon in vitro treatment with erlotinib, the difference in expression of the selected miRNAs 
in the group of erlotinib-sensitive cells as compared to the group of erlotinib-insensitive 
cells was not significant, either. 
 
A comparison of the results from NGS and PCR is presented in table 26 with fold-changes 
and p-values for NGS and also fold-changes for PCR (but no p-values since in PCR 
analysis t-test for ∆∆CP values did not show significant differences [no p-values <0.05]). 
(Please note that cut-off values defining up- and down-regulation were chosen less strict 
than for the Venn diagrams, in order to give a better visualization also of smaller effects.)  
„miRNAs identified from 
fibroblast analyses“ 
„additionally 
included mature 
miRNAs” 
„erlotinib only 
miRNAs” 
„overlap 
miRNAs” 
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Table 26 Comparison of NGS and qRT-PCR results for fold-changes of specific miRNAs 
differentially expressed in erlotinib-sensitive and -insensitive keratinocytes 
Fold-changes in expression of specific precursor and mature miRNAs in erlotinib-sensitive as 
compared to -insensitive primary human keratinocytes (n = 6 in each group) were determined by 
NGS and qRT-PCR. Cells were either incubated with 4 nM EGF (dark blue columns) or 5 µM 
erlotinib plus 4 nM EGF (green columns) or left untreated (light blue columns) prior to miRNA 
expression analyses. Significant p-values for NGS results (< 0.05) are marked in bold. MiRNAs 
selected by Venn diagrams and literature search as described in chapter III. MiRNAs with higher 
expression in erlotinib-sensitive cells than in -insensitive cells (fold-change ≥ 1.2) are marked with a 
green arrow (up-regulated) while those with lower expression (fold-change ≤ 0.8) are marked with a 
red arrow (down-regulated). Fold-changes in between those cut-offs are not regarded as 
differential. 
Abbreviations: EGF, epidermal growth factor; miRNA, micro ribonucleic acid; NGS, next generation 
sequencing; qRT-PCR, quantitative real-time polymerase chain reaction. 
 
 
 
Even though fold-changes greatly differed between NGS and PCR results, those miRNAs 
which were significantly (p-value < 0.05) up- or down-regulated in the NGS analyses were 
mainly also determined as up- or down-regulated in the PCR analyses, respectively, 
confirming the effect. 
In erlotinib-sensitive keratinocytes expression of miRNA mir-146a was down-regulated as 
compared to erlotinib-insensitive cells, across all three treatment options, in NGS 
(significantly) as well as in PCR assays. This was also observed for the mature form miR-
146a-5p. According to NGS results, mir-31 was also significantly down-regulated in 
sensitive cells; however, this effect was not confirmed by PCR. Depending on the cut-off 
values used to define down-regulation, mir-31 was either only differentially expressed in 
cells treated with erlotinib (fold-change 0.65) or also in those treated with EGF alone (fold-
miRNA
p-value p-value p-value
"overlap miRNAs"
mir-146a hairpin ↓ 0.64 0.0324 ↓ 0.43 ↓ 0.62 0.0440 ↓ 0.45 ↓ 0.55 0.0207 ↓ 0.46
"erlotinib only miRNAs"
mir-31 hairpin ↓ 0.77 0.0423 1.00 ↓ 0.79 0.0350 0.92 ↓ 0.65 0.0096 ↑ 1.60
mir-138-2 hairpin ↓ 0.72 0.1418 ↑ 1.59 ↓ 0.78 0.2511 1.08 ↓ 0.40 0.0002 ↓ 0.73
mir-221 hairpin 0.97 0.7817 0.93 0.82 0.1318 0.92 ↓ 0.70 0.0086 0.97
mir-520e hairpin 0.81 0.3243 ↑ 1.70 0.99 NA 1.18 ↓ 0.18 0.0000 ↓ 0.74
mir-944 hairpin 1.11 0.4501 ↑ 1.74 ↑ 1.57 0.0103 ↑ 1.43 ↑ 1.67 0.0020 ↑ 1.43
miR-146a-5p (mature) ↓ 0.71 0.0258 ↓ 0.45 ↓ 0.57 0.0055 ↓ 0.44 ↓ 0.50 0.0040 ↓ 0.39
miR-31-3p (mature) ↓ 0.59 0.0069 1.13 1.00 0.9889 0.93 0.90 0.6616 ↓ 0.75
mir-34a hairpin 1.00 0.9989 ↓ 0.60 0.83 0.2828 ↓ 0.76 ↓ 0.29 0.7909 1.18
miR-34a-5p (mature) 0.97 0.8406 1.08 ↓ 0.80 0.2050 0.91 ↓ 0.79 0.2779 1.03
mir-17 hairpin 0.97 0.8311 ↑ 1.42 1.04 0.7508 ↑ 1.27 ↓ 0.20 0.8213 ↑ 1.39
mir-30b hairpin 0.91 0.5923 1.19 1.19 0.2697 ↑ 1.21 0.83 0.9518 1.11
mir-7-1 hairpin ↑ 1.34 0.0809 1.04 ↑ 1.36 0.0807 1.14 ↓ 0.10 1.3762 ↑ 1.44
miR-7-1-3p (mature) 0.89 0.5409 1.15 1.05 0.8190 ↑ 1.20 ↓ 0.70 0.1464 ↑ 1.51
PCR
fold-change fold-changefold-change fold-changefold-change fold-change
NGS PCR NGS
 sensitive vs. insensitive
(no treatment)
sensitive vs. insensitive
(EGF)
sensitive vs. insensitive
(erlotinib)
additionally included 
mature miRNAs
miRNAs identified from 
fibroblast analyses
NGS PCR
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change 0.79) and those left untreated (fold-change 0.77). The two miRNAs mir-138-2 and 
mir-520e were significantly down-regulated in sensitive keratinocytes previously incubated 
with erlotinib (confirmed by PCR) but not under the other treatment conditions. On the 
other hand, mir-944 was up-regulated in sensitive cells under EGF as well as erlotinib + 
EGF treatment. A trend towards up-regulation of mir-944 was also visible in untreated 
cells (but in NGS did not reach the cut-off value of 1.2). 
Those miRNAs which were identified as significantly differentially expressed in fibroblasts 
were not significantly differentially expressed in keratinocytes, again indicating large 
differences in cellular processes in these two dermal cell types. Regulation of mir-34a and 
its mature form miR-34a-5p even seemed to be opposite in the two cell types. While in 
fibroblasts expression of mir-34a and miR-34a-5p were up-regulated in erlotinib-sensitive 
cells, in keratinocytes the two miRNAs were rather down-regulated in erlotinib-sensitive 
cells. 
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IV.2.2 Fibroblasts 
The amount of healthy donors for primary epidermal keratinocytes was very limited. 
However, a large number of samples of primary human dermal fibroblasts was available 
from the Clinical Pharmacology Department of the University Medicine Göttingen. Since 
fibroblasts are the most abundant cell type of the dermis, directly adjacent to the 
epidermis, and EGFR is also expressed in dermal fibroblasts, it was investigated whether 
these cells could also serve as a suitable cell model to study EGFRI-induced skin toxicity. 
 
 
IV.2.2.1 Effect of erlotinib on EGFR signaling in fibroblasts in vitro 
First of all, the in vitro effect of incubation with the EGFRI erlotinib was investigated using 
phospho kinase arrays, like for the keratinocytes (described in section IV.2.1.2). Two 
separate experiments were performed with different cell samples (FB64 p7 and FB120 
p8). Figures 28 and 29 show representative results for FB120 p8.  
 
 
 
 
Figure 28 In vitro effect of erlotinib on phosphorylation of proteins involved in EGFR 
signaling in fibroblasts 
Human phospho kinase arrays were conducted with dermal fibroblast cell lysates of FB120 p8. 
Some sections of the membranes after chemiluminescent visualization of the phosphorylated 
proteins are shown. A) No treatment. B) Stimulated with 4 nM EGF for 5 min. C) Incubated with 10 
µM erlotinib for 2 h then stimulated with 4 nM EGF for 5 min. A stronger signal (pixel density) 
corresponds to higher amounts of phosphorylated protein present and stronger signaling activity. 
Abbreviations: EGF, epidermal growth factor; FB, fibroblasts; p, passage. 
 
 
 
A   untreated B   EGF C   erlotinib 
      + EGF 
fibroblasts 
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Figure 29 Quantification of in vitro effect of erlotinib on phosphorylation of proteins involved in EGFR signaling in fibroblasts 
Human phospho kinase arrays were conducted with dermal fibroblast cell lysates of FB120 p8. The mean pixel density after chemiluminescent visualization of the 45 different 
phosphorylated proteins is shown. Light blue: no treatment. Dark blue: stimulated with 4 nM EGF for 5 min. Green: incubated with 10 µM erlotinib for 2 h then stimulated with 
4 nM EGF for 5 min. The signal for the protein ERK1/2 is too strong to fit the scale and is therefore cut-off at the end of it. The real end of the bar for ERK1/2 is shown in the 
additional section next to the graph where a larger scale is used. A stronger signal (pixel density) corresponds to higher amounts of phosphorylated protein present and 
stronger signaling activity. 
Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FB, fibroblasts; p, passage. 
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In dermal fibroblasts EGF also increased phosphorylation of most of the tested proteins 
involved in EGFR signaling cascades while erlotinib decreased the phosphorylation. Again 
the strength of the effect was different for the various signaling proteins. For quantification 
of the effects the EGF/no treatment and the erlotinib/EGF ratios were calculated as 
described for the keratinocytes in section IV.2.1.2. The five proteins on which erlotinib had 
the strongest effect across the experiments are listed in table 27. The values for all other 
proteins are provided in the Appendix B). 
 
 
Table 27 Mean pixel density for selected proteins from human phospho kinase arrays of 
two different fibroblast cell samples 
Human phospho-kinase arrays were conducted with two different fibroblast cell samples (FB64 p7 
and FB120 p8) following three in vitro treatment conditions (no treatment, 4 nM EGF for 5 min and 
10 µM erlotinib for 2 h + 4 nM EGF for 5 min). For clearer comparison of the stimulating effect of 
EGF and the inhibitory effect of erlotinib between the different cell samples, ratios were calculated 
(EGF/no treatment and erlotinib/EGF). Results for the five phosphorylated proteins on whose 
abundance EGF and erlotinib had the biggest effect are listed here. Abbreviations: EGF, epidermal 
growth factor; FB, fibroblasts; p, passage. 
 
mean pixel density for FB64 p7 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
ERK1/2 134053 254220 107268 1.90 0.42 
Akt 1/2/3 (S473) 19079 22766 12611 1.19 0.55 
EGF R 34264 74409 23720 2.17 0.32 
TOR 17408 17158 8974 0.99 0.52 
Src 14331 43802 7245 3.06 0.17 
 
mean pixel density for FB120 p8 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
ERK1/2 64330.5 182975 33812 2.84 0.18 
Akt 1/2/3 (S473) 4629 11387.5 3941.5 2.46 0.35 
EGF R 7628 24849 4612 3.26 0.19 
TOR 5835 8063 2369.5 1.38 0.29 
Src 5677 7298.5 1791 1.29 0.25 
 
 
The proteins on whose phosphorylation erlotinib had the strongest inhibitory effect differed 
in fibroblasts as compared to keratinocytes. Only EGFR and Src were among the top five 
in both cell types. In addition, in fibroblasts the effect seems to be strongest on the MAPK 
ERK 1/2 and the kinases Akt 1/2/3 and target of rapamycin (TOR).  
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IV.2.2.2 Effect of erlotinib on the phosphorylation of EGFR and ERK 1/2 in 
fibroblasts in vitro 
For further analyses of EGFR signaling across more than just the two example fibroblast 
samples used for the phospho kinase arrays, specific phospho-ELISAs were conducted. 
According to the results from the phospho kinase arrays and considering the commercial 
availability of validated assays, ELISAs for phospho-EGFR and phospho-ERK 1/2 were 
chosen. The relative amount of phosphorylated target protein, normalized to the amount 
of total target protein, was determined and compared between cells incubated with 
erlotinib and stimulated with EGF, cells only stimulated with EGF and cells left untreated. 
For better comparison between cells from different individuals, again the ratios EGF/no 
treatment and erlotinib/EGF were calculated as explained in section IV.2.1.2. The results 
for these ratios from the phospho-EGFR ELISA are presented in table 28. 
 
 
Table 28 In vitro effect of erlotinib on relative amount of phosphorylated EGFR in 
fibroblasts 
Phospho-EGFR ELISAs were conducted with six different fibroblast cell samples following three in 
vitro treatment conditions (no treatment, 40 nM EGF for 5 min and 10 µM erlotinib for 2 h + 40 nM 
EGF for 5 min). The relative amount of phosphorylated EGFR was determined in RFUs normalized 
to total protein. For clearer comparison of the stimulating effect of EGF and the inhibitory effect of 
erlotinib between the different cell samples, ratios were calculated (EGF/no treatment and 
erlotinib/EGF). Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor 
receptor; ELISA, enzyme-linked immunosorbent assay; FB, fibroblasts; p, passage; RFUs, relative 
fluorescence units. 
 
phospho-EGFR 
cell sample EGF/no treatment erlotinib/EGF 
FB19 p6 1.1380 0.8678 
FB21 p9 1.1058 0.8753 
FB25 p11 1.1565 0.8529 
FB26 p6 1.2093 0.8184 
FB33 p10 1.1934 0.8067 
FB43 p8 1.2495 0.8403 
 
 
Stimulation with EGF increased the amount of phosphorylated EGFR (EGF/no treatment > 
1), while prior incubation with erlotinib decreased it (erlotinib/EGF < 1) in all cell samples. 
Therefore, the phospho-EGFR ELISA seemed to be suitable to measure the in vitro effect 
of erlotinib. However, the results for the erlotinib/EGF ratio were very similar in all six 
tested cell samples. The assay did not seem to be sensitive enough to detect differences 
in the in vitro effect of erlotinib in human fibroblasts from different individuals. Therefore, it 
was not used for further analyses. Instead, phospho-ERK 1/2 ELISAs were tested for their 
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suitability for this task. Since the cell-based EGFR ELISA was found not sensitive enough, 
a lysate-based ELISA was tested for ERK 1/2. After establishment and optimization of the 
assay, the main ERK 1/2 ELISA experiments were conducted by the medical student 
Marcel Struß within our working group, under my supervision. The results are presented in 
table 29. 
 
Table 29 In vitro effect of erlotinib on relative amount of phosphorylated ERK 1/2 in 
fibroblasts 
Phospho-ERK 1/2 ELISAs were conducted with 54 different fibroblast cell samples following three 
in vitro treatment conditions (no treatment, 40 nM EGF for 5 min and 5 µM erlotinib for 2 h + 40 nM 
EGF for 5 min). Relative amount of phosphorylated ERK 1/2 was determined in RFUs normalized 
to total protein. For clearer comparison of the stimulating effect of EGF and the inhibitory effect of 
erlotinib between cell samples, ratios were calculated (EGF/no treatment and erlotinib/EGF). 
Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; ERK, 
extracellular signal-regulated kinase; FB, fibroblasts; RFUs, relative fluorescence units. 
 
phospho-ERK 1/2 
  
phospho-ERK 1/2 
cell sample 
EGF/no 
treatment erlotinib/EGF 
 
cell sample 
EGF/no 
treatment erlotinib/EGF 
FB19 p9 3.6883 0.2536 
 
FB96 p8 3.9190 0.3792 
FB21 p9 4.1130 0.3235 
 
FB98 p8 4.8371 0.5564 
FB26 p11 7.6180 0.4013 
 
FB99 p8 5.1002 0.2039 
FB33 p8 2.5443 0.5681 
 
FB103 p8 3.2308 0.4803 
FB40 p9 5.2113 0.4493 
 
FB106 p9 2.7031 0.8185 
FB43 p8 2.4889 0.3194 
 
FB112 p7 11.1117 0.5878 
FB46 p10 2.8345 0.3703 
 
FB114 p7 23.5336 0.4553 
FB53 p7 4.4225 0.4100 
 
FB117 p7 4.0906 0.4949 
FB57 p7 5.2379 0.1765 
 
FB118 p7 17.7995 0.3088 
FB64 p8 3.6602 0.0099 
 
FB120 p8 2.5310 0.4599 
FB72 p9 4.0739 0.4754 
 
FB122 p6 5.9503 0.4863 
FB74 p8 3.4761 0.5651 
 
FB124 p8 4.3149 0.4250 
FB75 p10 1.3296 0.6989 
 
FB125 p8 3.1734 0.4846 
FB76 p9 1.7068 0.9914 
 
FB126 p8 3.0523 0.6255 
FB79 p9 2.1351 0.9735 
 
FB127 p8 1.9762 0.6909 
FB80 p10 1.4940 0.8854 
 
FB128 p8 2.5256 0.8201 
FB81 p9 2.1457 0.7966 
 
FB129 p8 1.6903 0.3254 
FB82 p9 4.5296 0.3124 
 
FB130 p6 3.6520 0.4188 
FB83 p8 8.2605 0.3442 
 
FB131 p7 1.0400 1.0513 
FB84 p8 1.5823 1.1183 
 
FB132 p7 3.3119 0.5480 
FB85 p9 2.0481 0.6394 
 
FB133 p7 2.8670 0.3172 
FB86 p10 5.5561 0.7228 
 
FB134 p7 3.9009 0.5068 
FB87 p8 2.0339 0.7963 
 
FB135 p6 4.0618 0.5765 
FB90 p8 2.2504 0.6667 
 
FB136 p6 7.8450 0.2129 
FB92 p9 2.7265 0.4974 
 
FB137 p6 2.1229 0.6699 
FB93 p8 2.6828 0.8247 
 
FB138 p7 2.0504 0.6206 
FB95 p8 10.6493 0.3698 
 
FB139 p7 1.6598 0.5859 
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Stimulation with EGF increased the amount of phosphorylated ERK 1/2 in all fibroblast 
samples (EGF/no treatment > 1). Prior incubation with erlotinib decreased the amount of 
phosphorylated ERK 1/2 in all but two cell samples (erlotinib/EGF < 1). The phospho-ERK 
1/2 ELISA seemed to be suitable to measure the in vitro effect of erlotinib in human 
fibroblasts. 
The cell samples FB76, FB79, FB80 and FB99 were cultured again and used for an 
additional independent experiment (biological duplicate) to investigate the reproducibility 
of the results. Mean ratios and SDs are given in table 30. 
 
 
Table 30 Reproducibility of results for in vitro effect of erlotinib on fibroblasts from 
phospho-ERK 1/2 ELISA 
Phospho-ERK 1/2 ELISAs were conducted with four different fibroblast cell samples following three 
in vitro treatment conditions (no treatment, 40 nM EGF for 5 min and 5 µM erlotinib for 2 h + 40 nM 
EGF for 5 min). The relative amount of phosphorylated ERK 1/2 was determined in RFUs 
normalized to total protein. For clearer comparison of the stimulating effect of EGF and the 
inhibitory effect of erlotinib between the different cell samples, ratios were calculated (EGF/no 
treatment and erlotinib/EGF). Results are presented as mean values with SDs from two 
independent experiments. Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked 
immunosorbent assay; ERK, extracellular signal-regulated kinase; FB, fibroblasts; n number [of 
independent experiments]; p, passage; SD, standard deviation, RFUs, relative fluorescence units. 
  
phospho-ERK 1/2 
  
EGF/no treatment erlotinib/EGF 
cell sample n mean SD mean SD 
FB76 2 1.9051 0.2805 0.8381 0.2169 
FB79 2 4.6406 3.5433 0.8956 0.1102 
FB80 2 2.7174 1.7301 0.6287 0.3630 
FB99 2 4.4099 0.9762 0.1902 0.0194 
 
 
The standard deviations calculated for the biological duplicates of the phospho-ERK 1/2 
ELISA were rather high for the EGF/no treatment ratio but lower for the erlotinib/EGF 
ratio. The phospho-ERK 1/2 ELISA seemed to be suitable to detect differences in the in 
vitro effect of erlotinib (sensitivity towards erlotinib) on human dermal fibroblasts. 
Therefore, the results from the phospho-ERK 1/2 ELISA (table 29) were used to sort the 
fibroblast samples according to their sensitivity towards erlotinib for further analyses. A 
low erlotinib/EGF ratio means higher sensitivity towards erlotinib. This sorting is depicted 
in figure 30. 
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Figure 30 Fibroblasts grouped into erlotinib-sensitive and -insensitive 
The results from phospho-ERK 1/2 ELISAs, which were conducted with 54 different fibroblast cell samples following in vitro treatment with erlotinib (10 µM, 2 h) and 
subsequent stimulation with EGF (40 nM, 5 min) or stimulation with EGF alone, were used to calculate an erlotinib/EGF ratio for each cell sample. Cell samples were 
grouped into rather erlotinib-sensitive and rather erlotinib-insensitive according to the ratio. Four cell samples from each edge group were chosen for further analyses, 
marked by the red frames. A smaller ratio means higher sensitivity towards erlotinib. Abbreviations: EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent 
assay; ERK, extracellular signal-regulated kinase; FB, fibroblasts. 
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The four fibroblast cell samples with the lowest erlotinib/EGF ratio were chosen as rather 
erlotinib-sensitive cells and the four fibroblast samples with the highest erlotinib/EGF ratio 
(but < 1) were chosen as rather erlotinib-insensitive cells. For all eight cell samples the 
miRNA profiles were determined and compared between the two groups. 
 
 
IV.2.2.3 MiRNA profiles of erlotinib-sensitive versus -insensitive fibroblasts 
As already described for the keratinocytes, miRNA profiles were also determined for the 
dermal fibroblasts. Mature as well as precursor (hairpin) miRNAs which were differentially 
expressed between the four rather erlotinib-sensitive and the four rather erlotinib-
insensitive cell samples (both determined in vitro by the ERK 1/2-ELISA, see previous 
section) were identified. Again, it was also checked whether prior incubation with erlotinib 
+ EGF or EGF alone had an influence on the list of differentially expressed miRNAs. Since 
the lists of differentially expressed miRNAs obtained for the fibroblasts were a lot longer 
than those for the keratinocytes, miRNAs with a p-value < 0.02 instead of the usual 0.05 
are listed. The results for untreated cells are presented in table 31 and respective tables 
for cells incubated with EGF or erlotinib + EGF are included in Appendix B). The threshold 
for the fold change, set at ≥ 1.50 (up-regulated) or ≤ 0.66 (down-regulated) respectively, 
was retained. 
 
 
Table 31 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive fibroblasts (no treatment) 
Differentially expressed precursor and mature miRNAs in rather erlotinib-sensitive as compared to -
insensitive fibroblasts (n = 4 in each group) were determined by NGS and the program DESeq2. In 
vitro sensitivity towards erlotinib was previously determined by ERK 1/2-ELISA. MiRNAs with a p-
value < 0.02 and a fold change of ≥ 1.50 (up-regulated in erlotinib-sensitive cells) or ≤ 0.66 (down-
regulated in erlotinib-sensitive) respectively, are listed. The fold change as logarithm of the basis 2 
(log2 fold change) is given with its standard error (lfcSE, log fold change standard error). The result 
of the statistic Wald test (stat) together with the corresponding p-value is also listed. 
 
erlotinib-sensitive vs. -insensitive 
treatment: none 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-20a 1.2245 0.3097 2.3367 3.9543 7.68E-05 
hsa-mir-494 1.4506 0.3709 2.7333 3.9106 9.21E-05 
hsa-mir-199b 1.0134 0.2851 2.0187 3.5545 3.79E-04 
hsa-mir-382 1.2959 0.3793 2.4553 3.4163 6.35E-04 
hsa-mir-520e -1.6402 0.4907 0.3208 -3.3424 8.31E-04 
hsa-mir-127 1.2793 0.3851 2.4273 3.3221 8.93E-04 
hsa-mir-450b 1.0213 0.3239 2.0298 3.1537 1.61E-03 
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hsa-mir-889 1.2399 0.3955 2.3618 3.1349 1.72E-03 
hsa-mir-148b 0.8478 0.2826 1.7997 3.0000 2.70E-03 
hsa-mir-101-2 0.8467 0.2909 1.7984 2.9112 3.60E-03 
hsa-mir-411 1.0640 0.3683 2.0907 2.8888 3.87E-03 
hsa-mir-654 1.0489 0.3632 2.0690 2.8881 3.88E-03 
hsa-mir-323a 1.0728 0.3759 2.1035 2.8538 4.32E-03 
hsa-mir-379 1.1258 0.3992 2.1823 2.8205 4.80E-03 
hsa-mir-30b 0.9572 0.3402 1.9416 2.8138 4.90E-03 
hsa-mir-101-1 0.7779 0.2861 1.7146 2.7192 6.54E-03 
hsa-mir-17 0.8324 0.3113 1.7806 2.6742 7.49E-03 
hsa-mir-136 0.9454 0.3680 1.9258 2.5690 1.02E-02 
hsa-mir-342 0.9676 0.3804 1.9556 2.5439 1.10E-02 
hsa-mir-585 0.9698 0.3884 1.9586 2.4972 1.25E-02 
hsa-mir-106b 0.6790 0.2872 1.6011 2.3641 1.81E-02 
hsa-mir-199a-2 0.6648 0.2817 1.5854 2.3599 1.83E-02 
hsa-mir-323b 0.9831 0.4180 1.9767 2.3517 1.87E-02 
hsa-mir-7158 0.8414 0.3581 1.7918 2.3497 1.88E-02 
hsa-mir-199a-1 0.6628 0.2833 1.5831 2.3392 1.93E-02 
            
mature miRNA           
hsa-miR-22-5p -0.9825 0.2618 0.5061 -3.7524 1.75E-04 
hsa-miR-504-5p 1.8510 0.5015 3.6075 3.6909 2.23E-04 
hsa-miR-6756-5p -2.0247 0.5780 0.2458 -3.5032 4.60E-04 
hsa-miR-138-5p -1.1710 0.3510 0.4441 -3.3359 8.50E-04 
hsa-miR-20a-5p 1.0365 0.3184 2.0512 3.2553 1.13E-03 
hsa-miR-199b-5p 1.4812 0.4622 2.7918 3.2045 1.35E-03 
hsa-miR-651-5p 2.0364 0.6356 4.1021 3.2038 1.36E-03 
hsa-miR-145-3p -1.4868 0.4789 0.3568 -3.1046 1.91E-03 
hsa-miR-654-5p 1.3471 0.4346 2.5440 3.0997 1.94E-03 
hsa-miR-655-3p 1.5090 0.4971 2.8461 3.0356 2.40E-03 
hsa-miR-450b-5p 0.8490 0.2800 1.8012 3.0319 2.43E-03 
hsa-miR-22-3p -0.9057 0.3025 0.5338 -2.9941 2.75E-03 
hsa-miR-4485 -1.5206 0.5293 0.3485 -2.8731 4.06E-03 
hsa-miR-30b-5p 0.8988 0.3305 1.8645 2.7198 6.53E-03 
hsa-miR-27b-5p -1.1321 0.4175 0.4562 -2.7115 6.70E-03 
hsa-miR-148a-3p 1.2919 0.4826 2.4485 2.6768 7.43E-03 
hsa-miR-361-3p 0.7173 0.2687 1.6441 2.6697 7.59E-03 
hsa-miR-7641 -1.2389 0.4764 0.4237 -2.6006 9.31E-03 
hsa-miR-127-3p 1.0281 0.4086 2.0393 2.5162 1.19E-02 
hsa-miR-23a-5p -1.5575 0.6220 0.3397 -2.5039 1.23E-02 
hsa-miR-383-5p 1.5725 0.6356 2.9742 2.4741 1.34E-02 
hsa-miR-758-3p 0.9273 0.3773 1.9017 2.4576 1.40E-02 
hsa-miR-380-3p 1.5437 0.6285 2.9155 2.4564 1.40E-02 
hsa-miR-1268b -1.5223 0.6345 0.3481 -2.3991 1.64E-02 
hsa-miR-17-5p 0.6945 0.2903 1.6183 2.3920 1.68E-02 
 
 
 
120 
 
hsa-miR-4510 -0.9195 0.3895 0.5287 -2.3606 1.82E-02 
hsa-miR-143-5p -1.0984 0.4664 0.4670 -2.3553 1.85E-02 
hsa-miR-3135b -0.9745 0.4182 0.5089 -2.3301 1.98E-02 
 
 
In the erlotinib-sensitive fibroblasts one precursor miRNA and 13 mature miRNAs were 
significantly down-regulated while 24 precursor and 15 mature miRNAs were significantly 
up-regulated when compared to erlotinib-insensitive cells. Fold changes ranged between 
1.58 and 4.10 (0.53 and 0.25 for down-regulation respectively). 
 
For a better overview, those miRNAs which were significantly differentially expressed (p < 
0.05) under all three different in vitro treatments were determined, as depicted in figure 
31. These miRNAs are referred to as “overlap miRNAs”. 
 
 
 
 
Figure 31 Overlap of differentially expressed miRNAs in erlotinib-sensitive as compared to 
-insensitive fibroblasts between different in vitro treatments 
Significantly differentially expressed precursor (left) and mature (right) miRNAs in rather erlotinib-
sensitive as compared to -insensitive fibroblasts (n = 4 in each group). MiRNA expression was 
determined by NGS. Cells were either incubated with 4 nM EGF (dark blue circle) or 4 nM EGF 
plus 5 µM erlotinib (green circle) or left untreated (light blue circle) prior to sequencing. Numbers in 
overlapping parts of the circles represent the numbers of specific miRNAs which were significantly 
differentially expressed (p < 0.05) in both or all three treatment groups, respectively. 
Abbreviations: EGF, epidermal growth factor; miRNA, micro ribonucleic acid; NGS, next generation 
sequencing. 
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As for the keratinocytes, those miRNAs which were significantly differentially expressed in 
erlotinib-sensitive as compared to -insensitive fibroblasts regardless of the in vitro 
treatment were considered especially interesting. They represent a “baseline” difference 
between the erlotinib-sensitive and -insensitive cells, which is independent of stimulation 
with EGF or incubation with erlotinib. There was an overlap of 34 specific precursor 
miRNAs which were significantly differentially expressed in all three in vitro treatment 
groups and an overlap of 16 mature miRNAs.  
 
Those miRNAs which were only significantly differentially expressed in cells incubated 
with erlotinib and not in the other treatment groups were also considered especially 
interesting. They represent a difference in response to erlotinib in erlotinib-sensitive as 
compared to -insensitive fibroblasts. There were 27 different miRNA precursors and 26 
mature miRNAs only significantly differentially expressed in cells incubated with erlotinib. 
As already explained for the keratinocytes, also for these fibroblast miRNAs a through 
literature search was conducted to select those miRNAs which had already been found to 
be involved in response to EGFRIs in previous studies, which provided additional 
evidence for the suitability of the selected candidate miRNAs. Further analysis of all 
miRNAs would have exceeded the timeframe of this thesis. An overview table of the 
results of this literature search can be found in appendix B. Based on the literature search, 
expression of the following miRNAs in erlotinib-sensitive as compared to -insensitive 
fibroblasts was verified using qRT-PCR: mir-34a, miR-34a-5p, mir-17, mir-30b, mir-382, 
mir-494, mir-520e, mir-7-1, miR-7-1-3p, mir-31, miR-31-3p. In addition, the following 
miRNAs identified from the equivalent literature search for candidate miRNAs in 
keratinocytes (refer to Appendix A) were also tested in fibroblasts to compare their roles in 
the two cell types: mir-146a, miR-146a-5p, mir-138-2, mir-221. 
 
In general, in PCR analyses the differences in expression between cell samples grouped 
as erlotinib-sensitive and those grouped as erlotinib-insensitive were not significant for 
any of the selected miRNAs as tested with Student’s t-test. Figure 32 shows a comparison 
of ∆CP values for expression of miRNAs in untreated erlotinib-sensitive fibroblasts and 
untreated erlotinib-insensitive fibroblasts. Differential expression was also not significant in 
cells with prior in vitro treatment with erlotinib. 
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Figure 32 Comparison of miRNA expression in untreated erlotinib-sensitive and erlotinib-
insensitive fibroblasts determined by qRT-PCR 
∆CP values representing expression of different miRNAs in untreated fibroblasts as determined by 
qRT-PCR. Dark red: Mean ∆CP values of erlotinib-sensitive cell samples as determined by ELISAs 
(n = 6). Light red: Mean ∆CP values of erlotinib-insensitive cell samples (n = 6). MiRNAs were 
selected due to results from NGS and a literature search. Error bars represent SEM. Student’s t-
test showed no significant differences (p-value < 0.05). 
Abbreviations: ∆CP, delta crossing point; ELISA, enzyme-linked immunosorbent assay; NGS, next 
generation sequencing; qRT-PCR, quantitative real-time polymerase chain reaction; SEM, 
standard error of the mean. 
 
 
A comparison of the results from NGS and PCR is presented in table 40 with fold-changes 
and p-values for NGS and also fold-changes for PCR (but no p-values since in PCR 
analysis t-test for ∆∆CP values did not show significant differences [no p-values <0.05]). 
 
 
„miRNAs identified from 
keratinocyte analyses“ 
„additionally 
included 
mature 
miRNAs” 
„erlotinib 
only 
miRNAs” 
„overlap miRNAs” 
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Table 32 Comparison of NGS and qRT-PCR results for fold-changes of specific miRNAs 
differentially expressed in erlotinib-sensitive and -insensitive fibroblasts 
Fold-changes in expression of specific precursor and mature miRNAs in erlotinib-sensitive as 
compared to -insensitive primary human fibroblasts (n = 4 in each group) were determined by NGS 
and qRT-PCR. Cells were either incubated with 4 nM EGF (dark blue columns) or 5 µM erlotinib 
plus 4 nM EGF (green columns) or left untreated (light blue columns) prior to miRNA expression 
analyses. Significant p-values for NGS results (< 0.05) are marked in bold. MiRNAs selected by 
Venn diagrams and literature search as described in chapter III. MiRNAs with higher expression in 
erlotinib-sensitive cells than in -insensitive cells (fold-change ≥ 1.2) are marked with a green arrow 
(up-regulated) while those with lower expression (fold-change ≤ 0.8) are marked with a red arrow 
(down-regulated). Fold-changes in between those cut-offs are not regarded as differential. 
Abbreviations: EGF, epidermal growth factor; miRNA, micro ribonucleic acid; NGS, next generation 
sequencing; qRT-PCR, quantitative real-time polymerase chain reaction. 
 
 
 
As for the keratinocytes, for the fibroblasts again those miRNAs which were significantly 
(p-value < 0.05) up- or down-regulated in the NGS analyses were mainly also determined 
as up- or down-regulated in the PCR analyses, respectively, confirming the effect (even 
though fold-changes differed between NGS and PCR results). 
In erlotinib-sensitive fibroblasts expression of miRNA mir-34a was significantly up-
regulated as compared to erlotinib-insensitive cells, across all three treatment options, in 
NGS as well as PCR assays. This was also observed for the mature form miR-34a-5p 
(partially confirmed by PCR). The miRNAs mir-17, mir-30b, mir-382 and mir-494 were also 
up-regulated in erlotinib-sensitive as compared to -insensitive cells, as confirmed by PCR 
(in untreated cells fold-changes of mir-30b and mir-494 just below cut-off value of 1.2 in 
PCR). Further, mir-7-1 was significantly up-regulated in sensitive cells under treatment 
miRNA
p-value p-value p-value
"overlap miRNAs"
mir-34a hairpin ↑ 1.59 0.0261 ↑ 1.30 ↑ 1.78 0.0063 ↑ 2.48 ↑ 1.79 0.0117 ↑ 2.60
mir-17 hairpin ↑ 1.78 0.0075 ↑ 1.25 ↑ 1.81 0.0205 ↑ 1.73 ↑ 1.85 0.0108 ↑ 1.58
mir-30b hairpin ↑ 1.94 0.0049 1.11 ↑ 2.22 0.0001 ↑ 1.73 ↑ 1.99 0.0019 ↑ 2.00
mir-382 hairpin ↑ 2.46 0.0006 ↑ 1.70 ↑ 2.41 0.0012 ↑ 1.62 ↑ 2.35 0.0038 ↑ 2.63
mir-494 hairpin ↑ 2.73 0.0001 1.17 ↑ 2.49 0.0030 ↑ 2.19 ↑ 2.70 0.0005 ↑ 2.90
mir-520e hairpin ↓ 0.32 0.0008 ↓ 0.42 ↓ 0.45 0.0300 ↓ 0.79 ↓ 0.40 0.0128 0.85
"erlotinib only miRNAs"
mir-7-1 hairpin ↑ 1.47 0.0826 ↑ 1.30 ↑ 1.44 0.1164 ↑ 2.02 ↑ 1.56 0.0427 ↑ 1.72
mir-31 hairpin ↑ 1.34 0.1358 ↓ 0.69 ↑ 1.44 0.0985 ↑ 1.24 ↑ 1.55 0.0417 0.88
miR-34a-5p (mature) ↑ 1.30 0.2578 0.90 ↑ 1.57 0.0527 ↑ 1.27 ↑ 1.52 0.0509 0.93
miR-7-1-3p (mature) 0.96 0.9152 0.97 0.93 0.8494 ↑ 1.33 1.10 0.7928 ↑ 1.33
miR-31-3p (mature) 1.12 0.7816 ↑ 3.49 1.13 0.7701 ↑ 1.33 0.84 0.6308 ↓ 0.64
mir-146a hairpin ↑ 1.22 0.5293 1.17 ↑ 1.48 0.2410 ↑ 2.07 ↑ 1.47 0.2472 ↑ 1.37
miR-146a-5p (mature) ↑ 1.31 0.5259 1.00 ↑ 1.39 0.4727 ↑ 1.26 ↑ 1.40 NA 1.19
mir-138-2 hairpin ↓ 0.69 0.1401 ↓ 0.57 1.15 0.5816 1.13 0.83 0.4602 ↑ 1.27
mir-221 hairpin ↑ 1.22 0.2861 ↑ 1.56 ↑ 1.21 0.3096 ↑ 1.60 ↑ 1.33 0.1530 ↑ 1.75
fold-change
PCR
fold-changefold-change
NGS NGS
fold-changefold-change fold-change
 sensitive vs. insensitive
(no treatment)
NGS PCR
additionally included
mature miRNAs
miRNAs identified from
keratonocyte analyses
sensitive vs. insensitiv
 (EGF)
sensitive vs. insensitive
(erlotinib)
PCR
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with erlotinib. Up-regulation of mir-7-1 was also visible in untreated cells as well as cells 
incubated with EGF in NGS and PCR assays (but in NGS did not reach significance). In 
contrast, mir-520e was significantly down-regulated in erlotinib-sensitive fibroblasts as 
compared to erlotinib-insensitive cells, across all three treatment options, in NGS as well 
as PCR assays. 
Those miRNAs which were identified as significantly differentially expressed in 
keratinocytes were not significantly differentially expressed in fibroblasts, again indicating 
large differences in cellular processes in these two dermal cell types. Regulation of some 
miRNAs even seemed to be opposite in the two cell types. While in keratinocytes mir-
146a and its mature form miR-146a-5p were down-regulated in erlotinib-sensitive cells 
across all treatments, in fibroblasts those two miRNAs were rather up-regulated in 
erlotinib-sensitive cells. Similarly, in keratinocytes mir-221 was down-regulated in erlotinib-
sensitive cells, especially under treatment with erlotinib, but in fibroblasts mir-221 was 
upregulated in erlotinib-sensitive cells across all treatments. 
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Chapter V: Discussion 
 
V.1  Patient samples from the Dermatoxgen study 
 
V.1.1 EGFRI-induced skin rash and survival 
The aim of this study was to identify predictive biomarkers for the occurrence and severity 
of EGFRI-induced skin toxicity. To achieve this, plasma samples from patients enrolled in 
the Dermatoxgen study were analyzed with regard to the concentrations of various 
candidate analytes which are known to interact with, regulate or functionally modulate 
EGFR inhibition, such as ligands of EGFR or cross-reacting receptors, molecules 
regulating EGFR expression or EGFRIs themselves, which might show correlations with 
clinical parameters (skin rash, OS, PFS). 
 
A significant association between occurrence of EGFRI-induced skin rash and survival of 
the patients in the Dermatoxgen study was already shown in previous publications by this 
research group104,106,107 and confirmed the studies by Saltz et al37, Wacker et al38 and 
Perez-Soler et al39 and numerous others. These results confirmed that the Dermatoxgen 
patient cohort is suitable to investigate EGFRI-induced skin rash and search for potential 
biomarkers for this rash. 
 
 
V.1.2 Association between plasma concentrations of EGFRIs and skin rash and 
survival 
In the Dermatoxgen patient cohort the serum concentration of the EGFRI erlotinib was not 
significantly associated with development of skin rash or survival of the patients, as shown 
in the publication by Steffens et al107. In order to better reflect the erlotinib metabolism of 
the patients, rather than just measuring single serum concentrations, Steffens et al. 
determined a metabolic ratio by dividing the serum concentration of erlotinib by the serum 
concentration of its main metabolite O-desmethyl-erlotinib. The calculated metabolic ratio 
was significantly correlated with the occurrence of EGFRI-induced skin rash (p-value = 
0.0291). The metabolic ratio was also significantly associated with OS. A lower metabolic 
ratio means higher metabolic activity, which was associated with decreased survival.  
 
In this present work we now investigated whether a correlation between plasma 
concentrations of cetuximab and development of skin rash and survival time could also be 
identified. Therefore, in patients from the Dermatoxgen study who were treated with the 
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mAb cetuximab the plasma concentration of this EGFRI was determined by a specific 
ELISA. The cetuximab plasma concentration was not significantly associated with 
development of skin rash, but a trend of association of higher cetuximab levels with 
development of rash can be seen in the graphic presentations. With regard to survival, 
higher concentrations of cetuximab were significantly associated with increased survival of 
the patients, but only if the concentration values were dichotomized (not when quartered). 
Only very high and very low concentration values of cetuximab seem to correlate with 
survival (positively or negatively, respectively). 
It might be beneficial if a metabolic ratio for cetuximab could be determined, as it was 
previously done for erlotinib. However, there is no known metabolic product of cetuximab, 
whose concentration could be measured. The elimination routes of exogenous mAbs are 
not well characterized and it is believed that various mechanisms are involved, such as 
the reticuloendothelial system (RES) and target-mediated elimination, as well as non-
specific endocytosis120. The mAbs are degraded into small peptides by lysosomes, 
therefore, specific metabolites cannot be identified. 
Overall, at present metabolic ratios can only be determined for TKIs, not for mAbs. 
 
 
V.1.3 Association between plasma concentrations of the growth factors AREG 
and HGF and skin rash and survival 
 
V.1.3.1 AREG 
The plasma concentration of the EGFR ligand AREG was not significantly correlated with 
the development of EGFRI-induced skin rash or survival of the patients. This finding is in 
contrast to the results by Takahashi and colleagues, who found that patients with higher 
serum levels of AREG developed lower grades of skin toxicity79. This discrepancy in 
results could be due to the fact that they analyzed pre-treatment samples while in the 
Dermatoxgen study plasma samples were only available from four weeks after initiation of 
the EGFRI therapy. In previous studies the group around Takahashi showed that the 
serum levels of AREG increased during EGFRI therapy in 95 % of patients, while HGF 
levels only increased in 58 % of patients and also to a much lesser extent121. This might 
explain why higher concentrations of AREG were measured in the Dermatoxgen cohort 
(5-1303 pg/ml) than in Takahashi’s cohort (3-636 pg/ml) and also in a cohort analyzed by 
Ishikawa and colleagues (10-380 pg/ml)67. Both of the other groups used pre-treatment 
serum samples for their analyses. Our results confirm that HGF is more stable as a 
biomarker than AREG over the course of therapy. However, it might be advisable to use 
plasma taken prior to the start of the EGFRI therapy.  
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Further studies to investigate the role of AREG plasma concentrations in EGFRI-induced 
skin rash and therapy response are needed, since currently conflicting results exist. In a 
recent study by Wang et al. AREG was identified as a possible prognostic marker in 
pancreatic ductal adenocarcinoma122. In that study, protein levels of AREG in the tumor 
tissue were inversely correlated with disease-free and overall survival. However, Llovet 
and colleagues found that in patients suffering from metastatic colorectal cancer high 
amounts of AREG mRNA in the tumor tissue correlated with better therapy response and 
increased OS123. Another group (Yonesaka et al.) also recently showed a correlation 
between high plasma levels of AREG (in combination with low levels of the ErbB3 ligand 
heregulin) and increased objective response rate to cetuximab in metastatic colorectal 
cancer124. The working group around Ishikawa on the other hand observed a significant 
correlation between high serum concentrations of AREG and poor response to gefitinib in 
patients with NSCLC67.These studies show that AREG might play different roles in distinct 
types of cancer and that its concentration might have different meanings depending on 
whether it was determined in tumor tissue or blood serum/plasma.  
 
V.1.3.2 HGF 
In the Dermatoxgen patient cohort the plasma concentration of the MET ligand HGF was 
inversely correlated with OS of the patients (p-value = 2 x 10-5). This result confirms the 
observations reported by Takahashi and colleagues in 2014121. They analyzed serum 
levels of different growth factors in patients with metastatic colorectal cancer who were 
treated with an anti-EGFR antibody and also found a significant inverse correlation 
between serum levels of HGF and OS. The results presented in this thesis show that the 
correlation between HGF levels and OS is not restricted to patients suffering from 
colorectal cancer and being treated with mAbs. Instead it can also be observed in a 
patient cohort including different types of cancers (lung, colon, pancreatic and head and 
neck cancer) and EGFRIs (mAbs and TKIs). 
Subgroup analysis showed that the correlation between HGF concentration and OS was 
significant in patients suffering from lung and pancreatic cancer (p-values = 0.0018 and 
0.00014, respectively) but not in patients suffering from colon and head and neck cancer 
(p-values = 0.63 and 0.59, respectively). A lack of correlation in the two latter groups 
might be due to the small number of patients with head and neck cancer (n = 6) and the 
fact that during the rather short follow-up period (360 days) only few patients suffering 
from colon cancer died, which means a longer follow-up time would have been necessary 
to determine factors correlated with the survival time. 
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It is well established that over-activated HGF/MET signaling increases invasive growth 
and metastasis by inducing motility of tumor cells and survival in remote tissue sites77,78. 
This effect could explain why higher levels of HGF are associated with decreased survival 
and it would rather render HGF a prognostic biomarker. However, the correlation between 
plasma concentration of HGF and OS was only significant in the subgroup of patients who 
had developed skin rash and not in the group without rash. This suggests that HGF might 
rather have a predictive implication for the efficacy of EGFR inhibition. 
 
A significant inverse correlation between HGF levels and severity of EGFRI-induced rash 
was also observed when considering all four grades of rash (grades 0 to 3). This finding is 
in accordance with a Takahashi study from 2015, which also found that patients with 
higher serum levels of HGF developed lower grades of skin toxicity79. They measured a 
median HGF concentration of 1337 pg/ml in serum which is in accordance with our 
median of 1292 pg/ml determined in plasma. It remains unclear why no significant 
correlation was observed between HGF concentrations and skin rash yes/no (figure 14C). 
However, this might be due to some single outliers, which might call for further 
optimization of the ELISA assay and further standardization of sample handling at the 
various study sites. 
 
The mechanism behind the correlation between HGF levels and skin rash is not 
completely understood so far. HGF/MET signaling has been linked to resistance to EGFRI 
therapy in many types of cancer68, like NSCLC (gefitinib)125,126 and colon cancer 
(cetuximab)127. MET can activate a number of pathways which are normally also activated 
by EGFR, like the MAPK, PLCγ and PI3K/Akt pathways69. It is probable that in signaling 
networks as complex as the ones containing EGFR and MET, certain effectors or even 
pathways are redundant for certain functions under specific physiological conditions74,128. 
When EGFR is inhibited in cancer therapy, tumor cells possibly evade death by increasing 
MET signaling, which shares a high number of effectors with the EGFR pathways. This 
offers an explanation for the correlation between plasma concentration of the MET ligand 
HGF and OS of the patients. This compensation of EGFR inhibition by HGF/MET 
signaling might also happen in skin cells and could explain why higher plasma 
concentrations of HGF correlate with less severe EGFRI-induced skin rash. 
 
Several studies have already investigated possible signaling mechanisms of HGF and 
MET in keratinocytes. Animal studies in a mouse model for diabetes (impaired wound 
repair) showed that treatment of wounds with HGF increases re-epithelialization and 
reconstruction of an intact epidermal layer via migration and proliferation of 
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keratinocytes70. In 2007 Spix and colleagues found that in human corneal epithelial cells 
HGF stimulates EGFR and downstream effectors like ERK1/2 via MET and activation of 
EGFR ligands like AREG by proteolysis129. They also observed that directly after 
stimulation with HGF the resulting phosphorylation of ERK1/2 was not dependent on 
EGFR. Only about an hour after the HGF stimulation the phosphorylation of ERK1/2 could 
be regulated by EGFR. This indicates that HGF cannot just cross-activate the EGFR itself 
but also effectors of the EGFR independently of the receptor. The group also found 
indications for these mechanisms to be present in human epidermal keratinocytes. 
 
Overall, HGF seems to be a promising predictive biomarker for the efficacy of EGFRI 
therapy. It should be noted that in the subgroup of patients who developed no skin rash a 
trend towards an association between plasma levels of HGF and OS was also visible. 
Even though this association was not significant, it might indicate that the plasma 
concentration of HGF is not exclusively predictive for therapy efficacy but also partially 
prognostic for patients’ outcome (OS), independently of the activity of the EGFRI. It has 
been shown in a previous study in metastatic colorectal cancer patients that the 
occurrence of EGFRI-induced rash was significantly associated with OS in patients with 
mutations in codon 12 of KRAS in tumor cells130. Such a mutation leads to an EGFR-
independent activation of the MAPK pathway, rendering EGFRIs ineffective and making it 
surprising that EGFRI-induced rash was still associated with OS. This suggests that, in 
addition to being predictive for EGFRI efficacy, the skin rash might also partially be a 
prognostic marker, which would match observations in the Dermatoxgen samples for 
HGF. Possible mechanisms explaining this still remain to be investigated. Immunological 
processes might be involved. 
 
Of course due to its pivotal role in tumorigenesis and development of resistance to certain 
anti-cancer drugs, HGF is also a promising target for cancer therapy itself. In 2014 a 
randomized phase Ib/II trial evaluated the efficacy of a combination therapy with the 
EGFRI panitumumab and an anti-HGF antibody called rilotumumab in patients with 
metastatic colorectal cancer131. They found an improvement in objective response rate as 
compared to treatment with panitumumab alone (31 vs. 21 %). Therefore, HGF should 
also be further studied with regard to its role as target in cancer therapy. 
 
 
 
 
 
130 
 
V.1.4 No association between plasma levels of vitamin D and EGFRI-induced skin 
rash 
The suitability of 25-OH-vitamin D levels as biomarkers in EGFRI therapy was also 
investigated. No previous studies could be identified in which 25-OH-vitamin D has ever 
been investigated in this context. The mean 25-OH-vitamin D plasma concentration in the 
Dermatoxgen patient cohort was 21 ng/ml. In comparison, this concentration is higher 
than the mean concentration measured by Imtiaz and colleagues in a study cohort of 90 
breast cancer patients, which was 9.3 ng/ml132. However, this discrepancy might be due to 
a different role of vitamin D in breast cancer patients than in patients suffering from lung, 
colorectal, pancreatic or head and neck cancer, which is not elucidated so far. In the same 
publication a mean serum vitamin D level of 14.9 ng/ml was reported in healthy controls, 
indicating that vitamin D levels seem to be decreased in breast cancer patients. In 
addition the use of a different assay kit might have led to higher values in our study 
cohort. Literature values for vitamin D levels, which were determined in patients suffering 
from the same types of cancer as patients in the Dermatoxgen study and which were 
measured with an ELISA method instead of other methodologies (e.g. HPLC) could not be 
identified for comparison. 
 
There was no significant association between the plasma concentration of 25-OH-vitamin 
D and the development of EGFRI-induced skin rash in the Dermatoxgen cohort. VDREs 
had been identified in the promoter region80-82 and intron 183 of the EGFR gene in previous 
studies by other groups and 25-OH-vitamin D had been shown to either increase or 
decrease EGFR mRNA and protein levels in different cancer cells80,81. However, 
according to our results, plasma levels of 25-OH-vitamin D do not seem to have an 
influence on EGFR signaling in skin cells or at least not to an extend which affects EGFR 
inhibition by the applied drugs or development of EGFRI-induced skin rash. 
 
The vitamin D ELISA used in this study detects 25-OH-vitamin D2 and D3, so both types of 
vitamin D were taken into account for the analyses. Unfortunately, there are no 
standardized threshold values to define sufficiency and deficiency in vitamin D. Some 
studies and meta-analyses suggest that vitamin D levels > 30 ng/ml have a beneficial 
effect on OS in general and on the prevention and prognosis regarding certain diseases, 
such as common types of cancer and cardiovascular diseases133,134. Therefore, they 
suggest that plasma levels < 30 ng/ml define vitamin D insufficiency. However, a recent 
study by Hansen et al. found no beneficial effect on bone mineral density upon vitamin D 
supplementation for one year raising plasma levels from < 30 ng/ml (14 – 27 ng/ml) to > 
30 ng/ml in postmenopausal women117. They suggest that vitamin D serum concentrations 
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of ≥ 20 ng/ml represent vitamin D repletion and hence support the conclusion of the 
Institute of Medicine from 2011, stating that 20 ng/ml is the cut-off value defining vitamin D 
sufficiency116. Some experts would set this cut-off value even lower (< 10 ng/ml), 
especially when the plasma/serum concentrations are determined using immunological 
methods, because these methods are not as sensitive as others135. Considering the high 
variation in serum and plasma concentrations of vitamin D measured with different 
methods, such as HPLC, luminescence assays or ELISAs, it would be most advisable to 
postulate standardized individual reference values for each specific method, but so far 
such values have not been implemented136. Until such reference values are established, 
conduction of vitamin D assays and interpretation of results will remain variable and 
unreliable. 
 
In the Dermatoxgen patient cohort the plasma concentration of 25-OH-vitamin D was 
significantly correlated with metastasis (p-value = 0.0109). Patients who showed 
metastases at the beginning of the observation period had lower plasma concentrations of 
25-OH-vitamin D than those who showed no metastases. This association has also been 
shown in various other studies, e.g. in multiple melanoma patients118 and in breast cancer 
cells and mouse models of breast cancer119. The fact that the results of these previous 
investigations were confirmed in our study underlines the good quality of the Dermatoxgen 
plasma samples and the correct conduction of the assays. Further investigations about 
the mechanisms by which 25-OH-vitamin D deficiency mediates metastasis, were not part 
of the scope of this study. 
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V.2  Cell model 
 
V.2.1 Primary human dermal keratinocytes as cell model for studying EGFRI-
induced skin rash 
To date the molecular mechanisms leading to the occurrence of EGFRI-induced skin rash 
are not completely understood. In order to identify and establish reliable predictive 
biomarkers for this rash, it is of great importance to further elucidate the pathways and 
single signaling molecules involved in its development. Since epidermal keratinocytes are 
the main type of skin cells involved in the pathophysiology of EGFRI-induced rash58, they 
were chosen for further experiments to test their suitability as cell model for in vitro studies 
of the rash. First investigations were performed in epidermal keratinocytes from healthy 
human donors. 
Characterization of the primary keratinocytes by visual examination and identification of 
specific keratinocyte markers confirmed that isolation and cultivation of primary 
keratinocytes from the donated skin samples was successful. Using Western blot analysis 
a strong signal for cytokeratin CK10 was detected across all established keratinocytes 
cultures, and a slight signal for CK14, also across all cultures. Keratins are structural 
proteins, which form heterodimers to build strong filamentous bundles in keratinocytes. In 
basal cells mainly keratin 5 and 14 are expressed, while in the upper skin layers (mainly in 
the stratum spinosum and to some extend also in the stratum granulosum) keratin 1 and 
10 are the prevailing keratins137. This indicates that the established keratinocyte cultures 
mainly contained keratinocytes which were differentiated and rather resembled cells from 
the intermediate skin layers instead of the basal layer. Involucrin, which is a differentiation 
marker mainly found in cells of the two outer skin layers, stratum granulosum and stratum 
corneum, could not be identified in the established keratinocyte culture, indicating that the 
cells were not completely differentiated. It has to be noted however that no controls were 
available for Western blotting since the commercially available primary keratinocytes did 
not contain specifications about their differentiation status. Hence, the Western blot results 
have to be interpreted with caution. However, they can provide hints for characterization 
of the cell cultures and about potential inter-sample differences. The amounts of 
cytokeratin proteins detected seemed to be similar in all tested keratinocyte cultures, 
indicating that cells were in similar differentiation stages.  
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V.2.1.1 In vitro effect of erlotinib in keratinocytes 
Incubation of the established primary human keratinocytes with the EGFRI erlotinib 
showed that an optimal concentration to observe changes in cell signaling in vitro was 
between 5 and 10 µM. In comparison, Lankheet and colleagues measured a mean pre-
dose plasma concentration of 3.1 µM erlotinib (1222 ng/ml) in NSCLC patients treated 
with 150 mg erlotinib per day for three weeks138, which is similar to the mean serum 
concentration determined in the Dermatoxgen study: 1079.6 ng/ml. Lankheet and 
colleagues also measured a pre-dose concentration of 0.37 µM erlotinib (149 ng/ml) in 
tumor samples. The erlotinib concentrations used in the in vitro cell model described here 
are 1.5 to 25 fold higher than the plasma/tumor tissue concentrations measured in 
patients by Lankheet et al. However, it has to be taken into account that in our study 
healthy dermal cells were used, which might depend on EGFR signaling to a different 
extent than tumor cells (with overexpressed or over-activated EGFR) and therefore higher 
concentrations of EGFRIs might be needed to cause measurable in vitro effects. The 
erlotinib concentrations established in our study are in accordance with the concentrations 
used by several other groups in their in vitro experiments, e.g. by Commandeur et al for 
investigations about EGFR inhibition in 3D in vitro models of normal skin and cutaneous 
carcinoma (10 µM erlotinib used)139 and by Miyazaki et al for establishing two novel in 
vitro drug sensitivity tests to predict molecular target drug responses in lung cancer cells 
(0.2 µM - 20 µM erlotinib used)140. 
In our study we showed that in vitro stimulation with the EGFR ligand EGF led to a 
significant increase in the amount of phosphorylated proteins involved in the well-known 
EGFR signaling pathways, indicating increased signaling activity. Prior incubation with 
erlotinib resulted in a significant decrease in the amount of these phosphorylated proteins, 
indicating successful inhibition of EGFR signaling in vitro. The strength of this inhibitory 
effect was different for the various investigated signaling proteins and it was strongest for 
the proteins EGFR, JNK 1/2/3, c-Jun, Src and AMPKα1. JNK is known as kinase from the 
MAPK pathway and c-Jun as its target, which is part of a complex (AP-1), which upon 
activation by phosphorylation binds to specific DNA sequences in the nucleus and alters 
gene expression52. Src (short for sarcoma) is a tyrosine kinase which is known to be 
involved in numerous pathways, triggered by a variety of receptors, including receptor 
tyrosine kinases, G-protein coupled receptors and adhesion receptors141, rendering it 
difficult to analyze its role in one specific pathway. AMPKα1 is the catalytic subunit of the 
serine/threonine kinase AMPK, which regulates various key metabolic enzymes and 
protects the cell from ATP depletion. It is activated when decreases in ATP production 
result in relative increases in the levels of AMP or adenosine diphosphate in the cell. It is 
still not clear whether there is a cross-talk between EGFR and AMPK pathways. Guo and 
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colleagues found that activation of AMPK results in inhibition of glioblastoma cells, which 
is much more effective in tumors which are EGFR-activated142. Similarly, in breast cancer 
cell lines with amplification and over-expression of EGFR, activation of AMPK led to dose- 
and time-dependent inhibition of EGFR and eventually cell death, as shown by Jhaveri et 
al143. However, none of the groups further elucidated possible underlying mechanisms of 
the inhibitory effect of AMPK on EGFR signaling. It also remains elusive whether some 
kind of inverse feedback mechanism exists which might directly link an inhibition of EGFR 
with a decrease in the amount of phosphorylated AMPK in the cell or whether an inhibition 
of EGFR signaling might just lead to a reduced requirement of ATP in the cell and 
therefore also to a decrease of the cellular levels of activated AMPK. For further 
investigations of in vitro EGFR inhibition the proteins EGFR, JNK and c-Jun were chosen 
here, since their roles in EGFR signaling are considerably better understood. 
 
Specific ELISAs for EGFR, JNK and c-Jun conducted across all available primary 
keratinocyte cultures showed that the phospho-EGFR ELISA was most suitable to 
measure the in vitro effect of erlotinib in human keratinocytes, with the best reproducibility 
among the tested assays. Therefore, results from the phospho-EGFR ELISA were used to 
group all available primary keratinocyte cultures into erlotinib-sensitive and rather 
erlotinib-insensitive cells (six versus six cultures). For all twelve keratinocyte samples 
miRNA profiles were determined by using NGS and compared between the six rather 
erlotinib-sensitive and the six rather erlotinib-insensitive samples.  
 
 
V.2.1.2 Differences in miRNA profiles in erlotinib-sensitive versus -insensitive 
keratinocytes 
Differences in miRNA profiles in erlotinib-sensitive as compared to rather erlotinib-
insensitive keratinocytes were investigated using the same three different treatment 
options as in the prior experiments: EGF, erlotinib plus EGF and no treatment. Those 
miRNAs which were significantly differentially expressed across all three treatment 
options were considered to represent a “baseline” difference between the erlotinib-
sensitive and -insensitive cells, which is independent of stimulation with EGF or incubation 
with erlotinib. There was only one such overlap miRNA identified, which was the precursor 
mir-146a. 
Those miRNAs which were only significantly differentially expressed in cells incubated 
with erlotinib and not in the other treatment groups were also considered interesting 
because they might represent a difference in response to erlotinib in erlotinib-sensitive as 
compared to -insensitive keratinocytes. Nineteen respective precursor miRNAs and 13 
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mature miRNAs were identified. A literature search revealed that some of these identified 
miRNAs were also identified in other studies with potential roles in EGFR signaling and 
inhibition, which strengthened the evidence for these candidate miRNAs. Those miRNAs 
were mir-31, mir-138-2, mir-221, mir-520e and mir-944. 
 
mir-146a/miR-146a-5p 
In erlotinib-sensitive keratinocytes expression of precursor mir-146a and the 
corresponding mature form miR-146a-5p were down-regulated as compared to erlotinib-
insensitive cells, across all three treatment options, in NGS (significantly) as well as in 
PCR assays. 
Mir-146a is known as a tumor suppressor gene, whose expression was found to be lower 
in tumor tissue than in healthy control tissue as shown for example in NSCLC144 and 
pancreatic cancer145 patients. In a recent bioinformatics analysis conducted by Huang and 
colleagues, using twelve different online software programs, target genes of miR-146a-5p 
were predicted146. EGFR and JUN were among the “Top targets” found with most of the 
software. 
In addition, inhibition of mir-146a was found to result in up-regulation of EGFR in various 
cell lines, while re-expression of mir-146a led to a decrease in EGFR mRNA and protein 
levels (pancreatic cancer cells147, hepatocellular cancer cells148, NSCLC cells144). 
Interestingly, it was also shown in in vitro experiments that transfection with mir-146a had 
an additive inhibitory effect on cancer cell proliferation together with each of the TKIs 
afatinib, gefitinib and erlotinib as well as with the mAb cetuximab144,148. In our study 
keratinocytes in which phosphorylated EGFR was effectively down-regulated by erlotinib 
had lower baseline expression of mir-146a/miR-146a-5p than those in which erlotinib was 
rather not effective. In keratinocytes with low levels of mir-146a there might be less 
translational repression of EGFR, possibly resulting in higher dependence on EGFR 
signaling than in cells with high levels of mir-146a. Therefore, inhibition of EGFR 
phosphorylation by erlotinib might have a more pronounced effect in cells with previous 
lower levels of mir-146a. On the other hand, if due to high baseline expression of mir-146a 
there are low levels of EGFR, alternative signaling pathways might be up-regulated, such 
as the HGF/MET pathway for example, rendering later use of EGFRIs rather ineffective 
(e.g. because of less activation/phosphorylation of EGFR). However, this hypothesis 
warrants further confirmation, as the conducted cell-based phospho-ELISAs were not 
suitable to analyse differences in EGFR expression across cell samples. 
Taken together, mir-146a shows potential with regard to its baseline levels in skin cells as 
possible predictive marker for efficacy of EGFRIs, as well as potential as an adjuvant 
inhibitor which might be effective when administered together with an EGFRI.  
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mir-31 
According to NGS results, mir-31 was significantly down-regulated in erlotinib-sensitive 
keratinocytes as compared to rather erlotinib-insensitive ones. However, this effect was 
not confirmed by PCR and the effect was rather small in in cells treated with EGF alone 
(fold-change 0.79) and those left untreated (fold-change 0.77). This effect was also not 
observed for the mature form miR-31-3p. 
Nevertheless, the observed small association between low levels of mir-31 and increased 
sensitivity towards erlotinib is in accordance with the results previously obtained by 
several other groups. Four different research groups, partially using overlapping patient 
cohorts but also partially using independent ones, observed a significant association 
between high levels of miR-31-3p and/or miR-31-5p and low response to anti-EGFR 
therapy (mainly with cetuximab), defined by short PFS, in patients with metastatic 
colorectal cancer and WT Ras149-152. 
These results indicate that mir-31 is a promising predictive marker for response to EGFRI 
therapy. However, at this time clear targets of mir-31 have not been identified reliably and 
therefore the mechanism behind the predictive value of mir-31 remains unknown.  
 
mir-138-2/miR-138-5p 
There are two genomic loci known in humans which express the mature miRNA sequence 
of miR-138. The respective precursor miRNAs are named mir-138-1 and mir-138-2. In this 
study expression of mir-138-2 was investigated in keratinocytes. Expression of mir-138-2 
was down-regulated in erlotinib-sensitive as compared to -insensitive cells, which was 
significant in those cells which were previously treated with erlotinib. 
Contrary to these results, in a study by Gao et al. miR-138-5p was found to be the most 
down-regulated miRNA in a gefitinib-resistant lung cancer cell line as compared to a 
gefitinib-sensitive cell line153. They confirmed this down-regulation in 20 pairs of lung 
adenocarcinoma specimens and adjacent non-cancerous tissue samples. Using 
bioinformatics analysis and luciferase reporter assay they found that the G protein-
coupled receptor (GPR) 124 was a direct target of miR-138-5p. Interestingly, re-
expression of miR-138-5p was sufficient to re-sensitized the cells to gefitinib. Similarly, a 
recent Chinese study from 2016 found that in cervical cancer cells miR-138 could directly 
target the receptor MET and was down-regulated in the cancer cells as compared to 
adjacent non-cancerous tissue154. Based on these results it might be expected that in our 
cells miR-138 would also be up-regulated in erlotinib-sensitive as compared to -insensitive 
cells, leading to decreased levels of MET and therefore higher dependence on the EGFR 
signal cascade and higher efficacy of EGFRIs. However, miR-138-2 expression was 
down-regulated in our keratinocyte experiments in erlotinib-sensitive as compared to -
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insensitive cells, which was significant in those cells which were previously treated with 
erlotinib. Potential differences between miR-138 and mir-138-2 cannot be excluded, as 
well as differences of their functions in cancer cells as compared to skin cells. Considering 
the significant down-regulation of mir-138-2 only in those keratinocytes previously treated 
with erlotinib, it might be speculated that there could be some kind of feedback 
mechanism, inhibiting expression of mir-138-2 upon EGFR inhibition by erlotinib to 
increase levels of MET to compensate for the blockage of signaling via EGFR. However, 
this remains purely speculative and further insights into the regulation of miR-138/mir-138-
2 expression will be essential for further investigations and conclusions. It might be more 
promising to investigate the therapeutic potential of mir-138-2 in future studies. 
 
mir-221/miR-221 
In the keratinocyte experiments mir-221 was downregulated in erlotinib-sensitive cells 
when previously treated with erlotinib. It was previously demonstrated by Garofalo and 
colleagues that upon silencing of EGFR and MET in NSCLC cell lines, miR-221 
expression decreased, indicating regulation of this miRNA by the two receptor tyrosine 
kinases155. Interestingly, suppression of miR-221 also increased sensitivity of the cells 
towards the EGFRI gefitinib, presumably because miR-221 targeted apoptotic protease 
activating factor 1 (APAF1), which mediates gefitinib-induced apoptosis156. This means 
when expression of miR-221 is high, APAF1 is down-regulated leading to inhibition of the 
pro-apoptotic effect of gefitinib. Our results in keratinocytes are in accordance with the 
results by Garofalo et al. and suggest that upon inhibition of EGFR signaling by erlotinib, 
expression of miR-221 is down-regulated. It is unclear whether this inhibition of miR-221 
also to some extend confers the growth inhibitory effect of erlotinib via up-regulation of 
certain target genes of this miRNA. Further studies are warranted to investigate this 
possibility. Nevertheless, it has to be kept in mind that miR-221 was not significantly 
down-regulated in erlotinib-sensitive keratinocytes treated with EGF alone or left 
untreated, indicating that it only seems to play a role after administration of erlotinib. 
Hence, with regard to its potential as predictive biomarker for the efficacy of erlotinib, it 
would not be suitable to just determine the levels of miR-221 in skin cells of patients prior 
to treatment with erlotinib. Instead it would be necessary to cultivate a cell sample from 
the patient, incubate the cells with erlotinib and then measure the amount of miR-221 to 
predict the sensitivity to erlotinib. Feasibility of this method has to be considered. 
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mir-520e 
The miRNA mir-520e was significantly down-regulated in erlotinib-sensitive keratinocytes 
as compared to the rather erlotinib-insensitive ones, but only in cells previously incubated 
with erlotinib, not under the other treatment conditions. 
In a publication by Li and colleagues it was shown that miR-520e (and miR-520b) can 
directly bind to the 3’ UTR of EGFR and thereby inhibit EGFR expression157. The fact that 
mir-520e was only differentially expressed in keratinocytes previously treated with erlotinib 
leads to the speculation that inhibition of EGFR by erlotinib in erlotinib-sensitive 
keratinocytes might trigger a kind of feed-back mechanism leading to down-regulation of 
mir-520e and in turn less inhibition of EGFR expression to increase activation of EGFR 
signaling. However, at this time this assumption remains highly speculative.  
 
mir-944 
In erlotinib-sensitive keratinocytes mir-944 expression was up-regulated as compared to 
erlotinib-insensitive keratinocytes. mir-944 has previously been shown to target certain 
proteins involved in cell migration (SIAH1 and PTP4A1) in breast cancer cells and was 
suggested to be a tumor suppressor158. 
In a study from 2014 mir-944 was found to target the tumor suppressor protein suppressor 
of cytokine signaling (SOCS) 4 in NSCLC cells159. SOCS4 is known to regulate EGFR 
signaling by binding to EGFR and suppressing its signal transduction160. Higher levels of 
mir-944 lead to lower levels of SOCS4 and therefore to increased EGFR signaling and cell 
proliferation. However, a more recent study found that mir-944 can target the tyrosine 
kinase receptor ephrin type-A receptor 7 (EPHA7) and inhibit proliferation of NSCLC 
cells161. 
The two studies have contrary results. It is unclear which role of mir-944 is supported by 
our results in keratinocytes. However, it might be speculated that higher levels of mir-944, 
leading to increased EGFR signaling via suppression of SOCS4, could render cells more 
sensitive to EGFR inhibitors like erlotinib, due to a higher dependence of these cells on 
this signaling pathway. 
 
Summary of identified miRNAs 
A summary of data collected for each candidate miRNA including analysis of potential as 
predictive biomarker for efficacy of EGFRIs is provided in table 33.
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Table 33 Summary of suitability of identified miRNAs as predictive biomarkers in keratinocytes 
Summary of data collected about candidate miRNAs identified in keratinocytes in this study, including supporting and conflicting aspects concerning suitability as 
predictive biomarkers for efficacy of EGFRIs. Arrows mean up- or down-regulated in erlotinib-sensitive as compared to -insensitive cells, respectively. 
 suitability as predictive biomarker for EGFRI efficacy  
miRNA 
(expression in 
erlotinib-
sensitive cells) 
supporting aspects 
+ 
conflicting aspects 
- 
future steps 
mir-146a/ 
miR-146a-5p 
(↓) 
- differential expression observed for precursor 
and mature form, across all treatment options 
and using NGS and PCR (rather stable results) 
- EGFR and Jun reported as direct targets in 
literature (plausible mechanism)148 
 - check correlation between 
levels in skin cells and 
clinical response in patients 
- investigate therapeutic 
potential 
mir-31/ 
miR-31-3p 
(↓) 
- differential expression confirms publications in 
metastatic colorectal cancer treated with anti-
EGFR mAbs (associated with shorter PFS)149-
152 
- only small effect detected (low fold-change), 
not confirmed by PCR 
- no suggested target/mechanism yet 
- identify target(s) 
- confirm results in other types 
of cancer and with other 
types of EGFRIs 
mir-138-2 
(↓) 
- large fold-change and high significance of 
differential expression in erlotinib-treated cells 
- differential expression only significant in 
erlotinib-treated cells 
- opposite associated with erlotinib-sensitivity 
than reported in publication for gefitinib-
sensitivity in lung cancer cells153 
- potential therapeutic value 
could be further investigated 
mir-221 
(↓) 
- differential expression in erlotinib-treated cells is 
in accordance with a publication about 
expression in lung cancer cells treated with 
gefitinib155 
- association with erlotinib-sensitivity only 
observed upon incubation with erlotinib 
- investigate down-stream 
effect of miRNA inhibition 
and correlations in skin and 
cancer cells 
- confirm in patients 
mir-520e 
(↓) 
- large fold-change and high significance of 
differential expression in erlotinib-treated cells 
- EGFR reported as direct target in literature 
(plausible mechanism)157 
- association with erlotinib-sensitivity only 
observed upon incubation with erlotinib 
- identify target(s) in skin cells 
and further explore why 
differential expression only 
observed upon incubation 
with erlotinib 
mir-944 
(↑) 
- SOCS4 reported as target in literature, which 
can block EGFR (plausible mechanism)159 
- differential expression not significant in 
untreated cells 
- identify target(s) in skin cells 
- confirm correlation of miRNA 
level in skin and cancer cells 
of patients 
Abbreviations: EGFRI, epidermal growth factor receptor inhibitor; NGS, next generation sequencing; PCR polymerase chain reaction; SOCS, suppressor of 
cytokine signaling. 
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V.2.2 Primary human dermal fibroblasts as cell model for studying EGFRI-
induced skin rash 
Even though epidermal keratinocytes are thought to be the main type of skin cells 
involved in the pathophysiology of EGFRI-induced rash58, dermal fibroblasts may also 
play a role. It has long been known that fibroblasts are involved in inflammatory 
processes. They can determine quantity, quality, and duration of the inflammatory 
infiltrate, mainly by producing and secreting a variety of cytokines, which recruit or even 
inhibit different immune cells, as for example experimentally shown in a mouse model for 
arthritis162 and also thoroughly reviewed by Linthout et al163. In the skin of EGFRI-treated 
patients an immunological infiltrate can be found prior to and during the occurrence of 
EGFRI-induced skin toxicity64. Hence, dermal fibroblasts might also be involved in the 
development of EGFRI-induced skin rash and were therefore also further investigated in 
the study presented here for their suitability as cell model to study the rash. 
 
 
V.2.2.1 In vitro effect of erlotinib in fibroblasts 
Incubation of the established primary human dermal fibroblasts with the EGFRI erlotinib 
showed that, as for the keratinocytes, again an optimal concentration to observe changes 
in cell signaling was between 5 and 10 µM. 
In vitro stimulation with the EGFR ligand EGF also led to a significant increase in the 
amount of phosphorylated proteins involved in EGFR signaling pathways in fibroblasts 
and prior incubation with erlotinib resulted in a significant decrease in the amount of these 
phosphorylated proteins, indicating successful inhibition of EGFR signaling in vitro. 
Interestingly, the strongest inhibitory effect was found for different proteins as in the 
keratinocytes. In the fibroblasts the effect was strongest for EGFR, ERK1/2, Akt1/2/3, 
TOR and Src. Phosphorylation of EGFR and Src was also strongly inhibited by erlotinib in 
keratinocytes. However, in fibroblasts erlotinib decreased the level of phosphorylated 
protein most remarkably for the MAPK ERK. In vitro stimulation with EGF also stimulated 
phosphorylation of ERK to a much higher extend than phosphorylation of the other tested 
proteins. In fibroblasts the MAPK ERK seems to play a more important role in the EGFR 
signaling pathway than the MAPK JNK, while in keratinocytes JNK seems to be more 
important. No publications could be identified which previously compared EGFR signaling 
in keratinocytes and fibroblasts. 
It is also remarkable that in fibroblasts in vitro treatment with erlotinib has a very strong 
inhibitory effect on the kinases Akt (1/2/3) and TOR. These two proteins are important 
signaling molecules of the PI3K/Akt pathway. Erlotinib seems to have a strong inhibitory 
effect on this pathway in fibroblasts. In keratinocytes on the other hand erlotinib does not 
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seem to have such a considerable inhibitory effect on the proteins involved in the PI3K/Akt 
pathway. These results suggest that EGFR signaling as well as the effect of EGFRIs is 
different in human dermal fibroblasts as compared to keratinocytes, with different 
signaling molecules having distinct importance. This also has to be taken into 
consideration when selecting an appropriate cell model for investigations about EGFRI-
induced skin toxicity. 
For further investigations of in vitro EGFR inhibition in fibroblasts, specific ELISAs for 
EGFR and ERK 1/2 were conducted across all available primary fibroblast cultures. The 
ERK 1/2 ELISA was found to be most suitable to detect differences in EGFR inhibition 
upon incubation with erlotinib between the different cell samples. 
 
The results from the phospho-ERK 1/2 ELISA were used to group the various fibroblast 
cultures into erlotinib-sensitive and rather -insensitive cells. The “edge groups” were 
selected, meaning the four most erlotinib-sensitive and the four most erlotinib-insensitive 
cell samples. Two cell samples were excluded from this selection (FB131 and FB84) 
because in these cells incubation with erlotinib resulted in a higher amount of 
phosphorylated ERK 1/2 than stimulation with EGF alone, indicating that either the assay 
did not work correctly with them or there was another unidentified problem with the cells or 
their signaling cascades. In the selected edge groups the miRNA profiles were determined 
by NGS and compared between the four rather erlotinib-sensitive and the four rather 
erlotinib-insensitive samples. 
 
 
V.2.2.2 Differences in miRNA profiles in erlotinib-sensitive versus -insensitive 
fibroblasts 
Analyses were performed analogous to the ones in keratinocytes. In fibroblasts there were 
34 precursor and 16 mature miRNAs identified which were significantly differentially 
expressed in erlotinib-sensitive as compared to -insensitive cells across all three 
treatment options. A literature search revealed that some of these identified miRNAs were 
also identified in other studies with potential roles in EGFR signaling and inhibition, which 
strengthened the evidence for these candidate miRNAs. Those miRNAs were mir-34a, 
mir-17, mir-30b, mir-382, mir-494, and mir-520e. 
Those miRNAs which were only significantly differentially expressed in cells incubated 
with erlotinib and not in the other treatment groups and were confirmed by literature 
search were mir-7-1 and mir-31. 
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mir-34a/miR-34a-5p 
In erlotinib-sensitive fibroblasts expression of mir-34a (significantly) and its mature form 
miR-34-5p (non-significantly) were up-regulated as compared to rather erlotinib-
insensitive fibroblasts, which was observed across all three treatment options in NGS (and 
partially confirmed by PCR). These results agree with the results obtained by a Chinese 
group around Zhou, who investigated the role of miR-34a in two gefitinib-resistant lung 
adenocarcinoma cell lines and in a gefitinib-resistant mouse xenograft model164. They 
found that forced expression of miR-34a down-regulated the receptor tyrosine kinase MET 
by direct targeting and induced apoptosis in the gefitinib-resistant cell lines. In the 
gefitinib-resistant mouse xenograft model, the combination of miR-34a and gefitinib 
caused dramatic tumor regression, much more effectively than monotherapy with either 
one of them. In a very recent American study published in 2017 by Zhao and colleagues, 
a synergistic anti-proliferative effect was also observed for miR-34a together with next 
generation TKIs, like afatinib, and osimertinib, in EGFR mutant NSCLC cell lines165. Taken 
together, miR-34a is a promising candidate predictive biomarker for efficacy of EGFRIs, 
which might be worth investigating in more detail in clinical settings. 
 
mir-17 
The expression of mir-17 was up-regulated in erlotinib-sensitive fibroblasts as compared 
to the rather erlotinib-insensitive ones across all three treatment options. Recently 
published results of in vitro experiments with mir-17 by two different Chinese groups are 
contradicting. One group showed that expression of miR-17-5p was higher in gefitinib-
resistant NSCLC cells (A549/GR cell line) than in gefitinib-sensitive ones (A549 cell line) 
and that transfection with miR-17-5p mimic reduced sensitivity to gefitinib in the A549 
NSCLC cells166. The other group showed that expression of miR-17-5p was lower in 
erlotinib-resistant NSCLC cells (A549/ER) than in erlotinib-sensitive ones (A549)167. The 
second group confirmed their observation also in tumor samples and plasma of erlotinib-
sensitive as compared to erlotinib-resistant NSCLC patients. Our results in fibroblasts also 
confirm the results by the second group around Zhang. However, it remains unclear 
whether the use of the EGFRI gefitinib instead of erlotinib in fibroblasts would lead to 
different results. 
It should be noted that in 2015 low expression of mir-17 was also shown to be associated 
with resistance to chemotherapy with cisplatin168. This was suggested to be due to an up-
regulation of the target proteins cyclin-dependent kinase inhibitor 1A (CDKN1A) and 
cohesion complex component RAD21, which leads to increased cell cycle arrest and 
increased DNA repair, respectively, mediating resistance to cisplatin-induced apoptosis. 
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Since patients who are treated with an EGFRI usually also receive a type of 
chemotherapy in addition, the role of miR-17 in response to chemotherapy should also be 
further investigated. Large patient cohorts and control groups, e.g. receiving 
chemotherapy alone, will be essential to clarify the predictive role of miR-17. It is also 
important to identify the target(s) of mir-17 and to elucidate its mechanism of action. 
 
mir-30b 
As described for miR-221 in the keratinocyte section (refer to V.2.1.2) it was shown in the 
same study by Garofalo et al. in NSCLC cell lines that upon silencing of EGFR and MET 
miR-30b expression decreased, indicating regulation of this miRNA by the two receptor 
tyrosine kinases155. This decrease in miR-30b levels also increased sensitivity of the cells 
towards the EGFRI gefitinib. MiR-30b can target the pro-apoptotic factor Bcl-2-like protein 
11 (BIM), which was previously shown to mediate TKI-induced apoptosis169. The study by 
Garofalo et al. suggests that if expression of miR-30b is high, BIM is down-regulated 
leading to inhibition of the pro-apoptotic effect of gefitinib. In our fibroblast experiments 
however, miR-30b was up-regulated in erlotinib-sensitive as compared to rather erlotinib-
insensitive cells across all three treatment options. This is not in accordance with the 
results of the Garofalo study. However, it confirms a study conducted by Gu and 
colleagues conducted in 2013, who retrospectively examined expression of miR-30b in 41 
paraffin-embedded tumor samples from NSCLC patients who had been first-time treated 
with a TKI170. They observed that higher expression of miR-30b was associated with 
longer OS (miR-30b low expression group: median OS 7.5 months; miR-30b high 
expression group: median OS 17.4 months). Taken together, the results about potential 
functions of miR-30b in cancer and efficacy of EGFRIs as studied in cell lines and tumor 
samples are controversial. The Gu study has similar limitations to our study since 
association of miR-30b expression with patient outcome has not been studied in a control 
group of patients not treated with a TKI. Therefore, the predictive potential of miR-30b in 
EGFRI therapy remains uncertain.  
 
mir-382 
In fibroblasts the expression of mir-382 was increased in the erlotinib-sensitive group as 
compared to the erlotinib-insensitive one. According to literature the role of mir-382 seems 
to be different in different types of cancer. In breast cancer tissue miR-382-5p was found 
to be up-regulated171, while in hepatocellular carcinoma tissue it was found to be down-
regulated as compared to non-cancerous control tissue172. In the hepatocellular carcinoma 
study Golgi Membrane Protein 1 (GOLM1) was suggested as target of the mature miRNA 
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miR-382. However, this target protein does not explain the differential expression of mir-
382 observed in erlotinib-sensitive as compared to -insensitive fibroblasts. In the breast 
cancer study Ras-related and estrogen-regulated growth inhibitor (RERG) was suggested 
as target protein of miR-382-5p. This protein is a Ras superfamily small GTPase, which 
deactivates Ras/ERK signaling effectors, and therefore its suppression by miR-382-5p 
would lead to increased activation of the MAPK signaling pathway, which can be activated 
by EGFR. This mechanism might also be present in fibroblasts and such an increase in 
activation of MAPK signaling might also explain why higher expression of mir-382 renders 
fibroblasts more susceptible to the EGFRI erlotinib. However, at this time it is unclear to 
what extend the protein RERG is expressed and active in fibroblasts. Therefore, further 
investigations about expression and activity of RERG in fibroblasts and about targets of 
mir-382 in general will be necessary to draw reliable conclusions about this miRNA with 
respect to its role in response to EGFRIs. 
Interestingly, in a study in murine and human hepatocytes mir-382 was found to target the 
protein phosphatase and tensin homolog (PTEN), which when active dephosphorylates 
several signaling molecules from the PI3K-Akt pathway and therefore is an important 
inhibitor of this pathway173. It can be speculated that PTEN might also be a target of mir-
382 in fibroblasts and that via this mechanism increased expression of mir-382 might lead 
to increased activation of the EGFR-PI3K-Akt pathway and therefore to increased 
susceptibility of fibroblasts to the EGFRI erlotinib. 
 
mir-494 
The expression of mir-494 was increased in the erlotinib-sensitive group of fibroblasts as 
compared to the erlotinib-insensitive group. In the literature mir-494 is discussed with 
respect to its role in various types of cancer and numerous potential targets are suggested 
for this miRNA depending on the type of tissue. As already suggested for mir-382 (see 
previous section) the phosphatase PTEN has been shown to be a direct target of mir-494, 
e.g. in colorectal cancer tissue174 and NSCLC175. As already speculated for mir-382, PTEN 
might also be a target of mir-494 in fibroblasts and via this mechanism increased 
expression of mir-494 might lead to increased activation of the EGFR-PI3K-Akt pathway 
and therefore to increased susceptibility of fibroblasts to the EGFRI erlotinib. 
However, there are additional hypotheses which arise from review of the abundant 
literature on mir-494. A study by Kwak et al. for example found that in glioma cells miR-
494 directly targets the GTPase activating protein p190B, which in turn leads to 
stabilization of EGFR at the cell surface through decreased lysosomal degradation176. This 
mechanism could also explain why increased expression of mir-494 renders fibroblasts 
more sensitive to the EGFRI erlotinib. 
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A further study by Romano et al. suggests that miR-494 expression is up-regulated by 
ERK1/2 via its down-stream transcription factor AP-1 in NSCLS cells177. However, if this 
mechanism was also present in fibroblasts, erlotinib-sensitive fibroblasts should show a 
decrease in mir-494 levels upon incubation with erlotinib, due to an inhibition of the EGFR 
down-stream signaling molecule ERK1/2. Since this was not observed in our fibroblast 
experiments, it is questionable whether the mechanism suggested by Romano et al. is 
also present in skin cells. 
Specific target analyses for mir-494 in fibroblasts are inevitable to draw further 
conclusions. 
 
mir-520e 
In fibroblasts mir-520e was significantly down-regulated in erlotinib-sensitive as compared 
to rather erlotinib-insensitive cells across all three treatment options. As already discussed 
for the keratinocyte experiments, in a publication by Li and colleagues it was shown that 
miR-520e (and miR-520b) can directly bind to the 3’ UTR of EGFR and thereby inhibit 
EGFR expression in gastric cancer cells157. This mechanism might also be present in 
fibroblasts and lower levels of mir-520e would lead to increased expression of EGFR and 
therefore possibly also higher sensitivity towards EGFR inhibition by erlotinib. This 
mechanism would render mir-520e a very promising predictive biomarker for the response 
to erlotinib. 
However, in keratinocytes mir-520e was only differentially expressed in cells previously 
treated with erlotinib and not across the other treatment options. Whether the role of mir-
520e might be different in fibroblasts and keratinocytes or whether expression analyses 
did not work properly in one of the two cell types remains unknown and warrants further 
validation experiments.  
 
mir-7-1 
Mir-7-1 was up-regulated in erlotinib-sensitive fibroblasts as compared to -insensitive ones 
(significant in cells treated with erlotinib). It has been shown in a previous study that miR-7 
can down-regulate EGFR mRNA and protein expression in various cancer cell lines (lung 
cancer, breast cancer, glioblastoma) via two different target sites in the EGFR 3’UTR178. 
Microarray and bioinformatics analysis also conducted in that study suggested that there 
might be additional direct targets of miR-7 down-stream of EGFR in its signaling 
pathways, such as the protein kinase RAF-1. This might point to a synergistic effect of 
miR-7 on EGFR inhibition together with erlotinib and might explain the up-regulation of 
miR-7 detected in erlotinib-sensitive fibroblasts. Interestingly, in a study by Suto et al. 
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expression of the precursor mir-7 was found to sensitize two different colon cancer cell 
lines harboring KRAS mutations to the mAb cetuximab101. Cells with KRAS mutations are 
usually cetuximab-resistant. It was suggested by the authors that in cells with KRAS 
mutations KRAS signals to ERK 1/2 rather through RAF-1, instead of through BRAF, like it 
is mainly seen in KRAS WT cells. MiR-7 can target RAF-1 and thus might increase the 
cells’ sensitivity towards EGFR inhibition by cetuximab. A similar mechanism might exist 
in fibroblasts, which would match our results with the EGFRI erlotinib. However, the study 
by Suto also showed that in a cell line harboring a BRAF mutation mir-7 expression was 
not effective in sensitizing the cells to cetuximab. This result emphasizes that the various 
functions of miRNAs are highly specific and in further investigations mutation statuses of 
certain signaling molecules might also have to be taken into account. Nevertheless, mir-
7/mir-7-1 is a promising candidate as predictive biomarker for EGFRI efficacy and might 
be worth studying in more detail in clinical settings. 
 
mir-31 
In fibroblasts mir-31 was up-regulated in erlotinib-sensitive cells as compared to rather 
erlotinib-insensitive ones. This effect was only significant for those cells previously 
incubated with erlotinib. This result is not in accordance with the results obtained in 
keratinocytes and it is also contrary to the results previously published by other groups. As 
already discussed in the keratinocyte section, four different research groups, partially 
using overlapping patient cohorts but also partially using independent ones, observed a 
significant association between high levels of miR-31-3p and/or miR-31-5p and low 
response to anti-EGFR therapy (mainly with cetuximab), defined by short PFS, in patients 
with metastatic colorectal cancer and WT Ras149-152. However, the four mentioned studies 
did not identify clear targets of mir-31, which makes it impossible to say whether the same 
targets are also present in fibroblasts.  
 
Summary of identified miRNAs 
A summary of data collected for each candidate miRNA including analysis of potential as 
predictive biomarker for efficacy of EGFRIs is provided in table 34.
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Table 34 Summary of suitability of identified miRNAs as predictive biomarkers in fibroblasts 
Summary of data collected about candidate miRNAs identified in fibroblasts in this study, including supporting and conflicting aspects concerning suitability as 
predictive biomarkers for efficacy of EGFRIs. Arrows mean up- or down-regulated in erlotinib-sensitive as compared to -insensitive cells, respectively. 
 suitability as predictive biomarker for EGFRI efficacy  
miRNA 
(expression in 
erlotinib-
sensitive cells) 
supporting aspects 
+ 
conflicting aspects 
- 
future steps 
mir-34a/ 
miR-34a-5p 
(↑) 
- differential expression observed for precursor 
and mature form, across all treatment options 
and using NGS and partially also PCR (rather 
stable results) 
- differential expression confirms 2 publications 
about a synergistic effect with TKIs in cancer 
cells/a xenograft mouse model164,165 
- MET reported as direct target (plausible 
mechanism)164 
 - confirm predictive 
properties for efficacy of 
EGFRIs in patients 
mir-17 
(↑) 
- differential expression significant across all 
treatment options 
- differential expression confirms a publication 
about association of low levels with erlotinib-
resistance in NSCLC patients167 
- opposite association with erlotinib-sensitivity 
than reported for gefitinib-sensitivity in NSCLC 
cells in a Chinses study166 
- identify target(s) and 
elucidate mechanism of 
action 
- check predictive potential 
in patients and elucidate if 
there are differences 
between different EGFRIs 
mir-30b 
(↑) 
- differential expression confirms a previous 
retrospective study about association of 
expression in tumors with overall survival in 
patients treated with a TKI170 
- opposite association with erlotinib-sensitivity 
than reported for gefitinib-sensitivity in NSCLC 
cells in a publication155 
- identify target(s) and 
elucidate mechanism of 
action 
- confirm predictive potential 
in larger patient cohorts 
including an adequate 
control arm 
mir-382 
(↑) 
- large fold-change and high significance of 
differential expression across all treatment 
options, also confirmed by PCR 
- RERG and PTEN suggested as targets 
(plausible mechanisms)171,173 
 - clarify relevant target(s) 
(RERG and PTEN relevant 
in fibroblasts?) 
- confirm predictive 
properties for efficacy of 
EGFRIs in patients 
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mir-494 
(↑) 
- large fold-change and high significance of 
differential expression across all treatment 
options, also confirmed by PCR 
- PTEN and p190B suggested as targets 
(plausible mechanisms)174-176 
 - confirm predictive 
properties for efficacy of 
EGFRIs in patients 
mir-520e 
(↓) 
- large fold-change and high significance of 
differential expression, especially in untreated 
cells 
- EGFR reported as direct target in literature 
(plausible mechanism)157 
 - confirm predictive 
properties for efficacy of 
EGFRIs in patients 
mir-7-1 
(↑) 
- differential expression confirms a study in colon 
cancer cells where this miRNA sensitized cells 
with KRAS mutation to cetuximab101 
- EGFR and RAF reported as target in literature 
(plausible mechanism)178 
- differential expression only observed upon 
incubation with erlotinib and not confirmed for 
mature form 
- clarify mechanism of action 
and association with KRAS 
mutations 
- investigate why only 
significant in cells treated 
with erlotinib 
- confirm correlation of 
miRNA level in skin and 
cancer cells of patients 
mir-31 
(↑) 
- differential expression significant in cells 
previously treated with erlotinib 
- differential expression only observed upon 
incubation with erlotinib and not confirmed for 
mature form 
- opposite regulation than in keratinocytes 
- opposite association with erlotinib-sensitivity 
than reported association with response to anti-
EGFR therapy in patients in 4 previous 
studies149-152 
- identify target(s) 
- rather further investigate 
predictive potential in 
keratinocytes than in 
fibroblasts because so far 
results more promising in 
that cell type 
Abbreviations: EGFRI, epidermal growth factor receptor inhibitor; NGS, next generation sequencing; NSCLC, non-small cell lung cancer; PCR polymerase chain 
reaction; PTEN, phosphatase and tensin homolog; RERG, Ras-related and estrogen-regulated growth inhibitor; TKI, tyrosine kinase inhibitor. 
 
 
 
 
149 
 
V.2.3 Most suitable cell model - comparison between keratinocytes and 
fibroblasts 
Throughout all experiments and analyses included in this thesis, it has been clearly 
observed that primary human dermal keratinocytes and primary human dermal fibroblasts 
greatly differ, with regard to regulation of proteins involved in signaling cascades induced 
via EGFR as well as with regard to miRNA profiles. This means that the two dermal cell 
types are not interchangeable as cell models to study areas such as EGFR signaling and 
EGFRI-induced skin rash. Biomarkers established in one cell type most likely will not be 
usable in the other one. 
 
In vitro effect of erlotinib on EGFR signaling 
While for both cell types an optimal concentration of erlotinib to observe changes in cell 
signaling in vitro was found to be between 5 and 10 µM, the inhibitory effect of erlotinib 
was different for specific signaling proteins in keratinocytes and fibroblasts. In 
keratinocytes the MAPK JNK seemed to play a more important role in the EGFR signaling 
pathway than the MAPK ERK, while in fibroblasts it was the other way around. In addition, 
in fibroblasts in vitro treatment with erlotinib had a very strong inhibitory effect on proteins 
of the PI3K/Akt pathway (Akt (1/2/3) and TOR), while in keratinocytes erlotinib did not 
seem to have such a considerable inhibitory effect on this pathway. These results are in 
accordance with a study from 2002, in which strong activity of ERK1/2 and Akt was 
verified in vitro in fibroblasts in early as well as late passages (but not in senescent 
cells)179, suggesting an important role of these two pathways in proliferating fibroblasts. In 
contrast to the results described here, in some publications activity of ERK1/2 and Akt has 
also been described in dermal keratinocytes and was shown to be important for 
proliferation and differentiation in this cell type. For example, PI3K/Akt signaling has been 
shown to be essential in keratinocyte differentiation in mice in vivo180. Nevertheless, in 
human dermal keratinocytes the PI3K/Akt and ERK1/2 pathways might be more 
importantly regulated via other receptors than via EGFR, as also suggested in the study 
by Sadagurski and colleagues181, in which the insulin-like growth factor 1 receptor (IGF-
1R) very strongly mediated activation (phosphorylation) or inhibition of the signaling 
proteins ERK1/2 and Akt in primary mouse keratinocytes. Another explanation might be 
that the two signaling cascades are differentially active depending on the specific 
conditions present at a given time. Akt and ERK1/2 have for example been shown to 
become activated by mechanical stretching in human dermal keratinocytes182, indicating 
that external stimuli might change the activity of certain signaling molecules and therefore 
most likely also the effect of specific inhibitors on their activity. 
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At this time in the literature data about differences in specific EGFR signaling cascades in 
different human dermal cell types, such as keratinocytes and fibroblasts, is scarce.  
 
 
miRNA profiles 
With regard to identification of gene regulatory biomarkers it has been clearly shown in the 
NGS experiments described here that in both dermal skin types, keratinocytes as well as 
fibroblasts, differences in miRNA profiles between erlotinib-sensitive and -insensitive cells 
are much greater when looking at precursor (hairpin) miRNA molecules than at mature 
miRNAs. This should be kept in mind for all further investigations concerning miRNAs as 
biomarkers. It could be speculated that because precursor miRNAs are simply longer than 
mature miRNA molecules, they are more stable throughout experiments and allow for 
design of more specific primers and increased primer optimization options, which might 
yield better sequencing and PCR results. In addition, precursor miRNA levels might show 
earlier responses to changes within a cell than mature miRNAs, which are further down-
stream in the miRNA biogenesis process183. However, it also has to be kept in mind that 
differences in miRNA processing might only be evident in mature miRNAs and hence, 
depending on the research question, it should be carefully evaluated whether expression 
of precursor or mature miRNAs will be investigated in future biomarker studies. 
 
Those miRNAs which were identified in this study as significantly differentially expressed 
in keratinocytes were not significantly differentially expressed in fibroblasts and vice versa, 
again indicating large differences in cellular processes in these two dermal cell types. 
Regulation of mir-34a and its mature form miR-34a-5p even seemed to be opposite in the 
two cell types. While in fibroblasts expression of mir-34a and miR-34a-5p was up-
regulated in erlotinib-sensitive cells (mir-34a significantly, miR-34a-5p non-significantly), in 
keratinocytes the two miRNAs were rather down-regulated in erlotinib-sensitive cells (both 
not significantly). The same was observed for mir-146a and its mature form miR-146a-5p, 
which was significantly down-regulated in erlotinib-sensitive keratinocytes as compared to 
the -insensitive ones but rather up-regulated in the respective fibroblast groups (not 
significant). The reasons for these differences cannot be explained so far but highlight the 
fact that miRNA profiles are highly specific with respect to cell type, treatment and time 
point and it remains a challenge to further elucidate the exact mechanisms of regulation 
under different conditions. 
Taken together, in this study different miRNAs have been identified which show promising 
potential in predicting the efficacy of EGFR inhibition by erlotinib in keratinocytes or 
fibroblasts. The identified miRNAs were different in the two dermal cell types. Hence it is 
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suggested that further investigations about the clinical suitability of the identified miRNAs 
as predictive biomarkers should be performed in both cell types. However, it always has to 
be considered that the isolation of keratinocytes from patients might be easier than 
obtaining fibroblasts, since keratinocytes are part of the epidermis, which is more 
superficial than the dermis, from which fibroblasts originate. Therefore, if there are 
suitable biomarkers identified in both cell types, the ones determinable in keratinocytes 
might be preferred for establishment in clinical practice. 
 
It should be noted that some of the discussed miRNAs might also have a therapeutic 
potential and could possibly be applied together with EGFRIs to increase inhibition of 
proliferative signaling cascades via additional targets. However, such therapeutic potential 
is investigated by other research groups and is not part of the scope of this thesis. 
 
 
V.3  Conclusion 
In this study analysis of patient plasma from the Dermatoxgen study showed that the 
concentration of the EGFRI cetuximab was not significantly associated with the 
occurrence of EGFRI-induced skin rash. In a previous publication by our research group a 
metabolic ratio of erlotinib (erlotinib concentration divided by O-desmethylerlotinib) was 
shown to be significantly correlated with occurrence of EGFRI-induced rash and therefore 
is thought to be a promising predictive biomarker, especially with regard to optimization of 
dosage. However, this seems to be relevant only for TKIs and cannot be transferred to 
anti-EGFR mAbs, since they have no known/measurable metabolites. 
While the investigated analytes AREG and 25-OH-vitamin D also failed to show a 
correlation with the rash, the MET ligand HGF showed very promising results in this study. 
The plasma concentration of HGF was inversely correlated with severity of EGFRI-
induced skin rash. This inverse correlation was also seen with OS in patients who 
developed EGFRI-induced rash but not in patients with no rash. HGF seems to be a 
promising biomarker, whose predictive and/or prognostic value should definitely be 
confirmed/validated in a larger and well-controlled patient cohort. 
It was further shown in this study that primary human dermal keratinocytes and primary 
human dermal fibroblasts can be successfully cultured and can be sensitive to in vitro 
treatment with erlotinib, which can be determined by measuring the decrease in amount of 
phosphorylated EGFR in keratinocytes and phosphorylated ERK1/2 in fibroblasts, 
respectively, using specific ELISAs. In this study both dermal cell types have proven their 
suitability to be used as cell models to further study EGFRI-induced skin rash. However, it 
was also clearly shown that both cell types greatly differ with regard to regulation of 
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signaling cascades down-stream of EGFR, as well as with regard to miRNA profiles under 
specific conditions. Comparison of miRNA profiles between cells identified as rather 
erlotinib-sensitive and cells identified as rather erlotinib-insensitive combined with a 
literature review to identify the miRNAs with the most supporting data, led to identification 
of the precursor miRNAs mir-146a, mir-31, mir-221, mir-520e and mir-944 as most 
promising predictive biomarkers in keratinocytes for efficacy of EGFRIs. Of these, mir-
146a, mir-520e and mir-944 have known targets (EGFR and SOCS4, respectively) and a 
suggested mechanism of action which can plausibly explain their predictive potential, 
while mir-31 and mir-221 do not have such known targets but instead have already been 
shown to be associated with sensitivity to an EGFRI in at least one previously published 
study. In fibroblasts the precursor miRNA mir-34a has been identified as the by far most 
promising predictive biomarker with MET reported as direct target and an associated 
plausible mechanism of action and two confirmatory previous studies about a synergistic 
effect with TKIs in cancer cells and a xenograft model. Further identified promising 
predictive precursor miRNAs in fibroblasts were mir-382, mir-494 and mir-520e with the 
plausible suggested targets PTEN and RERG, PTEN and p190B and EGFR, respectively. 
Mir-7-1 also showed positive results with the plausible suggested targets EGFR and Ras 
and a confirmatory previous study showing an association with sensitivity to cetuximab in 
cancer cells. Taken together, the predictive potential of all these miRNAs is worth further 
confirming in larger, well-controlled patient cohorts in future studies. 
 
Overall, as final conclusion of this study it is suggested that it might be possible to develop 
a kind of “predictive profile” consisting of several biomarkers which taken together may 
have a predictive value on individual extent of EGFR inhibition in patients. Such a 
predictive profile should include several parameters. At this time the results of this study 
indicate that next to the metabolic ratio of erlotinib, the plasma concentration of HGF, the 
expression of mir-146a and mir-31 in dermal keratinocytes and the expression of mir-34a 
in dermal fibroblasts are promising parameters to include in such a predictive score, as 
also illustrated in figure 33. 
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Figure 33 Suggested predictive score for efficacy of EGFRIs 
If therapy with an EGFRI is indicated, prior to initiation of treatment blood and skin samples could 
be isolated from the patient to determine a predictive score consisting of the concentration of HGF 
in plasma and the expression of mir-146a and mir-31 in keratinocytes and mir-34a in fibroblasts. 
Based on the results it could be reconsidered if the therapy has promising efficacy and should 
indeed be initiated, whether closer monitoring of efficacy e.g. by tumor imaging should be 
performed due to questionable predicted efficacy etc. During the course of treatment blood 
samples could be drawn to determine changes in any of the parameters to monitor requirements 
for dosage optimization. 
 
 
 
V.4  Limitations 
The study population for this thesis (the Dermatoxgen cohort) has the limitation that all 
patients received an EGFRI and there was no control group of untreated patients or rather 
a group of patients who received chemotherapy alone, without an EGFRI. This renders it 
difficult to draw definite conclusions about purely prognostic or predictive biomarkers. 
However, if the concentration of a certain substance is correlated with outcome in patients 
who developed skin rash but not in the ones who did not develop rash, it can be assumed 
that this parameter is rather specifically predictive for EGFRI efficacy, because 
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development of the rash is thought to be mainly associated with the specific mechanism of 
action of the drug184. 
A further limitation with regard to the patient samples used in this study is that blood 
samples were only available from one time point for each patient, four weeks after 
initiation of EGFRI therapy. Control samples from before initiation of treatment and further 
samples drawn along the course of therapy would be helpful to check stability and 
reliability of potential biomarkers more efficiently. 
It also has to be noted that this study focused on biomarkers for efficacy of inhibition of 
EGFR signaling, irrespective of the type of EGFRI used (erlotinib, gefitinib, cetuximab or 
panitumumab). Different types of EGFRIs might have different additional off-target effects 
and respective additional predictive/prognostic biomarkers, which cannot be identified in 
the patient cohort investigated in this study. 
Concerning cell culture experiments a limitation is the unavailability of skin samples from 
patients treated with an EGFRI. Skin samples from healthy donors had to be used for all 
experiments. The work presented in this thesis represents first characterizations of skin 
cells as in vitro models to study EGFRI-induced skin rash and first investigations about the 
suitability of miRNA profiles of skin cells as predictive biomarkers. Conclusions drawn 
from this work should be further studied/validated in a clinical setting using skin samples 
from patients receiving EGFRI therapy. 
With regard to NGS experiments it was noted that detection of very slight differences in 
miRNA profiles is hampered by severe inter-run differences, meaning that the elaborate 
sample preparation procedure seems to result in different conditions in each individual 
sequencing run, which influence the sequencing results. In order to reliably detect also 
slight differences in miRNA profiles involving only low copy numbers of miRNAs, sample 
preparation has to be further standardized and samples which are to be compared should 
be sequenced one after the other as rapidly as possible. 
It was further noted that the miRNA PCR assays used in this study (miScript 
Precursor/Primer Assays by Qiagen) were not completely suitable to verify the differences 
in miRNA profiles determined by NGS. Even though, those miRNAs which were 
significantly up- or down-regulated in the NGS analyses were mainly also determined as 
up- or down-regulated in the PCR analyses, respectively, in the PCR analyses the 
differences in expression were not significant for any of the tested miRNAs, regardless of 
the significance in NGS experiments. Since the manufacturer does not provide the 
sequences of the primers, optimization of primers is not possible. Different assays might 
have to be tested for future experiments. 
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V.5  Outlook 
Today there are still new EGFRIs developed for the treatment of various types of cancers. 
The first-generation EGFRI TKIs erlotinib and gefitinib are still treatment standard, e.g. in 
NSCLC. However, when resistance mutations arise, such as the T790M mutation, 
alternative treatments become necessary. Hence, second-generation EGFRIs were 
developed, such as afatinib, which also targets EGFR with the T790M mutation185. 
However, since the second-generation EGFRIs also target WT EGFR, they still induce 
dose-limiting toxicity in patients186. Therefore, there is still need for development of new 
EGFRIs with increased specificity for mutant compared to WT EGFR. While the third-
generation EGFRI osimertinib has already been approved in the EU in 20168, numerous 
others, e.g. rociletinib, olmutinib, nazartinib and avitinib, are currently still under 
development and tested in clinical studies186. Considering the high amount of available 
established and new EGFRIs, biomarkers which can be used to predict the efficacy of 
EGFRIs are of very high importance to select patients which can really benefit from this 
type of treatment. Previous studies have shown that the markers in place today, e.g. 
mutation status of EGFR and KRAS, are not sufficient to select patients for efficient 
EGFRI therapy27,29. Therefore, new biomarkers are still needed. The potential predictive 
biomarkers identified in this study, namely plasma concentration of HGF and expression 
of several precursor miRNAs in skin cells, are very promising and their predictive 
properties should be further investigated in clinical settings in future studies. The 
precursor miRNAs mentioned in the conclusion were found to be worth investigating in 
skin samples of patients for the first time. Plasma levels of HGF and erlotinib metabolic 
ratio proved promising in the Dermatoxgen patient cohort and should definitely be further 
studied/validated in a larger patient cohort with a suitable control arm to confirm their 
predictive as compared to a rather prognostic value. This would also allow to stratify 
according to tumor type and type of EGFRI used to search for differences in predictive 
potential under different conditions. 
 
Later steps in biomarker development should then also be to establish thresholds for each 
biomarker to define which values represent “high” or “low” presence of the respective 
parameter. Following definition of such thresholds the next step will be to define 
consequences for results of biomarker measurements, e.g. change in dosage of a specific 
EGFRI, closer monitoring of therapy efficacy by more frequent tumor imaging or maybe 
even change in therapy away from using an EGFRI or at least adding an adjuvant drug to 
the EGFRI therapy, e.g. an anti-HGF or anti-MET substance in case of high HGF levels 
determined in a patient’s plasma. 
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A further idea to better study EGFRI-induced skin rash in vitro in future might be to use a 
3D skin model, e.g. like the ones described by Sadagurski et al181 and Commandeur et al 
(skin equivalents)139. In such models keratinocytes and fibroblasts are cultured together 
and could therefore be studied in parallel, which might be beneficial considering that the 
two cell types probably also interact in vivo. 
 
With regard to the miRNA experiments described in this thesis, the developed method 
should be further optimized and sample handling better standardized to allow to also 
detect smaller differences in miRNA profiles in the future. Moreover, investigations should 
be carried out in skin samples from patients treated with an EGFRI to validate the first 
results drawn from the experiments in skin cells from healthy donors. The method might 
also be used to identify miRNAs with a therapeutic potential, when patient samples from 
responders and non-responders are used. Over the next years miRNAs will become 
increasingly important in the area of biomarkers as well as in therapeutics in oncology. 
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Appendix 
A) Keratinocytes 
 
 
Figure 34 Quantification of in vitro effect of erlotinib on phosphorylation of proteins involved in EGFR signaling in keratinocytes 
Human phospho kinase arrays were conducted with keratinocyte cell lysates of HK3 p6. The mean pixel density after chemiluminescent visualization of the 45 different 
phosphorylated proteins is shown. Light blue: no treatment. Dark blue: stimulated with 4 nM EGF for 5 min. Green: incubated with 10 µM erlotinib for 2 h then stimulated with 
4 nM EGF for 5 min. A stronger signal (pixel density) corresponds to higher amounts of phosphorylated protein present and stronger signaling activity. 
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Figure 35 Quantification of in vitro effect of erlotinib on phosphorylation of proteins involved in EGFR signaling in keratinocytes 
Human phospho kinase arrays were conducted with keratinocyte cell lysates of HK4 p5. The mean pixel density after chemiluminescent visualization of the 45 different 
phosphorylated proteins is shown. Light blue: no treatment. Dark blue: stimulated with 4 nM EGF for 5 min. Green: incubated with 10 µM erlotinib for 2 h then stimulated with 
4 nM EGF for 5 min. A stronger signal (pixel density) corresponds to higher amounts of phosphorylated protein present and stronger signaling activity. 
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Table 35 Mean pixel density for all proteins from human phospho-kinase arrays of 3 different keratinocyte samples 
Human phospho-kinase arrays were conducted with three different keratinocyte cell samples (HK3 p6, HK4 p5, HK4 p8) following three in vitro treatment conditions (no 
treatment, 4 nM EGF for 5 min and 10 µM erlotinib for 2 h + 4 nM EGF for 5 min). For clearer comparison of the stimulating effect of EGF and the inhibitory effect of erlotinib 
between the different cell samples, ratios were calculated (EGF/no treatment and erlotinib/EGF). 
 
mean pixel density for HK3 p6 mean pixel density for HK4 p5 mean pixel density for HK4 p8 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
p38α 9257 20834 19411 2.25 0.93 14197 28490 15365 2.01 0.54 23003 25044 26302 1.09 1.05   
ERK1/2 4146 8193 6648 1.98 0.81 8088 13640 20449 1.69 1.50 6320 9400 12042 1.49 1.28   
JNK 1/2/3 4254 13344 4993 3.14 0.37 11292 16537 6933 1.46 0.42 9328 15247 8401 1.63 0.55   
GSK-3αβ 4257 11144 6919 2.62 0.62 17955 24583 16753 1.37 0.68 14265 20224 11439 1.42 0.57   
p53 (S392) 7604 11215 9440 1.47 0.84 7784 11159 5389 1.43 0.48 11360 13210 17600 1.16 1.33   
EGF R 5884 28853 6687 4.90 0.23 13143 38779 18868 2.95 0.49 9225 26717 17661 2.90 0.66   
MSK1/2 6851 14030 9594 2.05 0.68 13645 18716 11666 1.37 0.62 9848 13096 9683 1.33 0.74   
AMPKα1 1052 4001 2370 3.80 0.59 7833 10667 3559 1.36 0.33 4752 8422 4465 1.77 0.53   
Akt 1/2/3 (S473) 961 4329 2307 4.51 0.53 7371 10431 10278 1.42 0.99 5837 9662 5788 1.66 0.60   
Akt 1/2/3 (T308) 7468 10801 3089 1.45 0.29 9737 12734 6152 1.31 0.48 9025 7851 8112 0.87 1.03   
p53 (S46) 11411 15837 9948 1.39 0.63 9365 12674 6908 1.35 0.55 10314 11117 13412 1.08 1.21   
TOR 6194 9612 7924 1.55 0.82 7981 10659 7795 1.34 0.73 6737 8726 5491 1.30 0.63   
CREB 21876 47905 35917 2.19 0.75 34769 56251 26441 1.62 0.47 29126 39759 36996 1.37 0.93   
HSP27 11619 16861 18218 1.45 1.08 32599 64615 27547 1.98 0.43 36671 52802 38228 1.44 0.72   
AMPKα2 9104 16454 11697 1.81 0.71 16823 22308 13063 1.33 0.59 11567 17321 12701 1.50 0.73   
β-Catenin 1188 6082 3689 5.12 0.61 8032 13209 5571 1.64 0.42 7497 12559 8644 1.68 0.69   
p70 S6 Kinase 
(T389) 2829 5531 3632 1.96 0.66 5889 9046 4870 1.54 0.54 6288 8158 6935 1.30 0.85   
p53 (S15) 9070 11242 9569 1.24 0.85 8587 12514 7244 1.46 0.58 7149 8645 9444 1.21 1.09   
c-Jun 20885 35552 11892 1.70 0.33 22371 40513 14939 1.81 0.37 17372 27373 13679 1.58 0.50   
Src 1772 35532 2232 20.05 0.06 6088 11194 2641 1.84 0.24 5823 6115 5262 1.05 0.86   
Lyn 6535 8673 9738 1.33 1.12 10681 16419 7128 1.54 0.43 10610 11926 10205 1.12 0.86   
Lck 1884 1367 3573 0.73 2.61 6984 10070 3472 1.44 0.34 5946 6710 4582 1.13 0.68   
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STAT2 10656 17886 12811 1.68 0.72 21517 28507 17830 1.32 0.63 13986 19978 14816 1.43 0.74   
STAT5a 5886 12383 8532 2.10 0.69 5799 8561 7891 1.48 0.92 4821 7515 5708 1.56 0.76   
p70 S6 Kinase 
(T421/S424) 7654 11372 7104 1.49 0.62 10490 14143 4438 1.35 0.31 9455 11731 9768 1.24 0.83   
RSK1/2/3 10418 13291 9113 1.28 0.69 8092 11622 6495 1.44 0.56 8183 10719 8876 1.31 0.83   
eNOS 6839 6205 6146 0.91 0.99 5642 4851 4650 0.86 0.96 5073 6622 5890 1.31 0.89   
Fyn 3654 5283 5801 1.45 1.10 4578 13271 4596 2.90 0.35 6256 7909 6565 1.26 0.83   
Yes 3198 4904 6517 1.53 1.33 7714 13232 7997 1.72 0.60 7640 8695 7142 1.14 0.82   
Fgr 1993 3529 5000 1.77 1.42 5958 8667 4632 1.45 0.53 3935 4901 3489 1.25 0.71   
STAT6 7997 13154 10542 1.64 0.80 12898 16882 10946 1.31 0.65 8485 12311 8581 1.45 0.70   
STAT5b 5269 10659 7190 2.02 0.67 4740 8702 6866 1.84 0.79 3667 5785 4539 1.58 0.78   
STAT3 (Y705) 8084 9852 7505 1.22 0.76 6527 8941 5334 1.37 0.60 6858 8830 7490 1.29 0.85   
p27 1614 1235 984 0.77 0.80 3136 2956 1520 0.94 0.51 2329 2998 2689 1.29 0.90   
PLC-γ1 4823 4627 6131 0.96 1.32 7026 8822 6120 1.26 0.69 4998 6546 5084 1.31 0.78   
Hck 5520 8245 7635 1.49 0.93 4264 11387 6576 2.67 0.58 6600 7100 6018 1.08 0.85   
Chk-2 3595 5224 6670 1.45 1.28 7381 13872 7230 1.88 0.52 8310 10288 8768 1.24 0.85   
FAK 1246 2031 4023 1.63 1.98 6742 9168 4701 1.36 0.51 4885 6708 4938 1.37 0.74   
PDGF Rβ 1122 2612 1778 2.33 0.68 6614 9461 3930 1.43 0.42 3837 6274 4550 1.64 0.73   
STAT5a/b 3904 8139 5073 2.09 0.62 8170 15592 7540 1.91 0.48 6131 10003 7504 1.63 0.75   
STAT3 (S727) 5283 8195 4634 1.55 0.57 6604 12134 5164 1.84 0.43 6612 10912 8433 1.65 0.77   
WNK1 4069 6723 5172 1.65 0.77 14725 19949 17859 1.35 0.90 8923 12783 9401 1.43 0.74   
PYK2 2756 2373 2959 0.86 1.25 5980 7615 4063 1.27 0.53 4775 6329 5323 1.33 0.84   
PRAS40 13122 16425 14567 1.25 0.89 8383 19763 13207 2.36 0.67 9501 11435 11182 1.20 0.98   
HSP60 17917 20612 15047 1.15 0.73 14059 45695 28590 3.25 0.63 17490 31426 21905 1.80 0.70   
 
 
 
176 
 
Table 36 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive keratinocytes (incubation: EGF) 
Differentially expressed precursor and mature miRNAs in erlotinib-sensitive as compared to -
insensitive keratinocytes (n = 6 in each group) previously stimulated with 4 nM EGF were 
determined by NGS and the program DESeq2. In vitro sensitivity towards erlotinib was previously 
determined by EGFR-ELISA. MiRNAs with a p-value < 0.05 and a fold change of ≥ 1.50 (up-
regulated in erlotinib-sensitive cells) or ≤ 0.66 (down-regulated in erlotinib-sensitive) respectively, 
are listed. The fold change as logarithm of the basis 2 (log2 fold change) is given with its standard 
error (lfcSE, log fold change standard error). The result of the statistic Wald test (stat) together with 
the corresponding p-value is also listed. 
 
 
erlotinib-sensitive vs. -insensitive 
incubation: EGF 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-1181 -0.9241 0.3209 0.5270 -2.8800 3.98E-03 
hsa-mir-4284 -0.8849 0.3271 0.5415 -2.7051 6.83E-03 
hsa-mir-4461 0.9550 0.3545 1.9386 2.6944 7.05E-03 
hsa-mir-944 0.6490 0.2529 1.5681 2.5665 1.03E-02 
hsa-mir-9-3 -0.8497 0.3471 0.5549 -2.4482 1.44E-02 
hsa-mir-8082 -0.8114 0.3336 0.5698 -2.4322 1.50E-02 
hsa-mir-5000 -0.6807 0.2893 0.6239 -2.3527 1.86E-02 
hsa-mir-203b -0.6924 0.3094 0.6188 -2.2374 2.53E-02 
hsa-mir-203a -0.6441 0.2905 0.6399 -2.2173 2.66E-02 
hsa-mir-877 -0.7405 0.3433 0.5985 -2.1568 3.10E-02 
hsa-mir-3138 -0.6805 0.3234 0.6239 -2.1042 3.54E-02 
hsa-mir-3973 -0.6342 0.3134 0.6443 -2.0238 4.30E-02 
hsa-mir-146a -0.6885 0.3418 0.6205 -2.0143 4.40E-02 
hsa-mir-6797 -0.6631 0.3359 0.6315 -1.9740 4.84E-02 
hsa-mir-548ao 0.6478 0.3285 1.5668 1.9718 4.86E-02 
hsa-mir-1246 -0.6296 0.3200 0.6464 -1.9676 4.91E-02 
            
mature miRNA           
hsa-miR-146a-5p -0.8212 0.2957 0.5660 -2.7771 5.49E-03 
hsa-miR-199a-3p -0.7039 0.3021 0.6139 -2.3297 1.98E-02 
hsa-miR-203a -0.6213 0.2780 0.6501 -2.2354 2.54E-02 
hsa-miR-328-3p -0.6625 0.3139 0.6318 -2.1106 3.48E-02 
hsa-miR-744-3p 0.6363 0.3109 1.5544 2.0469 4.07E-02 
 
 
There were 13 precursor and four mature miRNAs significantly down-regulated and three 
precursor miRNAs and one mature miRNA significantly up-regulated in the erlotinib-
sensitive cells. Fold changes ranged between 1.55 and 1.94 (0.65 and 0.53 for down-
regulation respectively).  
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Table 37 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive keratinocytes (incubation: erlotinib + EGF) 
Differentially expressed precursor and mature miRNAs in erlotinib-sensitive as compared to -
insensitive keratinocytes (n = 6 in each group) previously incubated with 5 µM erlotinib and 4 nM 
EGF were determined by NGS and the program DESeq2. In vitro sensitivity towards erlotinib was 
previously determined by EGFR-ELISA. MiRNAs with a p-value < 0.02 and fold change of ≥ 1.50 
(up-regulated in erlotinib-sensitive cells) or ≤ 0.66 (down-regulated in erlotinib-sensitive) 
respectively, are listed. Fold change as logarithm of the basis 2 (log2 fold change) is given with its 
standard error (lfcSE, log fold change standard error). The result of the statistic Wald test (stat) with 
the corresponding p-value is also listed. 
 
 
erlotinib-sensitive vs. -insensitive 
incubation: erlotinib + EGF 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-520e -2.4886 0.3985 0.1782 -6.2441 4.26E-10 
hsa-mir-138-2 -1.3058 0.3455 0.4045 -3.7797 1.57E-04 
hsa-mir-944 0.7424 0.2406 1.6730 3.0851 2.03E-03 
hsa-mir-585 1.1030 0.3904 2.1480 2.8256 4.72E-03 
hsa-mir-1263 -1.0450 0.3955 0.4847 -2.6424 8.23E-03 
hsa-mir-31 -0.6154 0.2375 0.6527 -2.5913 9.56E-03 
hsa-mir-615 0.8141 0.3202 1.7582 2.5422 1.10E-02 
hsa-mir-203b -0.8346 0.3355 0.5607 -2.4879 1.29E-02 
hsa-mir-5690 -0.8531 0.3517 0.5536 -2.4252 1.53E-02 
hsa-mir-3615 -0.6497 0.2686 0.6374 -2.4186 1.56E-02 
hsa-mir-3911 -0.8821 0.3655 0.5426 -2.4132 1.58E-02 
hsa-mir-942 0.8371 0.3500 1.7865 2.3915 1.68E-02 
hsa-mir-137 -0.9345 0.3931 0.5232 -2.3774 1.74E-02 
            
mature miRNA           
hsa-miR-520e -1.4014 0.3285 0.3786 -4.2660 1.99E-05 
hsa-miR-138-5p -1.1798 0.3404 0.4414 -3.4664 5.27E-04 
hsa-miR-221-3p -0.5960 0.1954 0.6616 -3.0494 2.29E-03 
hsa-miR-146a-5p -1.0023 0.3481 0.4992 -2.8792 3.99E-03 
hsa-miR-138-2-3p -0.9914 0.3508 0.5030 -2.8261 4.71E-03 
hsa-miR-944 0.6969 0.2507 1.6210 2.7800 5.44E-03 
hsa-miR-16-2-3p 0.8118 0.2991 1.7554 2.7139 6.65E-03 
hsa-let-7e-3p -0.8953 0.3595 0.5376 -2.4907 1.27E-02 
hsa-miR-615-3p 0.7502 0.3100 1.6820 2.4197 1.55E-02 
hsa-miR-210-3p -0.8384 0.3530 0.5593 -2.3752 1.75E-02 
 
 
In keratinocytes which were incubated with erlotinib and then stimulated with EGF prior to 
sequencing, the list of significantly differentially expressed miRNAs is substantially longer 
than for untreated and only EGF-stimulated cells (when comparing erlotinib-sensitive to -
insensitive cells). Therefore, in 37 only the most significant miRNAs with a p-value < 0.02 
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are listed. This restriction results in a list of nine precursor and seven mature miRNAs 
down-regulated and four precursor and three mature miRNAs up-regulated in the erlotinib-
sensitive cells. Fold changes ranged between 1.62 and 2.15 (0.66 and 0.18 for down-
regulation respectively).
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Table 38 Overview of literature search for miRNAs found to be significantly differentially expressed in erlotinib-sensitive as compared to -insensitive 
keratinocytes by NGS 
Specific miRNAs which were significantly differentially expressed (p-value < 0.05) in all three in vitro treatment groups (none, 4 nM EGF or 5 µM erlotinib plus 4 nM EGF) 
represent a “baseline” difference between erlotinib-sensitive and -insensitive cells and are called “overlap miRNAs” here. Specific miRNAs which were only significantly 
differentially expressed in cells treated with erlotinib are called “erlotinib only” miRNAs here. For the “overlap” and the “erlotinib only” miRNAs a thorough literature search was 
conducted and publications concerning their association with cancer, EGFR or other tyrosine kinases, erlotinib or other EGFRIs, fibroblasts and keratinocytes were reviewed. 
√ means at least one publication has been found. (√) means a closely related or superordinate miRNA has been found in this context (e.g. hsa-mir-7 instead of hsa-mir-7-1). 
In the lists for mature miRNAs those miRNAs already listed for precursors are not included again. MiRNAs chosen for further analyses are marked in bold. 
 
"overlap miRNAs" 
          cue for literature search   
miRNA name miRNA cancer EGFR tyrosine kinase erlotinib keratinocytes fibroblasts comment 
hsa-mir-146a √ √ √ √ √ √ √ interesting 
         
         "erlotinib only 
miRNAs" 
          cue for literature search   
miRNA name miRNA cancer EGFR tyrosine kinase erlotinib keratinocytes fibroblasts comment 
precursors                 
hsa-mir-1263 - - - - - - -   
hsa-mir-137 √ √ - √ - √ -   
hsa-mir-138-2 √ (√) (√) (√) (gefitinib) (√) (√) (mir-138), interesting 
hsa-mir-197 √ √ - √ - √ -   
hsa-mir-31 √ √ √ √ (cetuximab) √ √ interesting 
hsa-mir-3615 √ √ - - - - -   
hsa-mir-5195 - - - - - - -   
hsa-mir-520e √ √ √ √ - - -  interesting, also for FB! 
hsa-mir-5690 - - - - - - -   
hsa-mir-585 √ √ - - - - -   
hsa-mir-609 √ - - - - - -   
hsa-mir-615 √ √ - (√) - - -   
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hsa-mir-622 √ √ - √ - - -   
hsa-mir-6510 - - - - - - -   
hsa-mir-675 √ √ (√) √ - √ √ 
(H19 = long non-coding 
precursor of miR-675) 
hsa-mir-6780b √ √ - - - - -   
hsa-mir-711 √ √ - - - - -   
hsa-mir-875 (√) √ - - - (√) - 
 hsa-mir-942 √ √ - - - - -   
                  
mature                 
hsa-let-7e-3p √ √ √ √ - - -   
hsa-miR-1282 √ √ - - - - -   
hsa-miR-1299 √ √ - - - - -   
hsa-miR-138-5p √ (√) √ √ (gefitinib) √ √ interesting, mir-138-2 chosen 
hsa-miR-16-2-3p √ (√) (√) (√) - (√) (√)   
hsa-miR-210-3p √ √ (√) (√) - (√) (√)   
hsa-miR-221-3p √ √ √ (√) - (√) (√) interesting 
hsa-miR-7641 √ √ - - - - -   
hsa-miR-944 √ √ - √ - √ -   
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B) Fibroblasts 
 
 
Figure 36 Quantification of in vitro effect of erlotinib on phosphorylation of proteins involved in EGFR signaling in fibroblasts 
Human phospho kinase arrays were conducted with dermal fibroblast cell lysates of FB64 p7. The mean pixel density after chemiluminescent visualization of the 45 different 
phosphorylated proteins is shown. Light blue: no treatment. Dark blue: stimulated with 4 nM EGF for 5 min. Green: incubated with 10 µM erlotinib for 2 h then stimulated with 
4 nM EGF for 5 min. A stronger signal (pixel density) corresponds to higher amounts of phosphorylated protein present and stronger signaling activity. 
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Table 39 Mean pixel density for all proteins from human phospho-kinase arrays of two different fibroblast samples 
Human phospho-kinase arrays were conducted with two different fibroblast cell samples (FB64 p7 and FB120 p8) following three in vitro treatment conditions (no treatment, 4 
nM EGF for 5 min and 10 µM erlotinib for 2 h + 4 nM EGF for 5 min). For clearer comparison of the stimulating effect of EGF and the inhibitory effect of erlotinib between the 
different cell samples, ratios were calculated (EGF/no treatment and erlotinib/EGF). 
 
mean pixel density for FB64 p7 mean pixel density for FB120 p8 
protein 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
no 
treatment 
EGF erlotinib 
EGF/no 
treatment 
erlotinib/ 
EGF 
p38α 48455 33452 37262 0.69 1.11 16413 15591 8104 0.95 0.52 
ERK1/2 134053 254220 107268 1.90 0.42 64331 182975 33812 2.84 0.18 
JNK 1/2/3 31304 33636 19622 1.07 0.58 6889 8930 4786 1.30 0.54 
GSK-3αβ 35587 37931 23447 1.07 0.62 14108 19551 10494 1.39 0.54 
p53 (S392) 39400 37560 27196 0.95 0.72 10888 10334 9604 0.95 0.93 
EGF R 34264 74409 23720 2.17 0.32 7628 24849 4612 3.26 0.19 
MSK1/2 48500 42084 30278 0.87 0.72 10066 13658 5942 1.36 0.44 
AMPKα1 19637 20536 10839 1.05 0.53 4540 6167 3295 1.36 0.53 
Akt 1/2/3 (S473) 19079 22766 12611 1.19 0.55 4629 11388 3942 2.46 0.35 
Akt 1/2/3 (T308) 66851 73386 38726 1.10 0.53 11092 15493 10034 1.40 0.65 
p53 (S46) 90862 89905 56668 0.99 0.63 14209 16816 11888 1.18 0.71 
TOR 17408 17158 8974 0.99 0.52 5835 8063 2370 1.38 0.29 
CREB 106105 92573 78798 0.87 0.85 28362 30446 19193 1.07 0.63 
HSP27 24846 24911 19649 1.00 0.79 6881 11764 4508 1.71 0.38 
AMPKα2 42436 43524 32276 1.03 0.74 12909 19528 10526 1.51 0.54 
β-Catenin 21551 18328 12956 0.85 0.71 3458 5233 3355 1.51 0.64 
p70 S6 Kinase 
(T389) 53872 74366 42203 1.38 0.57 6868 12281 5201 1.79 0.42 
p53 (S15) 63097 71452 50963 1.13 0.71 9070 11694 7106 1.29 0.61 
c-Jun 47208 41204 37222 0.87 0.90 7833 10276 5877 1.31 0.57 
Src 14331 43802 7245 3.06 0.17 5677 7299 1791 1.29 0.25 
Lyn 34875 24861 19574 0.71 0.79 9440 12425 5558 1.32 0.45 
Lck 17672 14847 10124 0.84 0.68 3958 6676 2784 1.69 0.42 
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STAT2 55007 56417 35881 1.03 0.64 15206 21569 11657 1.42 0.54 
STAT5a 29578 35512 21838 1.20 0.61 5226 8992 4143 1.72 0.46 
p70 S6 Kinase 
(T421/S424) 50392 65028 39881 1.29 0.61 13615 18662 10030 1.37 0.54 
RSK1/2/3 60980 87714 53284 1.44 0.61 12037 18244 8482 1.52 0.46 
eNOS 59493 53156 44472 0.89 0.84 5608 6911 4304 1.23 0.62 
Fyn 16314 16881 10913 1.03 0.65 5271 7356 3779 1.40 0.51 
Yes 39636 22497 21097 0.57 0.94 6502 9564 4961 1.47 0.52 
Fgr 15996 12807 9173 0.80 0.72 3094 5588 2839 1.81 0.51 
STAT6 37348 33422 23655 0.89 0.71 8813 15219 6981 1.73 0.46 
STAT5b 27802 33193 18316 1.19 0.55 4966 10092 4374 2.03 0.43 
STAT3 (Y705) 55209 64578 44114 1.17 0.68 8816 12867 6591 1.46 0.51 
p27 14853 12045 7530 0.81 0.63 2985 3197 1616 1.07 0.51 
PLC-γ1 96466 91609 71067 0.95 0.78 7595 9793 5630 1.29 0.57 
Hck 25273 15717 14407 0.62 0.92 5396 7576 4313 1.40 0.57 
Chk-2 41064 22688 21420 0.55 0.94 7866 11194 6144 1.42 0.55 
FAK 23624 16607 11723 0.70 0.71 3811 5907 2959 1.55 0.50 
PDGF Rβ 25026 18932 11300 0.76 0.60 4638 6810 4207 1.47 0.62 
STAT5a/b 28200 29490 16658 1.05 0.56 6289 10251 5878 1.63 0.57 
STAT3 (S727) 39278 47581 30870 1.21 0.65 11053 18198 9715 1.65 0.53 
WNK1 71225 73212 45498 1.03 0.62 11438 16083 7915 1.41 0.49 
PYK2 33731 20784 19913 0.62 0.96 6705 9206 4484 1.37 0.49 
PRAS40 54826 38643 31747 0.70 0.82 8383 12462 6479 1.49 0.52 
HSP60 40293 46245 35509 1.15 0.77 17836 25243 20169 1.42 0.80 
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Table 40 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive fibroblasts (incubation: EGF) 
Differentially expressed precursor and mature miRNAs in erlotinib-sensitive as compared to -
insensitive fibroblasts (n = 4 in each group) previously stimulated with 4 nM EGF were determined 
by NGS and the program DESeq2. In vitro sensitivity towards erlotinib was previously determined 
by ERK 1/2-ELISA. MiRNAs with a p-value < 0.02 and a fold change of ≥ 1.50 (up-regulated in 
erlotinib-sensitive cells) or ≤ 0.66 (down-regulated in erlotinib-sensitive) respectively, are listed. The 
fold change as logarithm of the basis 2 (log2 fold change) is given with its standard error (lfcSE, log 
fold change standard error). The result of the statistic Wald test (stat) together with the 
corresponding p-value is also listed. 
 
 
erlotinib-sensitive vs. -insensitive 
incubation: EGF 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-30b 1.1489 0.3009 2.2175 3.8184 1.34E-04 
hsa-mir-199b 1.0110 0.3004 2.0153 3.3649 7.66E-04 
hsa-mir-1273a -1.0836 0.3259 0.4718 -3.3247 8.85E-04 
hsa-mir-1273g -1.0559 0.3179 0.4810 -3.3210 8.97E-04 
hsa-mir-382 1.2671 0.3910 2.4068 3.2407 1.19E-03 
hsa-mir-342 1.2297 0.3967 2.3452 3.0997 1.94E-03 
hsa-mir-452 1.2955 0.4188 2.4547 3.0931 1.98E-03 
hsa-mir-450b 0.9669 0.3128 1.9546 3.0907 2.00E-03 
hsa-mir-148b 0.7591 0.2486 1.6924 3.0535 2.26E-03 
hsa-mir-494 1.3173 0.4433 2.4921 2.9715 2.96E-03 
hsa-mir-107 0.8711 0.3032 1.8290 2.8733 4.06E-03 
hsa-mir-4510 -0.8290 0.2934 0.5629 -2.8257 4.72E-03 
hsa-mir-127 1.2327 0.4442 2.3501 2.7754 5.51E-03 
hsa-mir-585 1.0837 0.3935 2.1195 2.7537 5.89E-03 
hsa-mir-615 -0.7948 0.2902 0.5764 -2.7387 6.17E-03 
hsa-mir-155 0.9491 0.3468 1.9307 2.7364 6.21E-03 
hsa-mir-34a 0.8328 0.3049 1.7811 2.7311 6.31E-03 
hsa-mir-148a 1.1817 0.4360 2.2684 2.7103 6.72E-03 
hsa-mir-379 1.1840 0.4379 2.2720 2.7040 6.85E-03 
hsa-mir-20a 0.9481 0.3541 1.9294 2.6773 7.42E-03 
hsa-mir-106b 0.7494 0.2825 1.6811 2.6531 7.98E-03 
hsa-mir-4508 -1.2907 0.4898 0.4088 -2.6350 8.41E-03 
hsa-mir-101-2 0.8362 0.3189 1.7853 2.6221 8.74E-03 
hsa-mir-3120 0.8283 0.3179 1.7755 2.6053 9.18E-03 
hsa-mir-374b 0.7545 0.2898 1.6870 2.6038 9.22E-03 
hsa-mir-25 0.6959 0.2754 1.6199 2.5272 1.15E-02 
hsa-mir-6838 -1.0350 0.4154 0.4880 -2.4913 1.27E-02 
hsa-mir-101-1 0.7985 0.3218 1.7393 2.4814 1.31E-02 
hsa-mir-19b-1 1.1539 0.4675 2.2251 2.4682 1.36E-02 
hsa-mir-300 1.3163 0.5340 2.4903 2.4651 1.37E-02 
hsa-mir-299 1.1065 0.4508 2.1532 2.4543 1.41E-02 
hsa-mir-103a-2 0.6920 0.2827 1.6155 2.4481 1.44E-02 
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hsa-mir-329-1 1.0451 0.4295 2.0635 2.4334 1.50E-02 
hsa-mir-4419a -0.8746 0.3670 0.5454 -2.3830 1.72E-02 
hsa-mir-196a-1 -0.9705 0.4082 0.5103 -2.3777 1.74E-02 
hsa-mir-889 0.9951 0.4191 1.9932 2.3742 1.76E-02 
hsa-mir-3529 0.8237 0.3485 1.7699 2.3632 1.81E-02 
hsa-mir-103a-1 0.6677 0.2827 1.5885 2.3619 1.82E-02 
hsa-mir-134 0.9904 0.4195 1.9867 2.3606 1.82E-02 
            
mature miRNA           
hsa-miR-22-3p -0.7501 0.1344 0.5946 -5.5822 2.38E-08 
hsa-miR-452-5p 2.1789 0.5188 4.5281 4.1996 2.67E-05 
hsa-miR-4510 -1.1409 0.2933 0.4535 -3.8894 1.00E-04 
hsa-miR-450b-5p 0.7362 0.1999 1.6657 3.6821 2.31E-04 
hsa-let-7d-3p -0.9480 0.2886 0.5184 -3.2844 1.02E-03 
hsa-miR-125b-1-3p -0.6121 0.1879 0.6542 -3.2578 1.12E-03 
hsa-miR-1285-5p -1.8478 0.5681 0.2778 -3.2526 1.14E-03 
hsa-miR-5684 -1.5474 0.4891 0.3421 -3.1640 1.56E-03 
hsa-miR-1827 -1.5010 0.4786 0.3533 -3.1366 1.71E-03 
hsa-miR-1273g-3p -1.4620 0.4768 0.3630 -3.0659 2.17E-03 
hsa-miR-127-5p 1.4988 0.4916 2.8260 3.0488 2.30E-03 
hsa-miR-138-5p -0.8402 0.2803 0.5585 -2.9980 2.72E-03 
hsa-miR-615-3p -1.1127 0.3722 0.4624 -2.9898 2.79E-03 
hsa-miR-1273d -1.8095 0.6157 0.2853 -2.9392 3.29E-03 
hsa-miR-299-3p 1.2538 0.4284 2.3847 2.9266 3.43E-03 
hsa-miR-20a-5p 0.8014 0.2760 1.7428 2.9033 3.69E-03 
hsa-miR-30b-5p 0.9882 0.3418 1.9837 2.8910 3.84E-03 
hsa-miR-300 1.9305 0.6801 3.8119 2.8386 4.53E-03 
hsa-miR-490-3p -1.9406 0.6875 0.2605 -2.8227 4.76E-03 
hsa-miR-199b-5p 1.3917 0.4942 2.6238 2.8160 4.86E-03 
hsa-miR-4648 -1.9378 0.6898 0.2610 -2.8091 4.97E-03 
hsa-miR-22-5p -0.7864 0.2813 0.5798 -2.7957 5.18E-03 
hsa-miR-3135b -1.1090 0.3982 0.4636 -2.7848 5.36E-03 
hsa-miR-149-3p -1.8630 0.6870 0.2749 -2.7117 6.69E-03 
hsa-miR-548h-5p 1.6784 0.6260 3.2007 2.6813 7.33E-03 
hsa-miR-653-3p -1.5127 0.5678 0.3504 -2.6644 7.71E-03 
hsa-miR-1303 -1.0440 0.3972 0.4850 -2.6282 8.58E-03 
hsa-miR-5585-3p -1.2743 0.4878 0.4134 -2.6127 8.98E-03 
hsa-miR-4508 -1.6642 0.6494 0.3155 -2.5627 1.04E-02 
hsa-miR-125b-2-3p 1.1948 0.4681 2.2891 2.5525 1.07E-02 
hsa-miR-655-3p 1.2337 0.4882 2.3518 2.5271 1.15E-02 
hsa-miR-145-3p -1.3832 0.5476 0.3834 -2.5256 1.15E-02 
hsa-miR-7851-3p -1.5984 0.6351 0.3302 -2.5166 1.18E-02 
hsa-miR-6780a-3p -1.6601 0.6606 0.3164 -2.5128 1.20E-02 
hsa-miR-3925-5p -1.7267 0.6943 0.3021 -2.4870 1.29E-02 
hsa-miR-17-5p 0.7216 0.2919 1.6490 2.4723 1.34E-02 
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hsa-miR-4492 -1.7022 0.6942 0.3073 -2.4519 1.42E-02 
hsa-miR-708-5p -0.8588 0.3606 0.5514 -2.3817 1.72E-02 
hsa-miR-548k 1.3489 0.5675 2.5472 2.3768 1.75E-02 
hsa-miR-3667-3p -1.6472 0.6935 0.3193 -2.3751 1.75E-02 
hsa-miR-27b-5p -0.9829 0.4186 0.5060 -2.3480 1.89E-02 
 
 
There were eight precursor and 28 mature miRNAs significantly down-regulated and 31 
precursor and 13 mature miRNA significantly up-regulated in the erlotinib-sensitive cells. 
Fold changes ranged between 1.59 and 4.53 (0.65 and 0.26 for down-regulation 
respectively). 
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Table 41 Differentially expressed miRNAs in erlotinib-sensitive as compared to -
insensitive fibroblasts (incubation: erlotinib + EGF) 
Differentially expressed precursor and mature miRNAs in erlotinib-sensitive as compared to -
insensitive fibroblasts (n = 4 in each group) previously incubated with 5 µM erlotinib and 4 nM EGF 
were determined by NGS and the program DESeq2. In vitro sensitivity towards erlotinib was 
previously determined by ERK 1/2-ELISA. MiRNAs with a p-value < 0.02 and a fold change of ≥ 
1.50 (up-regulated in erlotinib-sensitive cells) or ≤ 0.66 (down-regulated in erlotinib-sensitive) 
respectively, are listed. The fold change as logarithm of the basis 2 (log2 fold change) is given with 
its standard error (lfcSE, log fold change standard error). The result of the statistic Wald test (stat) 
together with the corresponding p-value is also listed. 
 
 
erlotinib-sensitive vs. -insensitive 
incubation: erlotinib + EGF 
precursor miRNA 
(hairpin) 
log2 fold 
change 
lfcSE fold 
change 
stat p-value 
hsa-mir-106b 1.0262 0.2807 2.0366 3.6563 2.56E-04 
hsa-mir-127 1.4375 0.4011 2.7086 3.5838 3.39E-04 
hsa-mir-494 1.4315 0.4098 2.6972 3.4932 4.77E-04 
hsa-mir-299 1.3938 0.4011 2.6276 3.4747 5.12E-04 
hsa-mir-199b 1.0230 0.2949 2.0322 3.4686 5.23E-04 
hsa-mir-379 1.3438 0.3884 2.5382 3.4602 5.40E-04 
hsa-mir-7158 1.2695 0.3799 2.4108 3.3420 8.32E-04 
hsa-mir-452 1.2786 0.3878 2.4260 3.2967 9.78E-04 
hsa-mir-4510 -1.0039 0.3184 0.4986 -3.1533 1.61E-03 
hsa-mir-889 1.2018 0.3869 2.3003 3.1064 1.89E-03 
hsa-mir-30b 0.9932 0.3202 1.9906 3.1018 1.92E-03 
hsa-mir-155 1.0103 0.3260 2.0144 3.0997 1.94E-03 
hsa-mir-134 1.2560 0.4053 2.3883 3.0989 1.94E-03 
hsa-mir-20a 1.0117 0.3329 2.0163 3.0394 2.37E-03 
hsa-mir-148a 1.2421 0.4102 2.3654 3.0277 2.46E-03 
hsa-mir-1-2 -1.5491 0.5265 0.3417 -2.9422 3.26E-03 
hsa-mir-136 1.2104 0.4145 2.3141 2.9202 3.50E-03 
hsa-mir-382 1.2349 0.4269 2.3536 2.8924 3.82E-03 
hsa-mir-1-1 -1.5349 0.5341 0.3451 -2.8739 4.05E-03 
hsa-mir-323a 1.1258 0.3971 2.1822 2.8353 4.58E-03 
hsa-mir-550a-3 -1.3207 0.4665 0.4003 -2.8311 4.64E-03 
hsa-mir-146b 1.0194 0.3750 2.0270 2.7185 6.56E-03 
hsa-mir-711 0.8425 0.3109 1.7932 2.7103 6.72E-03 
hsa-mir-585 1.0465 0.3947 2.0655 2.6516 8.01E-03 
hsa-mir-101-2 0.7650 0.2895 1.6994 2.6422 8.24E-03 
hsa-mir-25 0.7389 0.2809 1.6689 2.6301 8.54E-03 
hsa-mir-101-1 0.7615 0.2896 1.6953 2.6294 8.55E-03 
hsa-mir-103b-2 0.8183 0.3116 1.7633 2.6264 8.63E-03 
hsa-mir-409 1.1184 0.4274 2.1711 2.6171 8.87E-03 
hsa-mir-374c 0.8991 0.3491 1.8649 2.5755 1.00E-02 
hsa-mir-654 1.0299 0.4009 2.0419 2.5689 1.02E-02 
hsa-mir-224 0.9229 0.3593 1.8960 2.5685 1.02E-02 
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hsa-mir-199a-2 0.7221 0.2812 1.6496 2.5678 1.02E-02 
hsa-mir-199a-1 0.7099 0.2768 1.6357 2.5652 1.03E-02 
hsa-mir-17 0.8907 0.3494 1.8541 2.5492 1.08E-02 
hsa-mir-22 -0.6463 0.2556 0.6389 -2.5283 1.15E-02 
hsa-mir-154 1.3097 0.5187 2.4789 2.5248 1.16E-02 
hsa-mir-34a 0.8391 0.3329 1.7890 2.5206 1.17E-02 
hsa-mir-93 0.8001 0.3191 1.7413 2.5078 1.21E-02 
hsa-mir-520e -1.3333 0.5358 0.3969 -2.4884 1.28E-02 
hsa-mir-660 0.7458 0.3006 1.6769 2.4812 1.31E-02 
hsa-mir-450b 0.7777 0.3162 1.7143 2.4594 1.39E-02 
hsa-mir-107 0.7683 0.3139 1.7032 2.4477 1.44E-02 
hsa-mir-4284 -1.2944 0.5289 0.4077 -2.4474 1.44E-02 
hsa-mir-3529 0.7369 0.3027 1.6666 2.4342 1.49E-02 
hsa-mir-92a-2 0.7317 0.3019 1.6606 2.4238 1.54E-02 
hsa-mir-629 0.7785 0.3241 1.7154 2.4018 1.63E-02 
hsa-mir-4497 0.9083 0.3852 1.8769 2.3581 1.84E-02 
hsa-mir-615 -0.7262 0.3081 0.6045 -2.3571 1.84E-02 
hsa-mir-370 0.9735 0.4152 1.9636 2.3449 1.90E-02 
hsa-mir-376c 1.0974 0.4684 2.1397 2.3429 1.91E-02 
            
mature miRNA           
hsa-miR-4510 -1.2655 0.2400 0.4160 -5.2723 1.35E-07 
hsa-miR-22-3p -0.8717 0.1743 0.5465 -5.0022 5.67E-07 
hsa-miR-140-5p -0.8504 0.1892 0.5546 -4.4955 6.94E-06 
hsa-miR-299-3p 1.5046 0.3531 2.8374 4.2614 2.03E-05 
hsa-miR-106b-3p 0.7647 0.2263 1.6990 3.3785 7.29E-04 
hsa-miR-22-5p -0.8358 0.2485 0.5603 -3.3640 7.68E-04 
hsa-miR-361-3p 0.7875 0.2383 1.7261 3.3044 9.52E-04 
hsa-miR-1290 -1.1422 0.3725 0.4531 -3.0665 2.17E-03 
hsa-miR-20a-5p 0.8984 0.2994 1.8640 3.0005 2.70E-03 
hsa-miR-1827 -1.3873 0.4655 0.3823 -2.9804 2.88E-03 
hsa-miR-138-5p -0.8444 0.2907 0.5569 -2.9046 3.68E-03 
hsa-miR-3976 -0.9261 0.3258 0.5263 -2.8427 4.47E-03 
hsa-miR-17-5p 0.8752 0.3163 1.8342 2.7672 5.65E-03 
hsa-miR-758-3p 0.9601 0.3473 1.9454 2.7644 5.70E-03 
hsa-miR-30b-5p 0.8301 0.3118 1.7778 2.6625 7.76E-03 
hsa-miR-628-5p -1.5003 0.5660 0.3535 -2.6508 8.03E-03 
hsa-miR-1282 -1.1942 0.4506 0.4370 -2.6501 8.05E-03 
hsa-miR-127-5p 1.1813 0.4509 2.2678 2.6200 8.79E-03 
hsa-miR-409-5p 1.3147 0.5021 2.4874 2.6183 8.84E-03 
hsa-miR-4765 -1.2239 0.4704 0.4281 -2.6016 9.28E-03 
hsa-miR-145-3p -1.2037 0.4631 0.4342 -2.5989 9.35E-03 
hsa-miR-653-3p -1.0836 0.4287 0.4718 -2.5275 1.15E-02 
hsa-miR-379-3p 1.1485 0.4549 2.2168 2.5249 1.16E-02 
hsa-miR-199b-5p 1.2094 0.4878 2.3124 2.4795 1.32E-02 
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hsa-miR-615-3p -0.8787 0.3586 0.5439 -2.4501 1.43E-02 
hsa-miR-618 -0.9569 0.3911 0.5152 -2.4466 1.44E-02 
hsa-miR-93-5p 0.6571 0.2710 1.5769 2.4249 1.53E-02 
hsa-miR-127-3p 1.0631 0.4387 2.0894 2.4232 1.54E-02 
hsa-miR-450b-5p 0.5940 0.2460 1.5094 2.4143 1.58E-02 
hsa-miR-589-5p -0.8448 0.3511 0.5568 -2.4058 1.61E-02 
hsa-miR-25-3p 0.5853 0.2449 1.5003 2.3897 1.69E-02 
hsa-miR-708-3p -1.0520 0.4435 0.4823 -2.3720 1.77E-02 
hsa-miR-3074-3p -1.3518 0.5708 0.3918 -2.3684 1.79E-02 
hsa-miR-4429 -1.3181 0.5591 0.4011 -2.3577 1.84E-02 
 
 
Eight precursor and 19 mature miRNAs were down-regulated and 43 precursor and 15 
mature miRNAs up-regulated in the erlotinib-sensitive cells. Fold changes ranged 
between 1.50 and 2.84 (0.64 and 0.34 for down-regulation, respectively). 
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Table 42 Overview of literature search for miRNAs found to be significantly differentially expressed in erlotinib-sensitive as compared to -insensitive 
fibroblasts by NGS 
Specific miRNAs which were significantly differentially expressed (p-value < 0.05) in all three in vitro treatment groups (none, 4 nM EGF or 5 µM erlotinib plus 4 nM 
EGF) represent a “baseline” difference between erlotinib-sensitive and -insensitive cells and are called “overlap miRNAs” here. Specific miRNAs which were only 
significantly differentially expressed in cells treated with erlotinib are called “erlotinib only” miRNAs here. For the “overlap” and the “erlotinib only” miRNAs a 
thorough literature search was conducted and publications concerning their association with cancer, EGFR or other tyrosine kinases, erlotinib or other EGFRIs, 
fibroblasts and keratinocytes were reviewed. √ means at least one publication has been found. (√) means a closely related or superordinate miRNA has been 
found in this context (e.g. hsa-mir-7 instead of hsa-mir-7-1). In the lists for mature miRNAs those miRNAs already listed for precursors are not included again. 
MiRNAs chosen for further analyses are marked in bold. 
 
"overlap miRNAs" 
          cue for literature search   
miRNA name miRNA cancer EGFR tyrosine kinase erlotinib keratinocytes fibroblasts comment 
precursor                 
hsa-mir-101-1 √ √ - - - - -   
hsa-mir-101-2 √ √ - - - - -   
hsa-mir-106b √ √ - - - - √   
hsa-mir-107 √ √ √ √ - √ -   
hsa-mir-127 √ √ - - - - √   
hsa-mir-136 √ √ - - - - √   
hsa-mir-146b √ √ √ √ - - - interesting, see 146a in HK list 
hsa-mir-148a √ √ √ √ - - -   
hsa-mir-148b √ √ - √ - - -   
hsa-mir-155 √ √ √ √ - √ √   
hsa-mir-17 √ (√) - √ √ √ √ interesting (also mature) 
hsa-mir-196a-2 √ √ - - - - -   
hsa-mir-199a-1 √ (√) - - - - -   
hsa-mir-199a-2 √ (√) - - - - -   
hsa-mir-199b √ √ - √ - - -   
hsa-mir-20a √ √ - √ - - √   
hsa-mir-299 √ √ - - - - -   
hsa-mir-30b √ (√) √ √ - - √ interesting (also mature) 
hsa-mir-323a √ √ - - - - -   
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hsa-mir-329-1 √ √ - - - - -   
hsa-mir-34a √ √ √ √ √ √ √ interesting 
hsa-mir-379 √ √ - - - - -   
hsa-mir-382 √ √ - - - - -  one very interesting publication 
hsa-mir-450b √ - - - - - -   
hsa-mir-4510 - - - - - - -   
hsa-mir-452 √ √ - (√) - - -   
hsa-mir-494 √ √ √ √ - - √  interesting 
hsa-mir-520e √ √ √ √ - - -  interesting, also for HK! 
hsa-mir-585 √ √ - - - - -   
hsa-mir-660 √ √ - - - - -   
hsa-mir-7158 - - - - - - -   
hsa-mir-758 √ - - - - - -   
hsa-mir-889 √ √ - - - - -   
hsa-mir-93 √ √ (√) √ - - √   
                  
mature                 
hsa-miR-1303 √ √ - √ - - -   
hsa-miR-138-5p √ √ √ √ - √ √ interesting, see HK list 
hsa-miR-145-3p √ √ √ √ - √ √   
hsa-miR-22-5p √ √ √ √ - √ √   
hsa-miR-615-3p √ √ - - - - -   
hsa-miR-708-5p √ √ - - - - √   
                  
                  
                  
"erlotinib only 
miRNAs"                 
  cue for literature search   
miRNA name miRNA cancer EGFR tyrosine kinase erlotinib keratinocytes fibroblasts comment 
precursors                 
hsa-mir-1185-1 (√) (√) - - - - -   
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hsa-mir-1-2 √ √ (√) (√) - - (√)  publications no interesting results 
hsa-mir-1290 √ √ - √ - - -   
hsa-mir-152 √ √ - √ - - √   
hsa-mir-186 √ √ √ - - - √   
hsa-mir-19b-2 (√) (√) (√) - - - -   
hsa-mir-204 √ √ √ √ - - √   
hsa-mir-31 √ √ √ √ - √ √  interesting 
hsa-mir-320c-2 (√) (√) - (√) - - -   
hsa-mir-345 √ √ - - - √ -   
hsa-mir-370 √ √ √ √ - √ -   
hsa-mir-374c (√) (√) - (√) (√) - -   
hsa-mir-409 √ √ - √ - - √   
hsa-mir-4497 √ - - - - - -   
hsa-mir-485 √ √ - - - - -   
hsa-mir-500a √ √ - - √ - -   
hsa-mir-628 √ √ - - - - -   
hsa-mir-6779 - - - - - - -   
hsa-mir-7-1 (√) (√) (√) (√) (√) - - mir-7 interesting 
hsa-mir-711 √ √ - - - - (√)   
hsa-mir-7-2 √ √ (√) (√) (√) - - mir-7 interesting 
hsa-mir-7641-2 (√) - - - - - -   
hsa-mir-769 √ √ √ √ - - -   
hsa-mir-92a-1 √ √ (√) - - (√) (√)   
hsa-mir-92a-2 (√) (√) (√) - - (√) (√)   
hsa-mir-941-1 (√) (√) - - - - -   
hsa-mir-941-2 (√) (√) - - - - -   
                  
mature                 
hsa-let-7c-3p √ √ √ - - - -   
hsa-miR-106b-3p √ √ - - - √ √   
hsa-miR-126-5p √ √ √ √ - - √   
hsa-miR-1282 √ - - - - - -   
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hsa-miR-137 √ √ √ √ √ √     
hsa-miR-140-5p √ √ √ √ - - √ 
 hsa-miR-155-5p √ √ √ √ (√) √ √   
hsa-miR-193a-3p √ √ - √ -       
hsa-miR-25-3p √ √ - (√) - √ -   
hsa-miR-3074-3p (√) - - - - - -   
hsa-miR-3607-3p √ √ - - - - -   
hsa-miR-3919 - - - - - - -   
hsa-miR-3976 √ √ - - - - -   
hsa-miR-4327 - - - - - - -   
hsa-miR-4429 √ - - - - - -   
hsa-miR-4652-3p - - - - - - -   
hsa-miR-4765 - - - - - - -   
hsa-miR-4792 √ √ - - - - -   
hsa-miR-5088-3p √ - - - - - -   
hsa-miR-618 √ √ - - - - -   
hsa-miR-628-5p √ √ - √ - - -   
hsa-miR-93-5p √ √ - √ - - √   
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